

OM protein - protein search, using sw model						
Run on:	February 4, 2003, 09:38:23	Search time	38 Seconds	(without alignments)		
995,873	Million cell updates/sec					
Title:	US-09-704-272-6					
Perfect score:	1525					
Scoring table:	BLOSUM62	Gapext	0.5			
Searched:	908470	seeds,	13325620 residues			
Total number of hits satisfying chosen parameters:	908470					
Minimum DB seq length:	0	Maximum Match %:				
Maximum DB seq length:	200000000	Maximum Match 100%				
Post-processing:	Minimum Match 0%	Listing first 45 summaries				
Database :	A_Geneseg_101002: * 1: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1980.DAT: * 2: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1981.DAT: * 3: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1982.DAT: * 4: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1983.DAT: * 5: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1984.DAT: * 6: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1985.DAT: * 7: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1986.DAT: * 8: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1987.DAT: * 9: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1988.DAT: * 10: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1989.DAT: * 11: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1990.DAT: * 12: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1991.DAT: * 13: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1992.DAT: * 14: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1993.DAT: * 15: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1994.DAT: * 16: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1995.DAT: * 17: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1996.DAT: * 18: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1997.DAT: * 19: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1998.DAT: * 20: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA1999.DAT: * 21: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2000.DAT: * 22: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2001.DAT: * 23: /SIDS2/gcdata/geneseq/geneseqp-emb1/AA2002.DAT: *					
Pred. No.	is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.					
SUMMARIES						
Result No.	Score	Query Match Length	DB ID		Description	
1	1525	100.0	284	22	AAB62695	ABC1 protein ex
2	1525	100.0	2143	21	AAB38108	Human ABC1 choh
3	1525	100.0	2259	21	AAB38107	Human ABC1 F1A-
4	1525	100.0	2260	21	AAB38106	Human ABC1 choh
5	1525	100.0	2261	21	AAB38082	Human ABC1 choh
6	1525	100.0	2261	21	AAB38105	Human ABC1 choh
7	1525	100.0	2261	21	AAB38109	Human ABC1 choh
8	1525	100.0	2261	21	AAB38110	Human ABC1 choh
9	1525	100.0	2261	21	AAB38111	Human ABC1 choh
10	1525	100.0	2261	21	AAB38112	Human ABC1 choh

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result	No.	Score	Matteo	Quesada
-	-	-	-	-
1	1	1525	100	
	2	1525	100	
	3	1525	100	
	4	1525	100	
	5	1525	100	
	6	1525	100	
	7	1525	100	
	8	1525	100	
	9	1525	100	
	10	1525	100	

XX WO200132184-A2.
XX PN
XX XX
10- MAY -2001.
IPD XX
IPF 01 - NOV -2000; 2000WO-US30109.
XX PR 01 - NOV -1999; 99US-0162803.
PR XX 30 - JUN -2000; 2000US-0215564.
PA XX (WISC) WISCONSIN ALUMNI RES FOUND.
PA XX Attie AD, Cook M, Gray-Keller MP, Hayden MR,
XX Brooks Wilson A; Pinstone S;
PP1 XX WPI; 2001-335779/35.
XX

ALIGNMENTS

PS Disclosure; Page 9; 41pp; English.

XX

CC The invention relates to a new method for inhibiting cholesterol uptake
CC in the gut that comprises a administration of an inhibitor of an ABC1
CC protein. The method is useful for: lowering levels of LDL (low density
CC lipoprotein) cholesterol by reducing the activity of ABC1 protein in the individual
CC intestinal cells and the abundance of the ABC1 protein in the individual
CC by inhibiting the activity of the protein; identifying drugs that can
CC lower serum cholesterol and LDL levels comprising assaying the drug to
CC test if it can bind to an ABC1 protein; testing LDL cholesterol lowering
CC agents; and for modulation of ABC1 biological activity. Sequences
CC AA62692-97 represent predicted external domain of ABC1 protein.
XX

SQ Sequence 284 AA:

Query Match	100.0%	Score 1525;	DB 22;	Length 284;
Best Local Similarity	100.0%	Pred. No. 2; 3e-144;		
Matches	284;	Mismatches	0;	Indels 0;
		Gaps 0;		

Qy 1 FGKPSLELQPMMNEQYTFVSNDAPEDGTGLELLNAITKDGFGTRCMESNPIPTPQO 60

Db 1 FGKPSLELQPMMNEQYTFVSNDAPEDGTGLELLNAITKDGFGTRCMESNPIPTPQO 60

Qy 61 AGBBEWTATPYQTIMDLFQNGNTMQNSPACQCSSDKKKMLPVCGAGLPPPKRK 120

Db 61 AGBBEWTATPYQTIMDLFQNGNTMQNSPACQCSSDKKKMLPVCGAGLPPPKRK 120

Qy 121 QNTADILQDLTERNISDLYLKTYVQIASSLKNNIWNFRRGGFSLGVSTQALPPSQE 180

Db 121 QNTADILQDLTGRNSDLYLKTYVQIASSLKNNIWNFRRGGFSLGVSTQALPPSQE 180

Qy 181 YNDAIKOMKHKHLKADSSADRFLNSLGRTMGLDTRNKVYKWNNGWHAISFLNVIN 240

Db 181 YNDAIKOMKHKHLKADSSADRFLNSLGRTMGLDTRNKVYKWNNGWHAISFLNVIN 240

Qy 241 NATLRLNLQKGENPSHYGITATFNPBLNLTQKQOLSEVALMTSVD 284

Db 241 NATLRLNLQKGENPSHYGITATFNPBLNLTQKQOLSEVALMTSVD 284

RESULT 2

ID AAB38108

XX Human ABC1 transporter standard; Protein: 2143 AA.

AC AAB38108;

XX DT 29-JAN-2001 (first entry)

DE Human ABC1 transporter protein (R2144STOP).

XX KW Human ABC1 transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW coronary disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; propylaxias; drug screening; transgenic animal; mutant;
KW mutein.

XX OS Homo sapiens.

PN WO200055318-A2.

XX PD 21-SEP-2000.

XX PF 15-MAR-2000; 2000WO-1B00532.

XX PR 15-MAR-1999; 99US-0124102.

PR 08-JUN-1999; 99US-0138048.

PR 17-JUN-1999; 99US-013900.

PR 01-SEP-1999; 99US-0151977.

PA (UYBR-) UNITY BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.

XX Hayden MR, Wilson AR, Pimstone SN;

PI XX

DR WPI; 2000-587528/55.

DR N-PSDB; AAC69389.

XX New ABC1 polypeptide is useful for treating diseases associated with
PT ABC1 biological activity, e.g. Alzheimer's disease, Huntington's
PT disease and cancer -

PS Examples: Page -; 229pp; English.

XX

CC The invention relates to the human ABC1 cholesterol transporter protein
CC (B8082) and to nucleic acid sequences (C69120) which encode it. ABC1 is
CC a member of the ATP-binding cassette (ABC transporter) superfamily of
CC proteins, and plays a crucial role in cholesterol transport, particularly
CC intracellular cholesterol trafficking in monocytes and fibroblasts, being
CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is
CC located on chromosome 9q31, and mutations in this gene are associated
CC with two genetic HDL (high density lipoprotein) deficiency disorders,
CC Tangier disease (TD) and familial HDL deficiency (FHD). These diseases
CC are distinguishable in that TD is an autosomal recessive disorder, while
CC FHD is inherited as an autosomal dominant trait. Low levels of HDL ("good
CC cholesterol") in the blood correlate with a high risk of cardiovascular
CC disease, particularly coronary artery disease, but also cerebrovascular
CC disease, coronary restenosis, and peripheral vascular disease.
CC Conversely, a high level of HDL has protective effects against
CC cardiovascular disease. The invention provides genetic constructs and
CC transgenic cells and non-human animals comprising human ABC1 nucleic
CC acids, and methods of gene therapy for the treatment or prevention of
CC cardiovascular disease comprising the administration of an expression
CC construct encoding ABC1 or an active fragment thereof. The invention also
CC encompasses compounds which mimic ABC1 activity, compounds which
CC stimulate ABC1 expression and methods of screening for such compounds.
CC It further relates to methods for determining whether a patient has an
CC increased risk for cardiovascular disease due to polymorphisms in the
CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
CC or prevent cardiovascular disease, especially coronary artery disease,
CC cerebrovascular disease, coronary restenosis or peripheral vascular
CC disease. They may also be used in the treatment of diseases associated
CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
CC The invention specifically excludes proteins with the exact amino acid
CC sequences of GenBank Accession No. CAA10005_1 and X75926, and the nucleic
CC acid with the exact sequence as GenBank Accession No: AJ012376_1. The
CC present sequence represents a mutant human ABC1 cholesterol transporter
CC associated with an altered cholesterol level and therefore an altered
CC risk of cardiovascular disease.
CC Note: The present sequence is not shown in the specification, but is
CC derived from the native human ABC1 shown on pages 152-157.

SQ Sequence 2143 AA:

Query	Match	100.0%	Score 1525;	DB 21;	Length 2143;
Best Local Similarity	100.0%	Pred. No. 4	7e-143;		
Matches	284;	Mismatches	0;	Indels 0;	Gaps 0;

Qy 1 FGKPSLELQPMMNEQYTFVSNDAPEDGTGLELLNAITKDGFGTRCMESNPIPTPQO 60

Db 1371 FGKPSLELQPMMNEQYTFVSNDAPEDGTGLELLNAITKDGFGTRCMESNPIPTPQO 1430

Qy 61 AGEEENTTAPYQTIMDLFQNGNTMQNSPACQCSSDKKKMLPVCGAGLPPPKRK 120

Db 1431 AGEEENTTAPYQTIMDLFQNGNTMQNSPACQCSSDKKKMLPVCGAGLPPPKRK 1490

Qy 121 QNTADILQDLTGRNSDLYLKTYVQIASSLKNNIWNFRRGGFSLGVSTQALPPSQE 180

Db 1491 QNTADILQDLTGRNSDLYLKTYVQIASSLKNNIWNFRRGGFSLGVSTQALPPSQE 1550

Qy 181 VNDAIQMKHKLAKDSADRELNSLGFMFTGLDTANVKWFANKGWAISSEPLNVIN 240

PF	15-MAR-2000;	2000WO-TB00552.	Qy	121	QNTADILDLTGRNISDWLVKTVVQITAKSLKNKIVWNEFRYGGFSLGVNTQALPPSQE	180
XX			Db	1490	QNTADILDLTGRNISDWLVKTVVQITAKSLKNKIVWNEFRYGGFSLGVNTQALPPSQE	1549
PR	15-MAR-1999;	99US-0124702.	Qy	181	VNDAIKQMKHKLAKDSSADREFLNSLGRMTGLDTRNWKVNFKWNNRKGWHAISSFLNVIN	240
PR	08-JUN-1999;	99US-0138048.	Db	1550	VNDAIKQMKHKLAKDSSADREFLNSLGRMTGLDTRNWKVNFKWNNRKGWHAISSFLNVIN	1609
PR	17-JUN-1999;	99US-0139600.				
PR	01-JUN-1999;	99US-0151977.				
XX						
PA	(UYBR-)	UNIV BRITISH COLUMBIA.				
PA	(XENO)	XENON BIORESEARCH INC.				
XX						
P1	Hayden MR,	Wilson AR,	PS	241	NATLRLNQLQGENPSHYGTAFNHPLNTKQOLSEVALMTSVD	284
XX			DB	1610	NATLRLNQLQGENPSHYGTAFNHPLNTKQOLSEVALMTSVD	1653
DR	WPI;	2000-587528/55.				
XX						
XX						
PT	New ABC1 polypeptide is useful for treating diseases associated with		RESULT 5	AAB38082		
PT	ABC1 biological activity, e.g. Alzheimer's disease, Huntington's		ID	AAB38082 standard; Protein; 2261 AA.		
PT	disease and cancer -		XX			
XX			AC	AAB38082;		
PS	Examples; Page -; 229pp; English.		XX	29-JAN-2001 (first entry)		
XX			DT			
CC	The invention relates to the human ABC1 cholesterol transporter protein (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is a member of the ATP-binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease (TD) and familial HDL deficiency (FHA). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good cholesterol") in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease.		XX	Human ABC1 cholesterol transporter.		
CC	Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer. The invention specifically excludes proteins with the exact amino acid sequences of GenBank Accession No: CA010005_1 and X75926, and the nucleic acid with the exact sequence as GenBank Accession No: A012376_1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered risk of cardiovascular disease.		DE			
CC	Note: The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on pages 152-157.		XX	XX		
CC	Sequence 2260 AA;		CC	The invention relates to the human ABC1 cholesterol transporter protein (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is a member of the ATP-binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease (TD) and familial HDL deficiency (FHA). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good cholesterol") in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular		
SQ	Query Match 100.0%; Score 1525; DB 21; Length 2260;		CC			
	Best Local Similarity 100.0%; Pred. No. 5e-143;		CC			
	Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;		CC			
Qy	1 FGKVPSELEQPMWNEQVTFVSNDAPEDTGTLNLNLTKDGFGTGTCMEGNIPDPTPCQ	60	CC			
Db	1370 FGKVPSELEQPMWNEQVTFVSNDAPEDTGTLNLNLTKDGFGTGTCMEGNIPDPTPCQ	1429	CC			
Qy	61 AGEERWTAPVPTIMDLFQNGNWTMONPSACQCSSDIIKIKMLPVCPGGAGLPPPQRK	120	CC			
Db	1430 AGEERWTAPVPTIMDLFQNGNWTMONPSACQCSSDIIKIKMLPVCPGGAGLPPPQRK	1489	CC			

CC disease, coronary restenosis, and peripheral vascular disease.
 CC Conversely, a high level of HDL has protective effects against
 CC cardiovascular disease. The invention provides genetic constructs and
 CC transgenic cells and non-human animals comprising human ABC1 nucleic
 CC acids, and methods of gene therapy for the treatment or prevention of
 CC cardiovascular disease comprising the administration of an expression
 CC vector encoding ABC1 or an active fragment thereof. The invention also
 CC encompasses compounds which mimic ABC1 activity, compounds which
 CC stimulate ABC1 expression and methods of screening for such compounds.
 CC It further relates to methods for determining whether a patient has an
 CC increased risk for cardiovascular disease due to polymorphisms in the
 CC ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat
 CC or prevent cardiovascular disease, especially coronary artery disease,
 CC cerebrovascular disease, coronary restenosis or peripheral vascular
 CC disease. They may also be used in the treatment of diseases associated
 CC with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick
 CC disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
 CC The invention specifically excludes proteins with the exact amino acid
 CC sequences of GenBank Accession No.: CA10005_1 and X75926, and the nucleic
 CC acid with the exact sequence as GenBank Accession No.: A012376_1. The
 CC present sequence represents the human ABC1 cholesterol transporter.
 XX Sequence 2261 AA;

Query Match 100.0%; Score 1525; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 5e-143;
 Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FGKPSLEQPWNYNEQYTFVSNDAPEDTGTLELLNALTKDGFGRCMEGNPIPDTPCQ 60
 Db 1371 FGKPSLEQPWNYNEQYTFVSNDAPEDTGTLELLNALTKDGFGRCMENPIPDTPCQ 1430

Qy 61 AGEEWNTAPVPTIMDLFQNQWMTMONPSPACQCSSDKIKRMLPVCPGAGGLPPQRK 120
 Db 1431 AGEEWNTAPVPTIMDLFQNQWMTMONPSPACQCSSDKIKRMLPVCPGAGGLPPQRK 1490

Qy 121 QNTADILQDGNSIDYLKTYVQTLIAKSLRNKINWNEFRYGGFSLGVSNTOALPPSQE 180
 Db 1491 QNTADILQDGNSIDYLKTYVQTLIAKSLRNKINWNEFRYGGFSLGVSNTOALPPSQE 1550

Qy 181 VNDAIKQMKHKHLAKDSSADRFNSLGRFTMGLDTRNNYKWFNNKGMAISSFLNVIN 240
 Db 1551 VNDAIKQMKHKHLAKDSSADRFNSLGRFTMGLDTRNNYKWFNNKGMAISSFLNVIN 1610

Qy 241 NATLRAHQKGENPSHYGITATNHPLNLTKQSLSEVALMTTSVD 284
 Db 1611 NATLRAHQKGENPSHYGITATNHPLNLTKQSLSEVALMTTSVD 1654

RESULT 6
AAB38105
ID AAB38105 standard; Protein; 2261 AA.

AC AAB38105;

XX DT 29-JAN-2001 (first entry)

XX DE Human ABC1 cholesterol transporter TD-2 mutant protein (Q597R).

XX KW Human ABC1 transporter; chromosome 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
XX OS Homo sapiens.

XX PN WO20055318-A2.

XX PD 21-SEP-2000.
 XX PR 15-MAR-2000; 2000WO-B00532.
 XX PR 15-MAR-1999; 99US-0124702.
 XX PR 08-JUN-1999; 99US-0138048.
 XX PR 17-JUN-1999; 99US-0139600.
 XX PR 01-SEP-1999; 99US-0151977.
 XX PA (UYBR-) UNIV BRITISH COLUMBIA.
 XX PA (XENO-) XENON BIORESEARCH INC.
 XX PI Hayden MR, Wilson AR, Pimstone SN;
 XX DR 2000-587528/55.
 XX DR N-PSDB; AAC69386.

New ABC1 polypeptide is useful for treating diseases associated with ABC1 biological activity, e.g. Alzheimer's disease, Huntington's disease and cancer -

XX PS Examples; Page -; 229pp; English.

XX The invention relates to the human ABC1 cholesterol transporter protein (C69120) which encode it. ABC1 is a member of the ATP binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease (TD) and familial HDL deficiency (FHA). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FHA is inherited as an autosomal dominant trait. Low levels of HDL ("good cholesterol") in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease. Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer. The invention specifically excludes proteins with the exact amino acid sequences of GenBank Accession No.: CA10005_1 and X75926, and the nucleic acid with the exact sequence as GenBank Accession No.: A012376_1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered risk of cardiovascular disease.

Note: The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on pages 152-157.

XX Sequence 2261 AA;

XX Query Match 100.0%; Score 1525; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 5e-143;
 Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FGKPSLEQPWNYNEQYTFVSNDAPEDTGTLELLNALTKDGFGRCMEGNPIPDTPCQ 60
 Db 1371 FGKPSLEQPWNYNEQYTFVSNDAPEDTGTLELLNALTKDGFGRCMEGNPIPDTPCQ 1430

Qy 61 AGEEWNTAPVPTIMDLFQNQWMTMONPSPACQCSSDKIKRMLPVCPGAGGLPPQRK 120
 Db 1431 AGEEWNTAPVPTIMDLFQNQWMTMONPSPACQCSSDKIKRMLPVCPGAGGLPPQRK 1490

Qy 121 QNTADILQDGNSIDYLKTYVQTLIAKSLRNKINWNEFRYGGFSLGVSNTOALPPSQE 180
 Db 1491 QNTADILQDGNSIDYLKTYVQTLIAKSLRNKINWNEFRYGGFSLGVSNTOALPPSQE 1550

Qy 181 VNDAIKQMKHKHLAKDSSADRFNSLGRFTMGLDTRNNYKWFNNKGMAISSFLNVIN 240
 Db 1551 VNDAIKQMKHKHLAKDSSADRFNSLGRFTMGLDTRNNYKWFNNKGMAISSFLNVIN 1610

Qy 241 NATLRAHQKGENPSHYGITATNHPLNLTKQSLSEVALMTTSVD 284
 Db 1611 NATLRAHQKGENPSHYGITATNHPLNLTKQSLSEVALMTTSVD 1654

		RESULT	7
Db	1431	AGEEEWTAPVQTIMDLFQGNWTHMONSPACQSSDKLKMLPVCPGAGGLPPQRK	1490
Qy	121	QNTADILQDGTGRNISDYLKVITYVQTIAKSLKNIKIVNNEFRYGGFLGVSNTQALPSSQE	180
Db	1491	QNTADILQDGTGRNISDYLKVITYVQTIAKSLKNIKIVNNEFRYGGFLGVSNTQALPSSQE	1550
Qy	181	VNDAIKQMKKHLKAKDSADRFNLNSLGRFMGTLDRTRNNVKWENNGWHAISSEFLNVIN	240
Db	1551	VNDAIKQMKKHLKAKDSADRFNLNSLGRFMGTLDRTRNNVKWENNGWHAISSEFLNVIN	1610
Qy	241	NATLRANLQKGENPSHGTCTANHPLNLTKQOLSEVALMTTSVD	284
Db	1611	NATLRANLQKGENPSHGTCTA FNHPLNLTKQOLSEVALMTTSVD	1654
		Human ABC1 transporter mutant, R219K.	
	XX	ID AAB38109 standard; protein: 2261 AA.	
	XX	AC AAB38109;	
	XX	DT 29-JAN-2001 (first entry)	
	DE		
	XX		
	KW	Human ABC1 cholesterol transporter; chromosome 9q31;	
	KW	ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;	
	KW	Tangier disease; TD; familial HDL deficiency; FHD; Polymorphism;	
	KW	cerebrovascular disease; coronary artery disease; coronary restenosis;	
	KW	cerebrovascular disease; coronary artery disease; coronary disease;	
	KW	Alzheimer's disease; Niemann-Pick disease; Huntington's disease;	
	KW	X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;	
	KW	prognosis; prophylaxis; drug screening; transgenic animal; mutant;	
	KW	mutant.	
	XX		
	OS	Homo sapiens.	
	XX		
	PN	WO200055318-A2.	
	XX		
	PD	21-SEP-2000.	
	XX		
	XX	15-MAR-2000; 2000WO-1B00532.	
	XX		
	PR	15-MAR-1999; 99US-0124702.	
	PR	08-JUN-1999; 99US-0138448.	
	PR	17-JUN-1999; 99US-0139600.	
	PR	01-SEP-1999; 99US-0151977.	
	XX	(UYBR-) UNIV BRITISH COLUMBIA.	
	PA	(XENO-) XENON BIORESEARCH INC.	
	XX		
	PI	Hayden MR, Wilson AR, Pimstone SN;	
	XX		
	DR	WPI: 2000-587528/55.	
	XX		
PT	New ABC1 polypeptide is useful for treating diseases associated with ABC1 biological activity, e.g. Alzheimer's disease, Huntington's disease and cancer.		
PT	Examples: Page -; 229pp; English.		
PS			
XX	The invention relates to the human ABC1 cholesterol transporter protein CC (B3802) and to nucleic acid sequences (C6920) which encode it. ABC1 is CC a member of the ATP-binding cassette (ABC transporter) superfamily of CC proteins, and plays a crucial role in cholesterol transport, particularly CC intracellular cholesterol trafficking in monocytes and fibroblasts, being CC involved in cholesterol efflux from the cell. The gene encoding ABC1 is CC located on chromosome 9q31, and mutations in this gene are associated CC with two genetic HDL (high density lipoprotein) deficiency disorders, CC Tangier disease (TD) and familial HDL deficiency (FHD). These diseases CC are distinguishable in that TD is an autosomal recessive disorder, while CC FHD is inherited as an autosomal dominant trait. Low levels of HDL ("giga- CC PS		

cc cholesterol") in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease.	cc Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.
cc The invention specifically excludes proteins with the exact amino acid sequences of Genbank Accession No.: CAA10005_1 and X75926, and the nucleic acid with the exact sequence as GenBank Accession No.: AJ012316_1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered risk of cardiovascular disease.	cc Note: The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on pages 152-157.
xx sequence 2261 AA;	xx
Query Match 100.0%; Score 1525; DB 21; Length 2261; Best Local Similarity 100.0%; Pred. No. 5e-143; Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0	Query 1 FGKVPSELQPMWNEQQTFVSNDAPEDTGTLLENNALTKDGFETRCMEGNPIPDTPCQ 60 Db 1371 FGKVPSELQPMWNEQQTFVSNDAPEDTGTLLENNALTKDGFETRCMEGNPIPDTPCQ 1430
Qy 61 AGEEWEWTAPVPTIMDLFQNGNTWMQNPSPACQCSSDKIKKMLPVCPPGAGGLPPQRK 120 Db 1431 AGEEWEWTAPVPTIMDLFQNGNTWMQNPSPACQCSSDKIKKMLPVCPPGAGGLPPQRK 1490	Qy 121 QNTADILQLDTGRNISDYLKVTVQIATKSLNKIWNFRRGGFSLGVSNTQALPSQE 180 Db 1491 QNTADILQLDTGRNISDYLKVTVQIATKSLNKIWNFRRGGFSLGVSNTQALPSQE 1550
Qy 181 VNDAIKQMKKKHLKAQDSSADRFLNLSLGREMGFLDTRNNKVYWNENKGWHAISSFLNVIN 240 Db 1551 VNDAIKQMKKKHLKAQDSSADRFLNLSLGREMGFLDTRNNKVYWNENKGWHAISSFLNVIN 1610	Qy 241 NAILRANLQGENPNSHYGITAIFNHPLNLTQOOLSEVALMTTSVD 284 Db 1611 NAILRANLQGENPNSHYGITAIFNHPLNLTQOOLSEVALMTTSVD 1654
RESULT 8 AAB38110 ID AAB38110 standard; Protein; 2261 AA. XX DE Human ABC1 cholesterol transporter mutant, V399A. XX DE Human ABC1 cholesterol transporter; chromosome 9q31; XX Human ATP-binding cassette; HDL deficiency disorder; high density lipoprotein; KW Tangier disease; TD; familial HDL deficiency; FHD; polymorphism; KW Cardiovascular disease; coronary artery disease; coronary restenosis; KW Cerebrovascular disease; peripheral vascular disease; KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease; KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis; KW Prognosis; prophylaxis; drug screening; transgenic animal; mutant;	XX DE Human ABC1 cholesterol transporter mutant, V399A. XX DE Human ABC1 cholesterol transporter; chromosome 9q31; XX Human ATP-binding cassette; HDL deficiency disorder; high density lipoprotein; KW Tangier disease; TD; familial HDL deficiency; FHD; polymorphism; KW Cardiovascular disease; coronary artery disease; coronary restenosis; KW Cerebrovascular disease; peripheral vascular disease; KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease; KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;

KW	muttein.	1 FGKPSLEQPMWNEQYTFVSNDAPEDTGTLLELNALNTKDPGFTRCMEGNP1PDTPCQ 60
XX	Homo sapiens .	Db 1371 FGKPSLEQPMWNEQYTFVSNDAPEDTGTLLELNALNTKDPGFTRCMEGNP1PDTPCQ 1430
XX	WO200055318-A2 .	QY 61 AGEEEMWTAPVPTMDLFQNGWTMNPSACQCSSDKIKKMLPVCPAGGLPPORK 120
XX	21-SEP-2000 .	Db 1431 AGEEMWTAPVPTMDLFQNGWTMNPSACQCSSDKIKKMLPVCPAGGLPPORK 1490
XX	15-MAR-2000 ; 2000WO-1B00532 .	QY 121 QNTADILQDLTGRNISDLYKVTVQTLAKSLKNKIKWNEFRYGGFSLGYSNTQALPPSQE 180
PR	15-MAR-1999 ; 99US-0124702 .	Db 1491 QNTADILQDLTGRNISDLYKVTVQTLAKSLKNKIKWNEFRYGGFSLGYSNTQALPPSQE 1550
PR	08-JUN-1999 ; 99US-0138048 .	QY 181 VNDAKQMKKKHLKIAKDSADDREPLNSLGRFMGDLDRNNVYKWFENNGNHAISSEFLNVIN 240
PR	17-JUN-1999 ; 99US-0138060 .	Db 1551 VNDAKQMKKKHLKIAKDSADDREPLNSLGRFMGDLDRNNVYKWFENNGNHAISSEFLNVIN 1610
PR	01-SEP-1999 ; 99US-0151977 .	QY 241 NATRLANLQKGENPSHYGTTAEPNHLNLTKQOLSEVALMTTSVD 284
PA	(UYBR-) UNIV BRITISH COLUMBIA .	Db 1611 NAILRNLQRGENPSHYGTTAEPNHLNLTKQOLSEVALMTTSVD 1654
PA	(XENO-) XENON BIORESEARCH INC .	
XX	Hayden MR , Wilson AR , Pimstone SN ;	
XX	WPT ; 2000-587528/55 .	RESULT 9 AAB38111 ID AAB38111 standard; protein: 2261 AA .
XX	PT	XX XX AC AAB38111;
XX	PT	XX DT 29-JAN-2001 (first entry)
XX	PT	XX DE Human ABC1 cholesterol transporter mutant, V771M .
XX	CC	XX DE Human ABC1 cholesterol transporter; chromosome 9q31; HDL deficiency disorder; high density lipoprotein ATP-binding cassette; HDL deficiency disorder; high density lipoprotein Tangier disease; TD; familial HDL deficiency; FHD; polymorphism; cardiovascular disease; coronary artery disease; coronary restenosis; cerebrovascular disease; peripheral vascular disease; Alzheimer's disease; Niemann-Pick disease; Huntington's disease; Kwang disease; adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis; prognosis; prophylaxis; drug screening; transgenic animal; mutant; mutinein.
CC	CC	XX KW Homo sapiens .
CC	CC	XX WO200055318-A2 .
CC	CC	XX PD 21-SEP-2000 .
CC	CC	XX PF 15-MAR-2000 ; 2000WO-1B00532 .
CC	CC	XX PR 15-MAR-1999 ; 99US-0124702 .
CC	CC	XX PR 08-JUN-1999 ; 99US-0138048 .
CC	CC	XX PR 17-JUN-1999 ; 99US-0138600 .
CC	CC	XX PR 01-SEP-1999 ; 99US-0151977 .
CC	CC	XX DR 1551 VNDAKQMKKKHLKIAKDSADDREPLNSLGRFMGDLDRNNVYKWFENNGNHAISSEFLNVIN 1610
CC	CC	XX PA (UYBR-) UNIV BRITISH COLUMBIA .
CC	CC	XX PA (XENO-) XENON BIORESEARCH INC .
CC	CC	XX Hayden MR , Wilson AR , Pimstone SN ;
CC	CC	XX WPT ; 2000-587528/55 .
CC	CC	XX New ABC1 polypeptide is useful for treating diseases associated with ABC1 biological activity, e.g. Alzheimer's disease, Huntington's disease and cancer -
CC	CC	XX Examples ; Page - ; 229pp; English .
CC	CC	XX New ABC1 polypeptide is useful for treating diseases associated with ABC1 biological activity, e.g. Alzheimer's disease, Huntington's disease and cancer -
CC	CC	XX Examples ; Page - ; 229pp; English .
CC	CC	The invention relates to the human ABC1 cholesterol transporter protein (B38082) and to nucleic acid sequences (C99120) which encode it. ABC1 is a member of the ATP-binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q11, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease (TD) and familial HDL deficiency (FHD). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FHD is inherited as an autosomal dominant trait. Low levels of cardiovascular disease, particularly coronary artery disease, peripheral vascular disease, coronary restenosis, and peripheral vascular disease. Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods or gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer. The invention specifically excludes proteins with the exact amino acid sequences of Genbank Accession No.: CAA1005_1 and X75926, and the nucleic acid with the exact sequence as Genbank Accession No: AJ012376_1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered risk of cardiovascular disease.
CC	CC	Note: The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on pages 152-157.
CC	CC	XX Sequence 2261 AA ;
CC	CC	CC Best Local Similarity 100.0% ; Score 1525; DB 21; Length 2261;
CC	CC	CC Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL ('high density lipoprotein) deficiency disorders, Tangier disease (TD) and familial HDL deficiency (FHD). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FHD is inherited as an autosomal dominant trait. Low levels of HDL ('good cholesterol') in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease.

Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.

The invention specifically excludes proteins with the exact amino acid sequence of Genbank Accession No: CAA0005.1 and X75926, and the nucleic acid with the exact sequence as GenBank Accession No: AAI012376.1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered risk of cardiovascular disease.

Note: The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on Pages 152-157.

SQ Sequence 2261 AA;

Query Match 100.0%; Score 1525; DB 21; Length 2261;
Best Local Similarity 100.0%; Pred. No. 5e-143; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FGKYSLEQPMYNEQTYFSNDAPEDTLELLNLTQDPFGTRCMEGAPIDTPCQ	60
Db 1371 FGKYSLEQPMYNEQTYFSNDAPEDTLELLNLTQDPFGTRCMEGAPIDTPCQ	1430
Qy 61 AGEBWMTAPQTIMBLFQNQNTMQNPSPACQSSDKTKMLPVGCPAGGLPPQQRK	120
Db 1431 AGEEWMTAPQTIMBLFQNQNTMQNPSPACQSSDKTKMLPVGCPAGGLPPQQRK	1490
Qy 121 QNTADILQDTGRNISDYLTKVYVOTIASKLNKTIIWNEFRYGGFSLGVNTQALPPSQE	180
Db 1491 QNTADILQDTGRNISDYLTKVYVOTIASKLNKTIIWNEFRYGGFSLGVNTQALPPSQE	1550
Qy 181 VNDAIKQKHKHLAKDSSADREIINSLGRTMGTDRNNKVWNENNKGWHAISSFLNVIN	240
Db 1551 VNDAIKQKHKHLAKDSSADREIFLNSLGRTMGTDRNNKVWNENNKGWHAISSFLNVIN	1610
Qy 241 NAIILRANLQKGENPNSHYGIGTAFNHPLNLTQOOLSEVALMTSVD	284
Db 1611 NAIILRANLQKGENPNSHYGIGTAFNHPLNLTQOOLSEVALMTSVD	1654

RESULT 10
ID AAB38112 standard; Protein: 2261 AA.
XX AAB38112:
AC XX
DT 29-JAN-2001 (first entry)
DE Human ABC1 cholesterol transporter mutant, T74P.

XX Human ABC1 cholesterol transporter; Chromosome: 9q31;
KW ATP-binding cassette; HDL deficiency disorder; high density lipoprotein;
KW Tangier disease; TD; familial HDL deficiency; FHD; Polymorphism;

KW cardiovascular disease; coronary artery disease; coronary restenosis;
KW cerebrovascular disease; peripheral vascular disease;
KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
KW mutant.
XX Homo sapiens.
OS XX
WO200055318-A2.
PN XX
PD 21-SEP-2000.
XX XX
PF 15-MAR-2000; 2000WO-IB00532.
PR XX
PA (UBR) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
XX PR 15-MAR-1999; 99US-0124702.
PR 08-JUN-1999; 99US-0138048.
PR 17-JUN-1999; 99US-0139600.
PR 01-SEP-1999; 99US-0151977.
XX PR 17-JUN-1999; 99US-0151977.
XX PA (UBR) UNIV BRITISH COLUMBIA.
PA (XENO-) XENON BIORESEARCH INC.
XX PI Hayden MR, Wilson AR, Pimstone SN;
WPt; 2000-587528/55.
PT New ABC1 polypeptide is useful for treating diseases associated with ABC1 biological activity, e.g. Alzheimer's disease, Huntington's disease and cancer.
XX PT
PT Examples; Page - ; 229pp; English.
XX SQ Examples; Page - ; 229pp; English.
XX CC The invention relates to the human ABC1 cholesterol transporter protein (C69120) which encode it. ABC1 is a member of the ATP-binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease (TD) and familial HDL deficiency (FHD). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FHD is inherited as an autosomal dominant trait. Low levels of HDL ('good cholesterol') in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease. Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer. The invention specifically excludes proteins with the exact amino acid sequences of Genbank Accession No: CAA0005.1 and X75926, and the nucleic acid with the exact sequence as GenBank Accession No: AAI012376.1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered risk of cardiovascular disease.
Note: The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on Pages 152-157.

Sequence 2261 AA;

DE	Human ABC1 cholesterol transporter mutant, E117D.	CC	risk of cardiovascular disease.
XX	Human ABC1 cholesterol transporter; chromosome 9q31;	CC	The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on pages 152-157.
KW	ATP binding cassette; HDL deficiency disorder; high density lipoprotein;	CC	
KW	Tangier disease; TD; familial HDL deficiency; FHD; polymorphism;	XX	
KW	cardiovascular disease; coronary artery disease; coronary restenosis;	SQ	
KW	cerebrovascular disease; Peripheral vascular disease;	Sequence	2261 AA;
KW	Alzheimer's disease; Niemann-Pick disease; Huntington's disease;	Query Match	100 0%; Score 1525; DB 21; Length 2261;
KW	prognosis; prophylaxis; drug screening; transgenic animal; mutant;	Best Local Similarity	100 0%; Pred. No. 5e-143;
KW	mutant.	Matches	0; Missmatches 0; Indels 0; Gaps 0;
XX	Homo sapiens.	Matches 284; Conservative 0;	
XX	WO2005518-A2.	QY	1 FCKYPSLELQPMWNEQTYTVNSNDAPEDGTLELNALTKDGFTRCMGNPIOTPQQ 60
XX	PD 21-SEP-2000.	Db	1371 FSKYPSLELQPMWNEQTYTVNSNDAPEDGTLELNALTKDGFTRCMGNPIOTPQQ 1430
XX	PF 15-MAR-2000; 2000WO-IB00532.	QY	61 AGEEEWTPYPTIMDFQNGNTMONGNTPYQTLAKSLKRNKIWNFERYGFSLGVSNTQALPPQE 120
XX	PR 15-MAR-1999; 99US-0124702.	Db	1411 AGEEEWTPYPTIMDFQNGNTMONGNTPYQTLAKSLKRNKIWNFERYGFSLGVSNTQALPPQE 1490
XX	PR 08-JUN-1999; 99US-0138048.	QY	121 QNTADILQDLTGRRNISDLYLKTYQTLAKSLKRNKIWNFERYGFSLGVSNTQALPPQE 180
XX	PR 01-SEP-1999; 99US-0139600.	Db	1491 QNTADILQDLTGRRNISDLYLKTYQTLAKSLKRNKIWNFERYGFSLGVSNTQALPPQE 1550
XX	PR 01-SEP-1999; 99US-0151977.	QY	181 VNDAIKOMKKLKLAKSDADEFNLSGREMGTGLDTRNWKVWNNGWHAISSTFLNVIN 240
PA	(UYBR-) UNIV BRITISH COLUMBIA.	Db	1551 VNDAIKOMKKLKLAKSDADEFNLSGREMGTGLDTRNWKVWNNGWHAISSTFLNVIN 1610
PA	(XENO-) XENON BIORESEARCH INC.	QY	241 NAILRNLQKGENPSHYGTTAFNHLPLNLTKOOLSEVALMTTSVD 284
XX	PI Hayden MR, Wilson AR, Pimstone SN;	Db	1611 NAILRNLQKGENPSHYGTTAFNHLPLNLTKOOLSEVALMTTSVD 1654
DR	WPI, 2000-587528/55.	RESULT 13	
XX	PT New ABC1 polypeptide is useful for treating diseases associated with ABC1 biological activity, e.g. Alzheimer's disease, Huntington's disease and cancer -	AAB38116	
PT	PT XX	ID AAB38116 standard; protein: 2261 AA.	
PT	PT XX	XX AAB38116;	
PS	PS Examples; Page -; 229pp; English.	AC	
XX	XX DT 29-JAN-2001 (first entry)	XX	
CC	The invention relates to the human ABC1 cholesterol transporter protein (C69120) and to nucleic acid sequences (C69120) which encode it. ABC1 is a member of the ATP-binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease (TD) and familial HDL deficiency (FH). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FH is inherited as an autosomal dominant trait. Low levels of HDL ("good cholesterol") in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease.	DE	Human ABC1 cholesterol transporter mutant, S173IC.
CC	Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds.	XX	Human ABC1 cholesterol transporter; chromosome 9q31; high density lipoprotein; ATP-binding cassette; HDL deficiency disorder; FHD; polymorphism; Tangier disease; TD; familial HDL deficiency; FHD; polymorphism; cardiovascular disease; coronary artery disease; coronary restenosis; cerebrovascular disease; peripheral vascular disease; Alzheimer's disease; Niemann-Pick disease; Huntington's disease; X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis; prognosis; prophylaxis; drug screening; transgenic animal; mutant; mucolein.
CC	It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, and the like.	XX	Homo sapiens.
CC	The invention specifically excludes proteins with the exact amino acid sequences of Genbank Accession No.: CAA0005.1 and X75926, and the nucleic acid with the exact sequence as Genbank Accession No.: AY012376.1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered	OS	
CC	expression and methods of screening for such compounds.	XX	XX WO200055318-A2.
CC	It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, and the like.	XX	XX PR 21-SEP-2000.
CC	The invention specifically excludes proteins with the exact amino acid sequences of Genbank Accession No.: CAA0005.1 and X75926, and the nucleic acid with the exact sequence as Genbank Accession No.: AY012376.1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered	XX	XX PR 15-MAR-2000; 2000WO-1B00532.
CC	expression and methods of screening for such compounds.	XX	XX PR 15-MAR-1999; 99US-0124702.
CC	It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, and the like.	XX	XX PR 08-JUN-1999; 99US-0138048.
CC	The invention specifically excludes proteins with the exact amino acid sequences of Genbank Accession No.: CAA0005.1 and X75926, and the nucleic acid with the exact sequence as Genbank Accession No.: AY012376.1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered	XX	XX PR 17-JUN-1999; 99US-0139610.
CC	expression and methods of screening for such compounds.	XX	XX PR 01-SEP-1999; 99US-0151977.
CC	It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, and the like.	XX	XX PR (UBR-) UNIV BRITISH COLUMBIA.
CC	The invention specifically excludes proteins with the exact amino acid sequences of Genbank Accession No.: CAA0005.1 and X75926, and the nucleic acid with the exact sequence as Genbank Accession No.: AY012376.1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered	XX	XX PA (XENO-) XENON BIOPRESEARCH INC.
CC	expression and methods of screening for such compounds.	XX	XX PI Hayden MR, Wilson AR, Pimstone SN;
CC	It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, and the like.	XX	XX DR WPT; 2000-587528/55.
CC	The invention specifically excludes proteins with the exact amino acid sequences of Genbank Accession No.: CAA0005.1 and X75926, and the nucleic acid with the exact sequence as Genbank Accession No.: AY012376.1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered	XX	XX PT New ABC1 polypeptide is useful for treating diseases associated with ABC1 biological activity, e.g. Alzheimer's disease, Huntington's disease, Huntingdon's disease, Niemann-Pick disease, Huntington's disease, and the like.

PT disease and cancer -
 XX Examples; Page - ; 229pp; English.

CC The invention relates to the human ABC1 cholesterol transporter protein (B38082) and to nucleic acid sequences (C69120) which encode it. ABC1 is a member of the ATP-binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease ("TD" or "Tangier disease") and familial HDL deficiency ("FHAD"). These diseases are distinguishable in that TD is an autosomal recessive disorder, while FHAD is inherited as an autosomal dominant trait. Low levels of HDL ("good cholesterol") in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease. Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer. The invention specifically excludes proteins with the exact amino acid sequences of GenBank Accession No.: CAA10005_1 and X7526_1, and the nucleic acid with the exact sequence as GenBank Accession No.: AJ012376_1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered risk of cardiovascular disease.

CC Note: The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on pages 152-157.

XX Sequence 2261 AA;

Query Match 100.0%; Score 1525; DB 21; Length 2261;
 Best Local Similarity 100.0%; Pred. No. 5e-143;
 Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1 FGKPSLEQPKWNEQTFVSNDAPEDTGELLEUNALATDGFSTTRCMGNP1PDTCQ 60
 Db 1371 FGKPSLEQPKWNEQTFVSNDAPEDTGELLEUNALATDGFSTTRCMGNP1PDTCQ 1430
 Qy 61 AGEEEWTATPVPTMDLFQNGNWTMONPSACQCSSSDKKMFLPVCPAGGLPPORK 120
 Db 1431 AGEEEWTATPVPTMDLFQNGNWTMONPSACQCSSSDKKMFLPVCPAGGLPPORK 1490
 Qy 121 QNTADLQDTGRNISDLYLVKTYVOLAKSKLNK1WNVFRRYGGFSLGVSNTQALPPSQE 180
 Db 1491 QNTADLQDTGRNISDLYLVKTYVQIAKSLNK1WNVFRRYGGFSLGVSNTQALPPSQE 1550
 Qy 181 VNDAIKQMKKKHLKLAQDSSAADRFLNSLGRMTGLDTRNIVKWFNRNKGHIAISSPLVNVN 240
 Db 1551 VNDAIKQMKKKHLKLAQDSSAADRFLNSLGRMTGLDTRNIVKWFNRNKGHIAISSFLVNVN 1610
 Qy 241 NAILRNLQKGENPSHYGITAENHPLNLTQKQOLSEVALMTTSVD 284
 Db 1611 NAILRNLQKGENPSHYGITAENHPLNLTQKQOLSEVALMTTSVD 1654

RESULT 14
 AAB38117
 ID AAB38117 standard; Protein; 2261 AA.

XX AC AAB38117;
 XX AC 29-JAN-2001 (first entry)
 XX DT DE Human ABC1 cholesterol transporter mutant, 1883M.
 XX DE Human ABC1 cholesterol transporter; chromosome 9q31;
 KW Human ABC1 cholesterol transporter; HDL deficiency disorder; high density lipoprotein;
 KW ATP-binding cassette; HDL deficiency disorder; familial HDL deficiency; FHAD; polymorphism;
 KW cardiovascular disease; coronary artery disease; coronary vascular disease; coronary restenosis;
 KW cerebrovascular disease; peripheral vascular disease;
 KW Alzheimer's disease; Niemann-Pick disease; Huntington's disease;
 KW X-linked adrenoleukodystrophy; cancer; gene therapy; genetic diagnosis;
 KW prognosis; prophylaxis; drug screening; transgenic animal; mutant;
 KW mutein.
 XX OS Homo sapiens.
 XX PN WO2000055318-A2.
 XX PD 21-SEP-2000.
 XX PF 15-MAR-2000; 2000WO-IB00532.
 XX PR 15-MAR-1999; 99US-0124702.
 XX PR 08-JUN-1999; 99US-0138048.
 XX PR 17-JUN-1999; 99US-0139600.
 XX PR 01-SEP-1999; 99US-0151977.
 XX PA UYBR) UNIV BRITISH COLUMBIA.
 XX PA (XENO) XENON BIORESEARCH INC.
 XX PI Hayden MR, Wilson AR, Pimstone SN;
 XX DR 2000-587528/55.
 XX PT New ABC1 polypeptide is useful for treating diseases associated with ABC1 biological activity, e.g. Alzheimer's disease, Huntington's disease and cancer -
 XX PR
 XX PS Examples; Page - ; 229pp; English.

XX The invention relates to the human ABC1 cholesterol transporter protein (C69120) which encode it. ABC1 is a member of the ATP-binding cassette (ABC transporter) superfamily of proteins, and plays a crucial role in cholesterol transport, particularly intracellular cholesterol trafficking in monocytes and fibroblasts, being involved in cholesterol efflux from the cell. The gene encoding ABC1 is located on chromosome 9q31, and mutations in this gene are associated with two genetic HDL (high density lipoprotein) deficiency disorders, Tangier disease ("TD" or "Tangier disease") and familial HDL deficiency ("FHAD"). These diseases are distinguishable in that "TD" is an autosomal recessive disorder, while "FHAD" is inherited as an autosomal dominant trait. Low levels of HDL ("good cholesterol"), in the blood correlate with a high risk of cardiovascular disease, particularly coronary artery disease, but also cerebrovascular disease, coronary restenosis, and peripheral vascular disease. Conversely, a high level of HDL has protective effects against cardiovascular disease. The invention provides genetic constructs and transgenic cells and non-human animals comprising human ABC1 nucleic acids, and methods of gene therapy for the treatment or prevention of cardiovascular disease comprising the administration of an expression vector encoding ABC1 or an active fragment thereof. The invention also encompasses compounds which mimic ABC1 activity, compounds which stimulate ABC1 expression and methods of screening for such compounds. It further relates to methods for determining whether a patient has an increased risk for cardiovascular disease due to polymorphisms in the ABC1 gene. Human ABC1 proteins and nucleotides can be used to treat or prevent cardiovascular disease, especially coronary artery disease, cerebrovascular disease, coronary restenosis or peripheral vascular disease. They may also be used in the treatment of diseases associated with ABC1 biological activity, such as Alzheimer's disease, Niemann-Pick disease, Huntington's disease, X-linked adrenoleukodystrophy and cancer.

CC The invention specifically excludes proteins with the exact amino acid sequences of GenBank Accession No: CAA10005.1 and X75926, and the nucleic acid with the exact sequence as GenBank Accession No: AJ012376.1. The present sequence represents a mutant human ABC1 cholesterol transporter associated with an altered cholesterol level and therefore an altered risk of cardiovascular disease.
 CC Note: The present sequence is not shown in the specification, but is derived from the native human ABC1 shown on pages 152-157.

XX Sequence 2261 AA;

Query Match	100.0%	Score 1525; DB 21; Length 2261;
Best Local Similarity	100.0%	Pred. No. 5e-143; Pred. No. 5e-143;
Matches	284;	Mismatches 0; Indels 0; Gaps 0;
Conservative	0;	

Qy	1 FGKPSLEQPMYNEQTFVSNDAPDTGLELLNALTQDGFGTRCMEGNPIDPTPCQ	60
Db	1371 FGKPSLEQPMYNEQTFVSNDAPDTGLELLNALTQDGFGTRCMEGNPIDPTPCQ	1430
Qy	61 AGEEETTATPVPOQTMDLURQNGRTMNPSPACQCSSDDKIKMLPVCPAGGLPPQRK	120
Db	1431 AGEEETTATPVPOQTMDLURQNGRTMNPSPACQCSSDDKIKMLPVCPAGGLPPQRK	1490
Qy	121 QNTADILQDLTGRTNSDYLVKTYVQIIAKSLKNKIWNEFRYGGFSLGVSNTOALPPSQE	180
Db	1491 QNTADILQDLTGRTNSDYLVKTYVQIIAKSLKNKIWNEFRYGGFSLGVSNTOALPPSQE	1550
Qy	181 VNDAIKQMKHLKLAKDSSADRFNSLGRMIGLDTRNNVYWFNNKGWHAISSEFLNVIN	240
Db	1551 VNDAIKQMKHLKLAKDSSADRFNSLGRMIGLDTRNNVYWFNNKGWHAISSEFLNVIN	1610
Qy	241 NAILRANLQGENPNSHYGITAFNPLNLTKQIIVTAKSLKNKIWNEFRYGGFSLGVSNTOALPPSQE	284
Db	1611 NAILRANLQGENPNSHYGITAFNPLNLTKQIIVTAKSLKNKIWNEFRYGGFSLGVSNTOALMTTSVD	1654

RESULT 15
 ID AAB71749
 XX AC AAB71749;
 XX DT 17-MAY-2001 (first entry)
 XX DE Human ABC1 protein.
 XX KW High density lipoprotein-cholesterol : HDL-C; cardiovascular: ABC1.
 OS Homo sapiens.
 XX PN WO200115676-A2.
 XX PD 08-MAR-2001.
 XX PF 01-SEP-2000; 2000WO-IB01492.

XX PR 01-SEP-1999; 99US-0151977.
 PR 15-MAR-2000; 2000US-0526193.
 XX PR 23-JUN-2000; 2000US-0213958.
 PA (UYBR-) UNIV BRITISH COLUMBIA.
 (XENO-) XENON GENETICS INC.
 XX PI Hayden MR, Brooks-Wilson AR, Pimstone SN, Clee SM;
 XX DR WPI; 2001-244356/25.
 XX PT Treating a lower than normal high density lipoprotein-cholesterol (HDL-C) level, a higher than normal triglyceride level, or a cardiovascular disease, by administering a compound that modulates LXR- or RXR-mediated transcriptional activity -

XX PS Claim 16; Fig 2; 317pp; English.
 . . .
 XX CC The present invention relates to a method for treating a patient diagnosed as having a lower than normal high density lipoprotein-cholesterol (HDL-C) level, or a cardiovascular disease, involving administering a compound that modulates LXR- or RXR-mediated transcriptional activity or ABC1 expression or activity. The LXR gene product may be used in an assay to identify compounds useful for the treatment of a disease or condition selected a lower than normal HDL cholesterol level, a higher than normal triglyceride level, and a cardiovascular disease.
 XX SQ Sequence 2261 AA;
 XX Query Match 100.0%; Score 1525; DB 22; Length 2261;
 XX Best Local Similarity 100.0%; Pred. No. 5e-143; Pred. No. 5e-143;
 XX Matches 284; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 XX Matches 284; Mismatches 0; Indels 0; Gaps 0;
 Qy 1 FGKPSLEQPMYNEQTFVSNDAPDTGLELLNALTQDGFGTRCMEGNPIDPTPCQ 60
 Db 1371 FGKPSLEQPMYNEQTFVSNDAPDTGLELLNALTQDGFGTRCMEGNPIDPTPCQ 1430
 Qy 61 AGEEETTATPVPOQTMDLURQNGRTMNPSPACQCSSDDKIKMLPVCPAGGLPPQRK 120
 Db 1431 AGEEETTATPVPOQTMDLURQNGRTMNPSPACQCSSDDKIKMLPVCPAGGLPPQRK 1490
 Qy 121 QNTADILQDLTGRTNSDYLVKTYVQIIAKSLKNKIWNEFRYGGFSLGVSNTOALPPSQE 180
 Db 1491 QNTADILQDLTGRTNSDYLVKTYVQIIAKSLKNKIWNEFRYGGFSLGVSNTOALPPSQE 1550
 Qy 181 VNDAIKQMKHLKLAKDSSADRFNSLGRMIGLDTRNNVYWFNNKGWHAISSEFLNVIN 240
 Db 1551 VNDAIKQMKHLKLAKDSSADRFNSLGRMIGLDTRNNVYWFNNKGWHAISSEFLNVIN 1610
 Qy 241 NAILRANLQGENPNSHYGITAFNPLNLTKQIIVTAKSLKNKIWNEFRYGGFSLGVSNTOALPPSQE 284
 Db 1491 QNTADILQDLTGRTNSDYLVKTYVQIIAKSLKNKIWNEFRYGGFSLGVSNTOALPPSQE 1550
 Qy 181 VNDAIKQMKHLKLAKDSSADRFNSLGRMIGLDTRNNVYWFNNKGWHAISSEFLNVIN 240
 Db 1551 VNDAIKQMKHLKLAKDSSADRFNSLGRMIGLDTRNNVYWFNNKGWHAISSEFLNVIN 1610
 Qy 241 NAILRANLQGENPNSHYGITAFNPLNLTKQIIVTAKSLKNKIWNEFRYGGFSLGVSNTOALMTTSVD 284
 Job time : 48 secs
 Search completed: February 4, 2003, 09:39:19

GenCore version 5.1.3						
Copyright (c) 1993 - 2003 Compugen Ltd.						
MM protein - protein search, using sw model						
run on: February 4, 2003, 09:39:23 ; Search time 14 Seconds (without alignments)						
596.865 Million cell updates/sec						
title: US-09-704-272-6	perfect score: 1525	sequence: 1 FGKRYPSULEQWMYNEQTYF.....PLNLTQQQLSEVALMTTSVD 284	scoring table: BLOSUM62	Gapop 10.0 , Gapext 0.5	searched: 262574 seqs, 29422922 residues	total number of hits satisfying chosen parameters: 262574
minimum DB seq length: 0						
maximum DB seq length: 2000000000						
post-processing: Minimum Match 0%						
Maximum Match 100%						
Listing first 45 summaries						
Issued_Patents_AA:*						
1: /cgn2_6/podata/1/iaa/5A_COMBO.pep:*	2: /cgn2_6/podata/1/iaa/5B_COMBO.pep:*	3: /cgn2_6/podata/1/iaa/6A_COMBO.pep:*	4: /cgn2_6/podata/1/iaa/6B_COMBO.pep:*	5: /cgn2_6/podata/1/iaa/PCTUS_COMBO.pep:*	6: /cgn2_6/podata/1/iaa/backfile1.pep:*	Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.
SUMMARIES						
result No.	Score	Query Match	Length	DB ID	Description	
1	1423	93.3	1375	3 US-01-665-259-26	Sequence 26, Appl	
2	1423	93.3	1375	3 US-01-665-259-26	Sequence 26, Appl	
3	257	16.9	1457	3 US-08-665-259-27	Sequence 27, Appl	
4	257	16.9	1457	3 US-08-665-259-27	Sequence 27, Appl	
5	94.5	6.2	884	6 5208144-8	Patent No. 5208144	
6	92	6.0	2511	4 US-01-261-907-2	Sequence 2, Appl	
7	89.5	5.9	596	4 US-08-481-190-8	Sequence 8, Appl	
8	89.5	5.9	596	5 PCT-US93-00869-8	Sequence 8, Appl	
9	89	5.8	903	3 US-08-804-439A-22	Sequence 22, Appl	
10	89	5.8	903	3 US-08-720-229-22	Sequence 22, Appl	
11	88.5	5.8	903	1 US-08-220-151-8	Sequence 8, Appl	
12	88.5	5.8	903	1 US-08-413-118-8	Sequence 8, Appl	
13	88.5	5.8	903	3 US-08-473-446-8	Sequence 8, Appl	
14	88	5.8	888	2 US-08-861-464-6	Sequence 6, Appl	
15	88	5.8	888	2 US-08-396-001-6	Sequence 6, Appl	
16	88	5.8	888	4 US-09-323-433A-6	Sequence 6, Appl	
17	86.5	5.7	967	4 US-09-139-802-201	Sequence 201, Appl	
18	86	5.6	2509	1 US-08-1465-005A-10	Sequence 10, Appl	
19	85.5	5.6	953	4 US-09-245-281-43	Sequence 43, Appl	
20	85.5	5.6	953	4 US-09-207-359B-43	Sequence 43, Appl	
21	83.5	5.5	339	4 US-09-125-619-14	Sequence 14, Appl	
22	83.5	5.5	969	4 US-09-206-912-32	Sequence 32, Appl	
23	83.5	5.5	975	4 US-09-206-942-30	Sequence 30, Appl	
24	83.5	5.5	3224	2 US-08-705-660-34	Sequence 34, Appl	
25	83.5	5.5	3224	3 US-08-989-045-34	Sequence 34, Appl	
26	83	5.4	913	1 US-08-413-118-6	Sequence 6, Appl	
27	83	5.4	913	1 US-08-413-118-6	Sequence 6, Appl	
ALIGNMENTS						
RESULT 1						
US-08-665-259-26						
; Sequence 26, Application US/08665259						
; Patent No. 6028173						
GENERAL INFORMATION:						
APPLICANT: Landes, Gregory M.	APPLICANT: Burn, Timothy C.	APPLICANT: Connors, Timothy D.	APPLICANT: Dackowski, William R.	APPLICANT: Van Ray, Terence J.	APPLICANT: Klinger, Katherine W.	APPLICANT: NOVEL HUMAN CHROMOSOME 16 GENES, COMPOSITIONS, METHODS OF MAKING AND USING SAME
CITY: Framingham	CITY: One Mountain Road	CITY: Massachusetts	CITY: United States of America	CITY:	CITY:	CITY:
STATE:	STATE:	STATE:	STATE:	STATE:	STATE:	STATE:
ZIP: 01701	ZIP:	ZIP:	ZIP:	ZIP:	ZIP:	ZIP:
COMPUTER READABLE FORM:	MEDIUM TYPE: Floppy disk	COMPUTER: IBM PC compatible	OPERATING SYSTEM: PC-DOS/MS-DOS	SOFTWARE: Patentin Release #1.0, Version #1.30	CURRENT APPLICATION DATA:	APPLICATION NUMBER: US/08/665,259
FILING DATE: 17-JUN-1996	CLASSIFICATION: 435	ATTORNEY/AGENT INFORMATION:	NAME: Dugan, Deborah A.	REGISTRATION NUMBER: 37,315	REFERENCE/DOCKET NUMBER: IC5-9.1	TELECOMMUNICATION INFORMATION:
TELEPHONE: (508) 872-8400	TELEFAX: (508) 872-5415	INFORMATION FOR SEQ ID NO: 26:	SEQUENCE CHARACTERISTICS:	LENGTH: 1375 amino acids	TYPE: amino acid	STANDARDISATION: not relevant
TOPOLOGY: unknown	MOLECULE TYPE: protein	US-08-665-259-26	US-08-665 amino acids	US-08-665 amino acids	US-08-665 amino acids	US-08-665 amino acids
Query Match 93.3% , Score 1423; DB 3; Length 1375;	Best Local Similarity 93.0% , Pred. No. 6.2e-41;	Indels 10; Mismatches 10;	Gaps 0;			

Matches 91; Conservative 40; Mismatches 98; Indels 136; Gaps 15; Query 2 GKPSLEQPMYNEQYT-----FVSNDAPE-----DTGTLLELNALTQDKPFGT 46
 DDB 504 GDPLPVLSQSOHY NYTQPRGNF IPYANEERQYRLSPASPOOLVSLRPLSGVGA 562
 QY 47 ROM-----EGNPI-----54
 DB 563 TCVLKSPANGSLGPMLNLSSGESRLLAARFDSMCLESFTQGLPLSNSVFPPPPSAPSDS 622
 QY 55 ---PD-----IPCQASEEEWTAP VOPTIMDLFQNGNTWMONPSACQCSSDKI 100
 DDB 623 PYXPDEDSLQAWNMSLPPTAGPEWTSAPSPLRVHEVVR-----CTCSAQGT 670
 QY 101 KRMPLPVCPGGAGLPPQQRKQNTADILQDITGRNISDYLVKTYVQIIAKSLKNIWNEF 160
 DDB 671 GFS--CPSVWG -HPPQMRVVTGDLIDLTGHNVSEYLLFTSDRF-----RLH 715
 DDB 161 RYGGFLGVENTQALPPSOFVNDAIKMKKHLKAQDSADRNLNSLGREMGLDTRNNY 220
 DDB 716 RYGAITFG--NVQKSIAPS-----EGARYPPMVKIAVRVA 750
 QY 221 KWENNNKGWAISSSLVNNAILRANLQGE-NPSHYGITAENHPLNLTQHOLS-EVAL 278
 DDB 751 QVLYNNKGHSMPYLNSSLNAILRANLPKSICNPAAIXIVTNHPMNKTSSASLSLDYLL 810
 QY 279 MTTSV 283
 DDB 811 QGTDV 815

RESULT 4
 US-08-762-500-27 Sequence 27, Application US/08762500
 Patent No. 6030806
 GENERAL INFORMATION:
 APPLICANT: Landes, Gregory M.
 APPLICANT: Burn, Timothy C.
 APPLICANT: Connors, Timothy D.
 APPLICANT: Dackowski, William R.
 APPLICANT: Van Raay, Terence J.
 APPLICANT: Klingner, Katherine W.
 TITLE OF INVENTION: NOVEL HUMAN CHROMOSOME 16 GENES,
 NUMBER OF SEQUENCES: 83
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: GENOME CORPORATION
 STREET: One Mountain Road
 CITY: Framingham
 STATE: Massachusetts
 COUNTRY: United States of America
 ZIP: 01701
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/762,500
 FILING DATE: 09-DEC-1996
 CLASSIFICATION: 435
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/665,259
 FILING DATE: 17-JUN-1996
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: PCT/US96/10469
 ATTORNEY/AGENT INFORMATION:
 NAME: Dugan, Deborah A.
 REGISTRATION NUMBER: 37,315
 REFERENCE/DOCKET NUMBER: 1G5-9-3
 TELEPHONE: (508) 872-8400

TELEFAX: (508) 872-5415
 INFORMATION FOR SEQ ID NO: 27:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 1457 amino acids
 TYPE: amino acid
 STRANDEDNESS: not relevant
 TOPOLOGY: unknown
 MOLECULE TYPE: protein
 US-08-762-500-27

Query Match 16.9%; Score 257; DB 3; Length 1457;
 Best Local Similarity 24.9%; Pred. No. 8.6e-18;
 Matches 91; Conservative 40; Mismatches 98; Indels 136; Gaps 15;
 QY 2 GKPSLEQPMYNEQYT-----FVSNDAPE-----DTGTLLELNALTQDKPFGT 46
 Db 504 GDPLPVLSQSYH -NYTQPRGNF IPYANEERQYRLSPASPOOLVSLRPLSGVGA 562
 QY 47 ROM-----EGNPI-----54
 Db 563 TCVLKSPANGSLGPMLNLSSGESRLLAARFDSMCLESFTQGLPLSNSVFPPPPSAPSDS 622
 QY 55 ---PD-----TPCGAEEWTTAP -VOPTIMDLFQNGNTWMONPSACQCSSDKI 100
 Db 623 PVXPDEDSLQAWNMSLPPTAGPEWTSAPSPLRVHEVVR-----CTCSAQGT 670
 QY 101 KKMLPVCPGGAGLPPQQRKQNTADILQDITGRNISDYLVKTYVQIIAKSLKNIWNEF 160
 Db 671 GFS--CPSVWG -HPPQMRVVTGDLIDLTGHNVSEYLLFTSDRF-----RLH 715
 QY 161 RYGGFLGVENTQALPPSOFVNDAIKMKKHLKAQDSADRNLNSLGREMGLDTRNNY 220
 Db 716 RYGAITFG--NVQKSIAPS-----EGARYPPMVKIAVRVA 750
 QY 221 KWENNNKGWAISSSLVNNAILRANLQGE-NPSHYGITAENHPLNLTQHOLS-EVAL 278
 Db 751 QVLYNNKGHSMPYLNSSLNAILRANLPKSICNPAAIXIVTNHPMNKTSSASLSLDYLL 810
 QY 279 MTTSV 283
 Db 811 QGTDV 815

RESULT 5
 5208144-8 ; Patent No. 5208144
 ; APPLICANT: SMITH, JOHN A.; RAYCHORDHURY, RAKTIMA; NILES, JOHN L.
 ; TITLE OF INVENTION: METHOD FOR DETECTION OF HUMAN DNA
 ; CONTAINING THE GENE ENCODING LOW DENSITY LIPOPROTEIN RECEPTOR
 ; CURRENT APPLICATION DATA:
 ; NUMBER OF SEQUENCES: 42
 ; APPLICATION NUMBER: US/07/396,697
 ; FILING DATE: 22-AUG-1989
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 313,682
 ; FILING DATE: 22-FEB-1989
 ; APPLICATION NUMBER: 235,211
 ; FILING DATE: 23-AUG-1988
 ; SEQ ID NO:8;
 ; LENGTH: 884
 5208144-8

Query Match 6.2%; Score 94.5%; DB 6; Length 884;
 Best Local Similarity 23.6%; Pred. No. 0.5%;
 Matches 70; Conservative 37; Mismatches 111; Indels 79; Gaps 19;
 Qy 1 FGKPS---LELOPWW-----YNBQYTFVSNDAPEDTGTLLELNALTQDKPFGT 47
 Db 551 FGKENKEKKVLLVNNWLQWRIFQLRQNS--VSNECKQVCSHICL--RPGYSCA 603
 Qy 4B CMEGNP1 - PDTCQAGBEWTATPQTIMDLFQGN - WTMQNPSACOCSSDKI 103
 Db 604 CGCDEVMSVMDVNCASSTPMMDDPQW - HCGVDEVMDPQW - HCGVDEVMDPQW - 656

ATTORNEY/AGENT INFORMATION:
NAME: George M. Yahwak
REGISTRATION NUMBER: 26,824
REFERENCE/DOCKET NUMBER: CRF D-1057
TELECOMMUNICATION INFORMATION:
TELEPHONE: (203) 268-1951
TELEFAX: (203) 268-1951
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
TYPE: AMINO ACIDS
LENGTH: 596 amino acids
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
PCT-US33-00869-8

Query Match 5.9%; Score 89.5; DB 5; Length 596;
Best Local Similarity 23.0%; Pred. No. 1; Gaps 12;
Matches 63; Conservative 32; Mismatches 128; Indels 51; Gaps 11;

Qy 1.3 MYEQQT-----FVSNDAPEDGTIELLNLTKDGPGEFTCRBGNPLDPGCP 60
Db 293 MYRQKVTNAPCPPLLFGAFYVGNNVAPGTTTIPHTPYHTWAGT--PRGSKEPNQDV 350
Qy 61 AGEEETTAATPVQPTIMDLQFQNGNRTMOPNSPACQCSDDIKKMLVCPAGGLPPQPK 120
Db 351 YGED----MGRNEYSAQDPYFCHHGVDRMUNEWKAIGG--KBRD 390
Qy 121 QNTADILQD--LTGRNISDYLVYKTVOLLAKSKRKT-----WVNFRYGGFSLGVS 171
Db 391 ISEKDWLNSEFFYDEHHKPYRKVRDQLDTKMGYDYAPMPTPRNFKPKSASVGKV 450
Qy 172 TQALPPSQEYNDAIKQMKKKHLAKDSSADRFNSLGRFTGLDTRNNYKWNNGKWA 231
Db 451 TSLPANEVEPLAK-MDKTISPAINTREASSRSTQQEKNEQEMLTNNIR-YDNRGYR 507
Qy 232 ISSFLNVINNAIRLN-LOKGENSEPHSITAFNH 264
Db 508T FDFVELNDNN-VNARNEELKAERFAGSY-TSLPH 537

RESULT 9
US-08-804-439A-22
Sequence 22, Application US/08804439A
Patent No. 6015565
GENERAL INFORMATION:
APPLICANT: Rose, Timothy M.
APPLICANT: Strand, Kurt
TITLE OF INVENTION: GLYCOPROTEIN B OF THE RHV/KSHV
TITLE OF INVENTION: SUBFAMILY OF HERPES VIRUSES
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
STATE: La Jolla
COUNTRY: USA
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version 4.1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/804,439A
FILING DATE: February 21, 1997
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Hile, Lisa A.
REGISTRATION NUMBER: 38,347
TELECOMMUNICATION INFORMATION:
REFERENCE/DOCKET NUMBER: 09176/004001
INFORMATION FOR SEQ ID NO: 22:

TELEPHONE: (619) 678-5070
TELEFAX: (619) 678-5099
TELEX:
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 903 amino acids
TYPE: amino acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: protein
US-08-804-439A-22

Query Match 5.8%; Score 89; DB 3; Length 903;
Best Local Similarity 20.2%; Pred. No. 2,2;
Matches 57; Conservative 28; Mismatches 115; Indels 82; Gaps 11;

Qy 21 VSNDAPEDTGTIELLNLTKDGPGEFTCRBGNPLDPGCPQAGEBEENTAVPQPTIMDLFQ 80
Db 26 VASAAQSSPGT-----PGVAATAQANGGPATPA-----PPAPGPAPTGDTKP 68

Qy 81 NGWTWMTQNPSP-----ACCGCSTIKKMLPVCPGAGG-----
Db 69 KKNKKPKRPPRPPRPPGDNATYAAGHTAHLRHLRDIKAENTDANFYICPPPGATVYQE 128

Qy 114 --LPPQPKQNTADILQDLTGRNISDYLVKT--YVQTLAKSLKNUKIWNNEFRYGGFSLG 168
Db 129 PRRCPTPREGQNTYEGAVFKFENIAPKFKKMYKVDIVT--QWFGH RYSCF-MG 183

Qy 169 VSNTQALPPSQEVNDAI-----KOMKKHLAKDSSADRFNSLGRFTGLDTRN 218
Db 184 IFEDRAPPFFEEVTDKNAKGVCRSTAKVYNNILETTAHRDDH-----ETDMELKP 235

Qy 219 NVKWFNNKKGWHAISSEFLNVINNAIRLNQGENPSHYGIT 260
Db 236 ANAATRSTRGWHTD-----LYKNFSRVEAFHRYGTI 267

RESULT 10
US-08-720-229-22
Sequence 22, Application US/08720229
Patent No. 6022542
GENERAL INFORMATION:
APPLICANT: Rose, Timothy M.
APPLICANT: Bosch, Marinx L.
APPLICANT: Strand, Kurt
TITLE OF INVENTION: GLYCOPROTEIN B OF THE RHV/KSHV
TITLE OF INVENTION: SUBFAMILY OF HERPES VIRUSES
NUMBER OF SEQUENCES: 100
CORRESPONDENCE ADDRESS:
ADDRESSEE: Morrison & Foerster
STREET: 755 Page Mill Road
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304-1018
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/720,229
FILING DATE: 26-SEP-1996
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Schiff, J. Michael
REGISTRATION NUMBER: 40,253
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 813-5600
TELEFAX: (415) 494-0792
INFORMATION FOR SEQ ID NO: 22:

SEQUENCE CHARACTERISTICS:
 LENGTH: 903 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: protein
 US-08-720-229-22

Query Match Score 89; DB 3; Length 903;
 Best Local Similarity 20.2%; Pred. No. 2.2; Indels 82; Gaps 11;

Matches 57; Conservative 28; Mismatches 115; Indels 82; Gaps 13;

Query 21 VSNDAPEDTGTELLNALTKDGFTRCMENPIPDTCCAGEEEWTTAPVPTIMDLFQ 80
 Db 26 VASAPSSGT-----PGVAATQANGGATPA-----PAPGPAAPTGDTK 68

Qy 81 NGNTMQNPS-----ACQCSSDKKKMLPVCPGAGG-----
 Db 69 KKNKPKPNPPRAGDNATAAGHATLREHLDIKAENTDANFYVCPPTGATVYQQEQ 128

Qy 114 --LPPQRQKONTADLQLDTGRNISLYLVKT--YQQLIAKSLKNKIWNNEFRYGGPSLG 168
 Db 129 PRRCPRPREGONTYEGAVVFKENIATPYKMDVTS--QWMEGH-RYSQF-MG 183

Qy 169 VSNTQALPSQEVNDAI-----KQMKHKHLAKSDADRFLNSLRFMCLDTRN 218
 Db 184 IFEDRAPVPEEVTDKINAKGCRSTAKYVRNLETTAFHRDH-----ETDMELKP 235

Qy 169 VSNTQALPSQEVNDAI-----KQMKHKHLAKSDADRFLNSLRFMCLDTRN 218
 Db 184 IFEDRAPVPEEVTDKINAKGCRSTAKYVRNLETTAFHRDH-----ETDMELKP 235

Qy 219 NVKWFNNKGWHAISSFLVNINALLRNLQGENPHYGIT 260
 Db 236 ANAATRTSGWHTTD-----LKYNRSRVEAFHRIGTT 267

RESULT 12
 US-08-413-118-8
 Sequence 8, Application US/08413118
 ; Patent No. 5689920

GENERAL INFORMATION:
 APPLICANT: PAOLETTI, ENZO
 ATTORNEY/AGENT INFORMATION:
 APPLICANT: Limbach, Keith J.
 TITLE OF INVENTION: NUCLEOTIDE AND AMINO ACID SEQUENCES OF
 NUMBER OF SEQUENCES: 91
 CORRESPONDENCE ADDRESS:
 STREET: 530 Fifth Avenue
 CITY: New York
 STATE: NEW YORK
 COUNTRY: UNITED STATES OF AMERICA
 ZIP: 10016

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/220,151
 FILING DATE: 30-MAR-1994
 CLASSIFICATION: 435
 ATTORNEY/AGENT INFORMATION:
 NAME: Fromer, William S.
 REGISTRATION NUMBER: 25,506
 REFERENCE/DOCKET NUMBER: 454310-2540
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 840-3333
 TELEFAX: (212) 840-0712
 TELEX: 425066 CURTMS
 INFORMATION FOR SEQ ID NO: 8:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 903 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 FRAGMENT TYPE: N-terminal
 US-08-220-151-8

Query Match Score 88.5; DB 1; Length 903;
 Best Local Similarity 20.6%; Pred. No. 2.5;
 Matches 58; Conservative 32; Mismatches 109; Indels 83; Gaps 13;

Qy 21 VSNDAPEDTGTELLNALTKDGFTRCMENPIPDTCCAGEEEWTTAPVPTIMDLFQ 80
 Db 27 VASAPSSGT-----PGVARDPG-GER-----GCHSAAALGAAPTG---DPKP 68

Qy 81 NGNTMQNPS-----ACQCSSDKIKKMLPVCPGAGG-----
 Db 69 KKNKPKPNPPRAGDNATAAGHATLREHLDIKAENTDANFYVCPPTGATVYQQEQ 128

Qy 114 --LPPQRQKONTADLQLDTGRNISLYLVKT--YQQLIAKSLKNKIWNNEFRYGGPSLG 168
 Db 129 PRRCPRPREGONTYEGAVVFKENIATPYKMDVTS--QWMEGH-RYSQF-MG 183

Qy 169 VSNTQALPSQEVNDAI-----KQMKHKHLAKSDADRFLNSLRFMCLDTRN 218
 Db 184 IFEDRAPVPEEVTDKINAKGCRSTAKYVRNLETTAFHRDH-----ETDMELKP 235

Qy 219 NVKWFNNKGWHAISSFLVNINALLRNLQGENPHYGIT 260
 Db 236 ANAATRTSGWHTTD-----LKYNRSRVEAFHRIGTT 267

RESULT 12
 US-08-413-118-8
 Sequence 8, Application US/08413118
 ; Patent No. 5689920

GENERAL INFORMATION:
 APPLICANT: PAOLETTI, ENZO
 ATTORNEY/AGENT INFORMATION:
 APPLICANT: Limbach, Keith J.
 TITLE OF INVENTION: CANINE HERPESVIRUS GB, GC, AND QD AND USES THEREFOR
 NUMBER OF SEQUENCES: 128
 CORRESPONDENCE ADDRESS:
 ADDRESS: CURTIS, MORRIS & SAFFORD, P.C.
 STREET: 530 FIFTH AVENUE, 25TH FLOOR
 CITY: NEW YORK
 STATE: NEW YORK
 COUNTRY: UNITED STATES OF AMERICA
 ZIP: 10016

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/413,118
 FILING DATE: 29-MAR-1995
 CLASSIFICATION:
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/220,151
 FILING DATE: 30-MAR-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: Fromer, William S.
 REGISTRATION NUMBER: 25,506
 REFERENCE/DOCKET NUMBER: 454310-2670
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (212) 840-0712
 TELEFAX: (212) 840-3333
 INFORMATION FOR SEQ ID NO: 8:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 903 amino acids
 TYPE: amino acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: peptide
 FRAGMENT TYPE: N-terminal

US-08-413-118-8

Query Match 5.8%; Score 88.5; DB 1; Length 903;
 Best Local Similarity 20.6%; Pred. No. 2.5;
 Matches 58; Conservative 32; Mismatches 109; Indels 83; Gaps 13;

Qy 21 VSNDAPEDGTLELLNALTKDPGFGTRCMEGNPIDPTPOQAGEEWEWTAPVFDOTIMDLFQ 80
 Db 27 VASAAPSPT---PGVARDPG-GER----DPKP 68

Qy 81 NGNTWMQNSP-----ACQCSSDRIKRMPLPVCPAGG-----DPKP 68
 Db 69 KKNKKPKNPTPPRAGDNATVAAGHATLREHLDIKAENTDANFYVCPPPTATVYQFEE 128

Qy 114 ---LPQQQRQNTADILQLDTGRNISDYLVKT-YVQLIAKSLKNIKWNEFRYGGFSLG 168
 Db 129 PRRCPTRPQQNYTECAVFKENIAPYKFKATMYKDVTs--QWFGH-RYSQF-MG 183

Qy 169 VSNTQALPPSQEVNDAI-----KOMKKHLKLAKDSSADRFNSLGRPMGLDTRN 218
 Db 184 IFEDRAPVPEEVIDKINAKGVRSTARXVNRLLETAAFRDHD-----ETDMELKP 235

Qy 219 NVKVWNNGKWHAISSFLNVINNAILRANQGENPSHYGIT 260
 Db 236 ANAATRTSRGWTHTD-----LKYNPSRVEAFHRYGTT 267

RESULT 14

US-08-861-464-6

; Sequence 6, Application US/08861464
 ; GENERAL INFORMATION:
 ; APPLICANT: Guarante, Leonard P.
 ; ATTORNEY: Austruaco Jr., Nicanor
 ; TITLE OF INVENTION: Genes Determining Cellular Senescence
 ; NUMBER OF SEQUENCES: 16
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.
 ; STREET: Two Millett Drive
 ; CITY: Lexington
 ; STATE: MA
 ; COUNTRY: USA
 ; ZIP: 02173
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.30
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/473,446
 ; FILING DATE: 22-MAY-1997
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US 08/396,001
 ; FILING DATE: 28-FEB-1995
 ; PRIORITY APPLICATION DATA:
 ; APPLICATION NUMBER: PCT/US94/09351
 ; FILING DATE: 15-AUG-1994
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Frommer, William S.
 ; REGISTRATION NUMBER: 25,506
 ; REFERENCE/DOCKET NUMBER: 454310-2670
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (212) 840-3333
 ; TELEFAX: (212) 840-0712
 ; INFORMATION FOR SEQ ID NO: 8:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 903 amino acids
 ; TYPE: amino acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; MOLECULE TYPE: Peptide
 ; FRAGMENT TYPE: N-terminal
 ; INFORMATION FOR SEQ ID NO: 6:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 888 amino acids
 ; TYPE: amino acid
 ; TOPOLOGY: linear

MOLECULE TYPE: protein ; MOLECULE TYPE: protein
 US-08-396-001-6 ; US-08-396-001-6

Query Match Score: 88;	DB: 2;	Length: 888;	Query Match Score: 88;	DB: 2;	Length: 888;
Best Local Similarity: 19.4%;	Pred. No.: 2.8;		Best Local Similarity: 19.4%;	Pred. No.: 2.8;	
Matches 61; Conservative 36;	Mismatches 105;	Gaps 13;	Matches 61; Conservative 36;	Mismatches 105;	Gaps 13;

```

  Qy  24 DAPEDTGTLLELLNALITKDPGFGTRCMEGNPIDPDCOAGEEEWTAPVYDQTIMDL-FCN 81
  Db  34 DDPEENATSNAFANKVSDQDFAN-----GPPSQ-----MFPHIQMMGGMGMGP 77
  Qy  82 GWTMWNPSACQCSSDKIKKMLPVCP-----GAGGLPPPQRKQNTADI 126
  Db  78 YSOMMQVPHNC-----PFEPFPDFNDPTAPLSSPLNAGG--PMLFKNDSLP 124
  Qy  127 LQDLT-----GRNISDYLVKTYQIITASLKNKTIWNEFRYGGFSLGVSNTOALPP 177
  Db  125 FOMLSSCAAATQGGQNLPINDNSMKVLIASADPLWTHSNVPGSASVATEETTA--- 181
  Qy  178 SQEVNDAIKKQMKHLKLAKDSSADRFLNISLGRMTGLDTRNNVKVNFKNMHAIS-SF 235
  Db  182 -----TQESLPSKR-----ESNKASSFRROTFLSPSDL 214
  Qy  236 LNVIINNAIL-----RANLQGENPS-----HYGITAFNHPLNLTK 270
  Db  215 .INAANNVTLSKDFQSDMQNFSRAKKPSVGANNTAKTRTQSISFDNTSPSTSFIPTNSVS 274
  Qy  271 QOLSEVALMTSVD 284
  Db  275 EKLSDFKIETSKED 288

```

RESULT 15

US-08-396-001-6

Sequence 6, Application US/08396001

GENERAL INFORMATION:

APPLICANT: Guarante, Leonard P.

APPLICANT: Austriaco Jr., Nicancor

APPLICANT: Claus, James

APPLICANT: Cole, Francesca

APPLICANT: Kennedy, Brian

TITLE OF INVENTION: Genes Determining Cellular Senescence in Yeast

TITLE OF INVENTION: Yeast

NUMBER OF SEQUENCES: 16

CORRESPONDENCE ADDRESS:

ADDRESSEE: Hamilton, Brook, Smith & Reynolds, P.C.

STREET: Two Mililitia Drive

CITY: Lexington

STATE: MA

COUNTRY: USA

ZIP: 02273

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: PatentIn Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/396,001

FILING DATE: 28-FEB-1995

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Graham, Patricia

REGISTRATION NUMBER: 32,227

REFERENCE/DOCKET NUMBER: MIT-6408A2

TELECOMMUNICATION INFORMATION:

TELEPHONE: 617-861-6240

TELEFAX: 617-861-9540

INFORMATION FOR SEQ ID NO: 6:

SEQUENCE CHARACTERISTICS:

LENGTH: 888 amino acids

TYPE: amino acid

TOPOLOGY: linear

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on : February 4, 2003, 09:40:23 ; Search time 13 Seconds
(without alignments)
484.314 million cell updates/sec

Title: US-09-704-272-6

Perfect score: 1525

Sequence: 1 FGKYPSELQDQWMYNBQYTF.....PLNLTKQQLSEVALMTTSYD 284

Scoring table: BiSUM62

Gapop 10.0 , Gapext 0.5

Searched: 129505 seqs, 22169297 residues

Total number of hits satisfying chosen parameters: 129505

Minimum DB seq length: 0

Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%

Maximum Match 100%

Listing first 45 summaries

Database : Published_Applications_AA;*

1: /cn2_6/podata/1/pubpaas/US08_NEW_PUB.pep:*

2: /cn2_6/podata/1/pubpaas/US08_NEW_PUB.pep:*

3: /cn2_6/podata/1/pubpaas/US06_NEW_PUB.pep:*

4: /cn2_6/podata/1/pubpaas/US06_NEW_PUB.pep:*

5: /cn2_6/podata/1/pubpaas/US07_NEW_PUB.pep:*

6: /cn2_6/podata/1/pubpaas/US07_NEW_PUB.pep:*

7: /cn2_6/podata/1/pubpaas/US07_PUBCOMB.pep:*

8: /cn2_6/podata/1/pubpaas/US08_PUBCOMB.pep:*

9: /cn2_6/podata/1/pubpaas/US09_PUBCOMB.pep:*

10: /cn2_6/podata/1/pubpaas/US09_NEW_PUB.pep:*

11: /cn2_6/podata/1/pubpaas/US10_NEW_PUB.pep:*

12: /cn2_6/podata/1/pubpaas/US10_PUBCOMB.pep:*

13: /cn2_6/podata/1/pubpaas/US60_NEW_PUB.pep:*

14: /cn2_6/podata/1/pubpaas/US60_PUBCOMB.pep:*

Pred. No. 1 is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB ID	Description
1	1513	99.2	2261	10	US-09-995-542-11	Sequence 11, Appl
2	1513	99.2	2261	10	US-09-846-546-11	Sequence 11, Appl
3	1423	93.3	2201	10	US-09-995-542-9	Sequence 9, Appl
4	733.5	48.1	2273	10	US-09-995-542-12	Sequence 12, Appl
5	724.5	47.5	2310	10	US-09-995-542-10	Sequence 10, Appl
6	664	43.5	2121	10	US-09-995-542-3	Sequence 3, Appl
7	663.5	43.5	2167	10	US-09-995-542-2	Sequence 2, Appl
8	663.5	43.5	1550	10	US-09-995-542-8	Sequence 8, Appl
9	663.5	43.5	2100	10	US-09-995-542-6	Sequence 6, Appl
10	663.5	43.5	2146	10	US-09-995-542-5	Sequence 5, Appl
11	662.5	43.4	2144	10	US-09-858-194-2	Sequence 2, Appl
12	460.5	30.2	199	10	US-09-767-870-18	Sequence 18, Appl
13	267	17.5	2001	9	US-10-072-621-8	Sequence 8, Appl
14	267	17.5	2436	10	US-09-795-693-8	Sequence 9, Appl
15	140	9.2	664	10	US-09-767-870-9	Sequence 6, Appl
16	88	5.8	888	10	US-09-826-752-6	Sequence 5, Appl
17	87.5	5.7	522	10	US-09-876-889-53	Sequence 6, Appl
18	86.5	5.7	969	9	US-09-381-553-12	Sequence 122, App
19	86.5	5.7	977	10	US-09-925-297-79	Sequence 797, App

ALIGNMENTS

RESULT 1
US-09-995-542-11
; Sequence 11, Application US/0999542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Uliaa, Learnai
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and Title of Invention: Uses Thereof
; FILE REFERENCE: 00-638-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; CURRENT FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: 60/253,520
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SEQ ID NO 11
; LENGTH: 2261
; TYPE: PRT
; ORGANISM: Homo sapiens
; US-09-995-542-11

Query Match 99.2% Score 1513; DB 10; Length 2261;
Best Local Similarity 99.3%; Pred. No. 2.6e-138;
Matches 282; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 FGKYPSELQWMYNEQTYTEVNSDAPEDTGTLLENNALTKDGFGRMMEGNPVIDPTPCQ 60
Db 1371 FGKYSLELQWMYNEQTYTFVNSDAPEDTGTLLENNALTKDGFGRMMEGNPVIDPTPCQ 1430
QY 61 AGEETWTAPVPTIMDFQNGNTWMQNPSPACQCSDRIKKMLPVCPGAGGLPPQQRK 120
Db 1431 AGEETWTAPVPTIMDFQNGNTWMQNPSPACQCSDRIKKMLPVCPGAGGLPPQQRK 1490
QY 121 QNTADILQDLTGRNISDYLKVQIIAKSLKNIKWNFYRGFGSLSGVNSTQALPPSQE 180
Db 1491 QNTADILQDLTGRNISDYLKVQIIAKSLKNIKWNFYRGFGSLSGVNSTQALPPSQE 1550
QY 181 VNDAIKMKKKHLAKKSSADREFLNSLGRFMGLDTNNVXWENNGWHAISSTLNVIN 240
Db 1551 VNDATKMKKKHLAKKSSADREFLNSLGRFMGLDTNNVXWENNGWHAISSTLNVIN 1610

Page 2

RESULT 5
 US-09-995-542-10
 ; Sequence 10, Application US/09995542
 ; Patient No. US20020127647A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Ulias, Laarni
 ; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
 ; Software: PatentIn Ver. 2.0
 ; SEQ ID NO: 10
 ; LENGTH: 2310
 ; TYPE: PRT
 ; ORGANISM: Mus musculus
 US-09-995-542-10

Query Match 47.5%; Score 724.5; DB 10; Length 2310;
 Best Local Similarity 47.28; Pred. No. 1.5e-61; Indels 39; Gaps 4;

Matches 143; Conservative 39; Mismatches 82; Indels 39; Gaps 4;

QY 1 FGKYPSELQPMYNEQYTFSVNSDADPDTGTLLELLNALTQKMLPVCPAGGLPPQQC 60
 Db 1396 FGFPPALTHPNWYGHQYTFMSDEPANEHNLLEVADYLNRPFGNRCLKEEWLPEYC- 1454

Qy 61 AGEEETTAP-VPTQTIMDFQNGNTMQNPDSKIKKMLPVCPAGGLPPQR 1514
 Db 1455 INATSWKTPSVSPNITHFLQOKWTAHPSPSKCKSTREKLMLPCEAGGLEPPQR 1514

Qy 121 QNTADILQDLTRGRNISDLYKTYVQTLAKSLRKNIWNEFRGGFSLGVSNTOALPPSQE 180
 Db 1515 QRSTEVIQDLTRGRNISDLYKTYVALLRSLSKDRFLNSGR----- 1573

Qy 181 VNDAIKQMKHLKLAKDSSADRFLNSGR----- 281
 Db 1574 ----- 1615

Qy 222 VWFNNKGWHAISSFLNVINNIALRANLQKGNNPSHGTTAFNHPNLTRQSEVALMT 281
 Db 1616 VWFNNKGWHALVSLNVAHNATLRASTRASHPRDPEEYGITVISQPLNLTKEQSLDITVLIT 1675

Qy 282 SVD 284
 Db 1676 SVD 1678

; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
 ; TITLE OF INVENTION: Uses Thereof
 ; FILE REFERENCE: 00-658-A
 ; CURRENT APPLICATION NUMBER: US/09/995-542
 ; CURRENT FILING DATE: 2001-11-28
 ; PRIOR APPLICATION NUMBER: 60/253, 520
 ; PRIOR FILING DATE: 2000-11-28
 ; NUMBER OF SEQ ID NOS: 24
 ; SEQ ID NO: 3
 ; LENGTH: 2121
 ; TYPE: PRT
 ; ORGANISM: Mus musculus
 US-09-995-542-3

Query Match 43.5%; Score 664; DB 10; Length 2121;
 Best Local Similarity 45.3%; Pred. No. 1.e-55;
 Matches 129; Conservative 47; Mismatches 107; Indels 2; Gaps 2;

Qy 1 FGKYPSELQPMYNEQYTFSVNSDADPDTGTLLELLNALTQKMLPVCPAGGLPPQQC 60
 Db 1228 FGQYPLQLSPAMYGPQVSFSEADPGPDRMKLLEAGLQEPNSQDKDARGSECT 1287

Qy 61 AGEEETTAP-VPTQTIMDFQNGNTMQNPDSKIKKMLPVCPAGGLPPQR 119
 Db 1288 HSLACYTVEPVPPVASYLASGNWTPESSESPACOCSQGPARRLLPDCPAGAGGPPQQA 1347

Qy 120 QNTADILQDLTRGRNISDLYKTYVQTLAKSLRKNIWNEFRGGFSLGVSNTOALPPSQ 179
 Db 1348 VAGLGEVQNLTRGRNDSLFLVKTFLSPLVRGLKTKWDDEVRGFFSL-GRDPDLPFGH 1406

Qy 180 EVNDAIKOMKKHLKLAKDSSADRFLNSLGRMTGUDTRNWKYENNGWHAISSFLNVI 239
 Db 1407 EVVRTAEIRALLSPQGNALDRLLNLTQWALGDARSLSLKIWENNGWHAMVAFNRA 1466

Qy 240 NNAILRNLOKGENPSHYGTTAFAHNPBLNUTKQOLSEVALMTSYD 284
 Db 1467 NGGLHLALPSGPVRHAHSITTLNHLNLTKEQLEATIASSVD 1511

RESUL 7
 US-09-995-542-2
 ; Sequence 2, Application US/09995542
 ; Patient No. US20020127647A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Shutter, John
 ; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
 ; Software: PatentIn Ver. 2.0
 ; SEQ ID NO: 2
 ; LENGTH: 2167
 ; TYPE: PRT
 ; ORGANISM: Mus musculus
 US-09-995-542-2

Query Match 43.5%; Score 664; DB 10; Length 2167;
 Best Local Similarity 45.3%; Pred. No. 1.1e-55;
 Matches 129; Conservative 47; Mismatches 107; Indels 2; Gaps 2;

Qy 1 FGKYPSELQPMYNEQYTFSVNSDADPDTGTLLELLNALTQKMLPVCPAGGLPPQQC 60
 Db 1274 FGQYPLQLSPAMYGPQVSFSEADPGPDRMKLLEAGLQEPNSQDKDARGSECT 1333

Qy 61 AGEEETTAP-VPTQTIMDFQNGNTMQNPDSKIKKMLPVCPAGGLPPQR 119
 Db 1334 HSLACYTVEPVPPVASYLASGNWTPESSESPACOCSQGPARRLLPDCPAGAGGPPQQA 1393

PRIOR APPLICATION NUMBER: 60/253,520
; PRIORITY FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 2100
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-95-542-6

Query Match 43.5%; Score 663.5; DB 10; Length 2100;
Best Local Similarity 44.7%; Pred. No. 1.2e-55; Mismatches 96; Indels 11; Gaps 2;

Matches 127; Conservative 50; Organism: Homo sapiens

RESULT 8
US-09-995-542-8
Sequence 8, Application US/0995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Uliasz, Laarni
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; Uses Thereof
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; CURRENT FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: 60/253,520
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 8
; LENGTH: 1550
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-995-542-8

Query Match 43.5%; Score 663.5; DB 10; Length 1550;
Best Local Similarity 44.7%; Pred. No. 7.4e-56; Mismatches 96; Indels 11; Gaps 2;

Matches 127; Conservative 50; Organism: Homo sapiens

RESULT 9
US-09-995-542-6
Sequence 6, Application US/0995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Uliasz, Laarni
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; Uses Thereof
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; CURRENT FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: 60/253,520
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 2146
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-95-542-5

Query Match 43.5%; Score 663.5; DB 10; Length 2146;
Best Local Similarity 44.7%; Pred. No. 1.2e-55; Mismatches 96; Indels 11; Gaps 2;

Matches 127; Conservative 50; Organism: Homo sapiens

RESULT 10
US-09-995-542-5
Sequence 5, Application US/0995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Uliasz, Laarni
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; Uses Thereof
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; CURRENT FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: 60/253,520
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 240
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-95-542-5

Query Match 43.5%; Score 663.5; DB 10; Length 240;
Best Local Similarity 44.7%; Pred. No. 1.2e-55; Mismatches 96; Indels 11; Gaps 2;

Matches 127; Conservative 50; Organism: Homo sapiens

RESULT 11
US-09-995-542-6
Sequence 6, Application US/0995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Uliasz, Laarni
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; Uses Thereof
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; CURRENT FILING DATE: 2001-11-28
; PRIOR APPLICATION NUMBER: 60/253,520
; PRIOR FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 5
; LENGTH: 1397
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-95-542-5

Query Match 43.5%; Score 663.5; DB 10; Length 1397;
Best Local Similarity 44.7%; Pred. No. 1.2e-55; Mismatches 96; Indels 11; Gaps 2;

Matches 127; Conservative 50; Organism: Homo sapiens

RESULT 12
US-09-995-542-6
Sequence 6, Application US/0995542
; Patent No. US20020127647A1
; GENERAL INFORMATION:
; APPLICANT: Shutter, John
; APPLICANT: Uliasz, Laarni
; TITLE OF INVENTION: ATP-Binding Cassette Transporter-Like Molecules and
; Uses Thereof
; FILE REFERENCE: 00-658-A
; CURRENT APPLICATION NUMBER: US/09/995,542
; CURRENT FILING DATE: 2001-11-28

Qy 181 VNDAIKOMKKHLAKDSDADRFNLNSLGRPMTGLDTRNNVKWVNKNKGHAISSEFLNYIN 240
 ; NUMBER OF SEQ ID NOS: 21
 ; SOFTWARE: PatentIn Ver. 2.0
 Db 1432 LGRSVELWALLSPLPGALDRVLKNTNPAHSLDAQDSLKWNKNKGHSMYAFVNRS 1491
 ; SEQ ID NO: 18
 ; LENGTH: 199
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-09-767-870-18

RESULT 11
 US-09-858-194-2
 ; Sequence 2, Application US/09858194
 ; Patent No. US20061590A1
 ; GENERAL INFORMATION:
 ; APPLICANT: GLUCKSMANN, MARIA
 ; APPLICANT: CURTIS, RORY A.J.
 ; TITLE OF INVENTION: 38594, A NOVEL HUMAN TRANSPORTER AND USES THEREOF
 ; FILE REFERENCE: MNI-153
 ; CURRENT APPLICATION NUMBER: US/09/858,194
 ; CURRENT FILING DATE: 2001-05-14
 ; PRIOR APPLICATION NUMBER: 60/204,211
 ; PRIOR FILING DATE: 2000-05-12
 ; NUMBER OF SEQ ID NOS: 3
 ; SOFTWARE: PatentIn Ver. 2.0
 ; SEQ ID NO: 2
 ; LENGTH: 2144
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 US-09-858-194-2

Query Match Score 460.5; DB 10; Length 199;
 Best Local Similarity 41.0%; Pred. No. 2.1e-37;
 Matches 73; Indels 11; Gaps 2;

Qy 22 SMDAPEDTGTELLNALTDPGEFTGRMENGNIPDTPOAGEEETWATPVTQIMDFQN 81
 ; SEQ ID NO: 18
 Db 1 SEAPGDPGRARLEALQEAG-----LEEPYQHSSHRFAPEVAEVAKLAS 50

Query Match Score 460.5; DB 10; Length 199;
 Best Local Similarity 41.0%; Pred. No. 2.1e-37;
 Matches 73; Indels 11; Gaps 2;

Qy 22 SMDAPEDTGTELLNALTDPGEFTGRMENGNIPDTPOAGEEETWATPVTQIMDFQN 81
 ; SEQ ID NO: 18
 Db 1 SEAPGDPGRARLEALQEAG-----LEEPYQHSSHRFAPEVAEVAKLAS 50

Query Match Score 460.5; DB 10; Length 199;
 Best Local Similarity 41.0%; Pred. No. 2.1e-37;
 Matches 73; Indels 11; Gaps 2;

Qy 82 GNWTMQNPSPACOCSDKIKMLPVCPGAGLPPORKNTADILQDTGRNISDYLVK 141
 ; SEQ ID NO: 18
 Db 51 GNWTPESSPACOCSRPGARRLLPDCPAAGGPPQAVTGSGEVQNLTGRNLSFLVK 110

Query Match Score 460.5; DB 10; Length 199;
 Best Local Similarity 41.0%; Pred. No. 2.1e-37;
 Matches 73; Indels 11; Gaps 2;

Qy 142 TYQOIAKSLKNKIWNFERYGGFSLGVSNTOALPPSQEVNDAIKOMKKHLAKDSSAD 201
 ; SEQ ID NO: 18
 Db 111 TYPPLVROGLKTKKKWVNNEVRYGGFSLG-GRDPGLPSQELGRSVEELWALLSPLPGALD 169
 ; SEQ ID NO: 18

Query Match Score 460.5; DB 10; Length 199;
 Best Local Similarity 41.0%; Pred. No. 2.1e-37;
 Matches 73; Indels 11; Gaps 2;

Qy 202 REFLNSLGREMTGLDTRNNVKWVNKNKGWHAA 231
 ; SEQ ID NO: 18
 Db 170 RVKLNLTWAHSLDAQDLKTFWNKNKGWHHS 199

RESULT 13
 US-10-072-621-8
 ; Sequence 8, Application US/10072621
 ; Patent No. US20020169137A1
 ; GENERAL INFORMATION:
 ; APPLICANT: Reiner, Peter B.
 ; APPLICANT: Connop, Bruce P.
 ; APPLICANT: Pollard, Michelle
 ; TITLE OF INVENTION: REGULATION OF AMYLOID PRECURSOR PROTEIN EXPRESSION
 ; FILE REFERENCE: 100103 402
 ; CURRENT APPLICATION NUMBER: US/10/072,621
 ; CURRENT FILING DATE: 2002-02-08
 ; NUMBER OF SEQ ID NOS: 10
 ; SOFTWARE: FastSEQ for Windows Version 4.0
 ; SEQ ID NO: 8
 ; LENGTH: 2001
 ; TYPE: PRT
 ; ORGANISM: Homo sapiens
 ; FEATURE:
 ; NAME/KEY: VARIANT
 ; LOCATION: 30, 70, 280, 477, 558, 1471, 1651, 1689, 1724
 ; OTHER INFORMATION: xaa = Any Amino Acid
 ; NAME/KEY: VARIANT
 ; LOCATION: 30, 70, 280, 477, 558, 1471, 1651, 1689, 1724
 ; OTHER INFORMATION: xaa = Any Amino Acid
 US-10-072-621-8

Query Match Score 662.5; DB 10; Length 2144;
 Best Local Similarity 44.7%; Pred. No. 1.5e-55;
 Matches 50; Mismatches 96; Indels 11; Gaps 2;

Qy 1 FGKPSLELQPMYNEQTYFVNSDAPEDTGTELLNALTDPGEFTGRMENGNIPDTPOQ 60
 ; SEQ ID NO: 18
 Db 1261 FGHPALRSLSPTMYQAVQVSFSESDAPGDPGRARLEALQEAG-----LEEPYQ 1310

Query Match Score 662.5; DB 10; Length 2144;
 Best Local Similarity 44.7%; Pred. No. 1.5e-55;
 Matches 50; Mismatches 96; Indels 11; Gaps 2;

Qy 61 AGEEWNTATPYQPOTIMDFQNGNNTMQNPSPACQSSDKIKMLPVCPGAGLPPORK 120
 ; SEQ ID NO: 18
 Db 1311 HSSHRSAPAEVAKVLAISGNWTPESPSPACQCSRPGARRLLPDCPAAGGPPQAV 1370

Query Match Score 662.5; DB 10; Length 2144;
 Best Local Similarity 44.7%; Pred. No. 1.5e-55;
 Matches 50; Mismatches 96; Indels 11; Gaps 2;

Qy 121 QNTADILQDILQDTGRNISDLYKTYVQIAKSLKNKIWNFERYGGFSLGVSNTOALPPSQE 180
 ; SEQ ID NO: 18
 Db 1371 TGSGEVVQNLGRNLSDFDLYKTYVQIAKSLKNKIWNFERYGGFSLG-GRDPGLPSGDE 1429

Query Match Score 662.5; DB 10; Length 2144;
 Best Local Similarity 44.7%; Pred. No. 1.5e-55;
 Matches 50; Mismatches 96; Indels 11; Gaps 2;

Qy 181 VNDAIKOMKKHLAKDSDADRFNLNSLGRPMTGLDTRNNVKWVNKNKGHAISSEFLNYIN 240
 ; SEQ ID NO: 18
 Db 1430 LGRSVELWALLSPLPGALDRVLKNTNPAHSLDAQDSLKWNKNKGHSMYAFVNRS 1489

Query Match Score 662.5; DB 10; Length 2144;
 Best Local Similarity 44.7%; Pred. No. 1.5e-55;
 Matches 50; Mismatches 96; Indels 11; Gaps 2;

Qy 241 NAILRANLQGENPSHYGTTAFNHPUNLTKQSEVALMMTSVD 284
 ; SEQ ID NO: 18
 Db 1490 NAILRANLQGENPSHYGTTAFNHPUNLTKQSEVALMMTSVD 1533

Query Match Score 662.5; DB 10; Length 2144;
 Best Local Similarity 44.7%; Pred. No. 1.5e-55;
 Matches 50; Mismatches 96; Indels 11; Gaps 2;

Qy 144 FGTRMEG-----NPPIP-DTPCQ-----AGEPEWITAP-V 71
 ; SEQ ID NO: 18
 Db 1137 FDSMCLESFTQGLPLSNVYPPPSPAPDSPASPDLDQAWNVSLLPTAGQEMNTAPS 1196

Query Match Score 662.5; DB 10; Length 2144;
 Best Local Similarity 44.7%; Pred. No. 1.5e-55;
 Matches 50; Mismatches 96; Indels 11; Gaps 2;

Qy 72 POTIMDLFQNGNNTMQNPSPACOCSDSRKMLPVCPGAGLPPORKNTADILQDT 131
 ; SEQ ID NO: 18
 Db 1197 PRLYREPV-----CPCNSVG-----HPPDMRVVTGDIUDIT 1240

Query Match Score 662.5; DB 10; Length 2144;
 Best Local Similarity 44.7%; Pred. No. 1.5e-55;
 Matches 50; Mismatches 96; Indels 11; Gaps 2;

Qy 132 GRNISDLYKTYVQIAKSLKNKIWNFERYGGFSLGVSNTOALPPSQEVNDAIKOMKKHH 191
 ; SEQ ID NO: 18
 Db 1241 GHNVSEYLFLFTSDRF-----RLHRGAITFG-NVLKSIPIAS--FGTRAPPNVRK 1286

Query	Match	17.5%	Score 267;	DB 10;	Length 2436;
Best Local Similarity	29.2%	Pred. No. 5	7e-17;		
Matches	80;	Conservative	35;	Mismatches	73;
				Indels	86;
				Gaps	12.
Qy	44 FGTRCMEG-----NPIP-DTPCQ-----AGEEENTTAP-V 71				
Ddb	1572 FDSMCLEFTQGLPLSNFVPPPSAFSDSPASDDELDQANNVSLPTAPEMWNTSAPL 1631				
Qy	72 PFTMDLFQNGNWMTMQNSPACQCSSDSDKIKRMLPYCPGAGGLPPQRKQNTADILQDT 131				
Ddb	1632 PRLVREPVRL-----CTCSAQGTGFES--CPSSVGG-HPPQMRRVVTGDLTDIT 1675				
Qy	132 GRISDYLVKTYQVQTLAKSLNKIWNFERRGGFSIGVSVNTOALPSEQNDAIKOMKHK 191				
Ddb	1676 GHNVSEYVLTFLPSDFR-----RLHRGATIFPG---AVLKSPASFGTRAPMVRK 1721				
Qy	192 LKLAKDSSADRFLNLSLGREFMTGLDTRNNVKWENNNKGWHIASSELNVINNAILRNLQKG 251				
Ddb	1722 -----:-----IAVRRAQVFYNNKGWHIASSELNVINNAILRNLPKS 1759				
Qy	252 E-NPSHYGITAENHPLNLTKOOLS-EVALMUTTSV 283				
Ddb	1760 KGNPAAVGTTVNHPMKNTSASLSDYLOCTG 1793				

RESULT 15
US09-767-870-9
; Sequence 9, Application US/09767870
; Patent No. US20020031549A1
; GENERAL INFORMATION:
; APPLICANT: Ruben et al.
; TITLE OF INVENTION: ABC Transport Polynucleotides, Polypeptides, and Antibodies
; FILE REFERENCE: PTO10P1
; CURRENT APPLICATION NUMBER: US/09/767,870
; CURRENT FILING DATE: 2001-01-24
; PRIOR APPLICATION NUMBER: PCT/US00/19736
; PRIORITY FILING DATE: 2000-07-20
; PRIORITY APPLICATION NUMBER: 60/145,215
; PRIOR FILING DATE: 1999-07-23
; PRIORITY APPLICATION NUMBER: 60/149,445
; PRIOR FILING DATE: 1999-08-18
; PRIORITY APPLICATION NUMBER: 60/164,730

```

; PRIORITY FILING DATE: 1999-11-12
; SEQ ID NOS: 21
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 9
; LENGTH: 664
; TYPE: PRT
; ORGANISM: Homo sapiens
US-09-767-870-9

Query Match          9.28%
Best Local Similarity      58.8%
Matches   30;  Consistent    7

```

QY	234	SFLVINNATLRLNQKGENDPSHY
	:	: : : : : :
Db	3	AFVNRSNATLRLHLLPPGPARHAH

Search completed: February 4, 2000
Job time : 22 secs

Search completed: February 4, 2003, 09:44:20
Job time : 22 secs

PRIOR FILING DATE: 1999-11-12
NUMBER OF SEQ ID NOS: 21
SOFTWARE: Patentin Ver. 2.0
SEQ ID NO 9
LENGTH: 664
TYPE: PRT
ORGANISM: Homo sapiens
PRTR-09-7767-870-q

GenCore version 5.1.3
Copyright (c) 1993 - 2003 Compugen Ltd.

OM protein - protein search, using sw model

Run on: February 4, 2003, 09:38:27 ; Search time 19 Seconds
(without alignments)
1436.957 Million cell updates/sec

Title: US-09-704-272-6
Perfect score: 1525

Sequence: 1 FGKYPSELQPMYEQYTF.....PLNLTKQQLSEVALMTTSVD 284

Scoring table: BLOSUM62

Gapop 10.0 , Gapext 0.5

Searched: 283224 seqs, 96134422 residues

Total number of hits satisfying chosen parameters: 283224

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database : PIR73.*
1: pirl:*

2: pir2:*

3: pir3:*

4: pir4:*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query	Match	Length	DB ID	Description
1	1423	93.3	2201	2	A54774	ATP binding cassette transporter ABC1 - mouse
2	267	17.5	1529	2	A59189	ATP binding cassette transporter ABC1 - mouse
3	257	16.9	1474	2	B54774	ATP binding cassette transporter ABC1 - mouse
4	215.5	14.1	1447	2	T15200	hypothetical protein
5	108.5	7.1	432	2	T14292	glutamate-ammonia ligase
6	100.5	6.6	434	1	AJBBQ	glutamate-ammonia ligase
7	98	6.4	877	2	F90070	Clumping factor B
8	97	6.4	908	2	T16057	hypothetical protein
9	95.5	6.3	429	1	AJFBQD	glutamate-ammonia ligase
10	94.5	6.2	263	2	C64339	hypothetical protein
11	94.5	6.2	430	2	S18600	glutamate-ammonia ligase
12	94.5	6.2	4660	2	T42737	gp330 protein precursor
13	92.5	6.1	428	1	AJRZQD	glutamate-ammonia ligase
14	91	6.0	459	2	B83793	hypothetical protein
15	90.5	5.9	428	2	S32228	glutamate-ammonia ligase
16	90	5.9	773	2	F90537	lipoprotein limop
17	89.5	5.9	423	2	S39482	glutamate-ammonia ligase
18	89.5	5.9	596	1	S33540	catechol oxidase (hypothetical protein)
19	89.5	5.9	649	2	B96729	glycoprotein B pre-munchback-related protein
20	89	5.8	903	1	VGBEB1	hypothetical protein
21	88.5	5.8	363	2	AG2023	hypothetical protein
22	88.5	5.8	865	2	AG2023	hypothetical protein
23	88.5	5.8	903	1	VGBEK1	glycoprotein B pre-munchback-related protein
24	88.5	5.8	982	2	T43676	hypothetical protein
25	88.5	5.8	1071	2	T18597	hypothetical protein
26	88.5	5.8	1650	2	S53457	dominant autoantigen
27	88	5.8	678	2	S12456	virD3 protein - Ag
28	88	5.8	791	2	S67265	hypothetical protein
29	88	5.8	888	2	S64016	probable regulator

RESULT 1						
A54774	ATP binding cassette transporter ABC1 - mouse					
C:Species: Mus musculus (mouse mouse)						
C:Date: 05-Apr-1995 #sequence_change 02-Feb-2001						
C:Accession: A54774						
R;Luciani, M.F.; Denizot, F.; Savary, S.; Mattei, M.G.; Chimini, G.						
Gnomics 21, 150-159, 1994						
A:Title: Cloning of two novel ABC transporters mapping on human chromosome 9.						
A:Reference number: A54774; MUID: 94375008; PMID: 8088782						
A:Accession: A54774						
A:Molecule type: mRNA						
A:Residues: 1-2201 <JUC>						
A:Cross-references: GB:X7526; PID:9495256; PMID:CAA53530.1; PID:9495257						
C:Superfamily: unassigned ATP-binding cassette proteins; ATP-binding cassette homolog						
C:Keywords: ATP; duplication; nucleotide binding; P-loop						
F;856-1047/Domain: ATP-binding cassette homology <ABC1>						
F;73-880/Region: nucleotide-binding motif A (P-loop)						
F;1869-7060/Domain: ATP-binding cassette homology <ABC2>						
F;1886-1893/Region: nucleotide-binding motif A (P-loop)						
Query Match Best Local Similarity 93.3%; Score 1423; DB 2; Length 2201;						
Matches 264; Conservative 10; Mismatches 10; Indels 0; Gaps 0;						
QY 1 FGKYPSELQPMYEQYTFVSNDAPEDTGTLELLNALTQDPGFTRCMEGNPIPDTPCQ 60						
Db 1311 FGKYPSELQPMYEQYTFVSNDAPEDTGMQELLNALTQDPGFTRCMEGNPIPDTPCL 1370						
QY 61 AGEEENTTAPVQTIMDLQFQNWTMONPSACQCSDDTKKMLPVCPGAGGLPPQRK 120						
Db 1371 AGEDWTIISPVQSTIVLDFQNGNWTHKNPSPACQCSDDTKKMLPVCPGAGGLPPQRK 1430						
QY 121 QNTADILQDTGRNISDYLKVTKYVQIATSKLKNTWNEFRYGGFLGVNTQALPPSQE 180						
Db 1431 QKTADILQNLTRNISDYLKVTKYVQIATSKLKNTWNEFRYGGFLGVNSQALPPSHE 1490						
QY 181 VNDATIKOMKKHKLAKDSSADRFNLNSIGRFTMGLDTRNKYWFNNKGWHAISSEFLNVIN 240						
Db 1491 VNDATIKQMKKLLKLTQDSADRFLSIGRFNAGLDTKNNYWFNNKGWHAISSEFLNVIN 1550						
QY 241 NAIILRNLQKGENDPSHYGITAFNHP1NLTKQOLSEVALMTTSVD 284						
Db 1551 NAIILRNLQKGENDPSHQYGITAFNHP1NLTKQOLSEVALMTTSVD 1594						
RESULT 2						
A59189 ATP-binding cassette transporter - human (fragment)						
N;Alternate names: KIAA1062 protein						
C:Species: Homo sapiens (man)						
C:Date: 18-Feb-2000 #sequence_change 18-Feb-2000						

C;Accession: A59189 R;Kikuno, R.; Nagase, T.; Ishikawa, K.; Hirosawa, M.; Miyajima, N.; Tanaka, A.; Kotani, R;DNA Res. 6, 197-205, 1999 A;Title: Prediction of the coding sequences of unidentified human genes. XIV. The complete A;Reference number: Z22961; MUID:99397452; PMID:10470851	Qy 55 ---PD-----TPCQAGEEEWTTAP-VPOTIMDLFQNGNWTMQNPSACQCSSDKI 100 Db 638 PVXPDDDSLQAWNMLPPAGPEWTSASLSPRLVHEPR-----CTCSAGT 685
A;Accession: A59189 A;Status: preliminary; not compared with conceptual translation A;Molecule type: mRNA A;Residues: 1-1529 <KIK> A;Cross-references: GB:AB028985; NID:95688460; PIDN:BAA83014.1; PID:956894 A;Experimental source: chromosome 9; Clone hjo3579; clone lib pBluescriptII SK plus; tis C;Genetics: A;Map position: 9 A;Note: KIAA1062 C;Superfamily: unassigned ATP-binding cassette proteins; ATP-binding cassette homology	Qy 101 KKMLPVCPGAGGLPPQPKONTADILQDGTGRNSDYLVKTQVIIAKSLKNNKIYNEF 160 Db 686 GFS---CPSSVG-HPPQMRVVTGDLDTGHNVEYLFSDRF-----RLH 730
Query Match 17.5% Best Local Similarity 29.2%; Pred. No. 2,4e-13; Matches 80; Conservative 35; Mismatches 73; Indels 86; Gaps 12;	Qy 161 RYGGFSLGVSTQALPPQEINDAIKQMKHLKAQDSADRFLNSLGFMGTDTRNN 220 Db 731 RYGAIFG--NVQKSIPAS-----FGARVPMPVKLAVERVA 765
Qy 44 FGTRCMEG-----NPPIP-DTPCQ-----AGEPEWTTAP-V 71 Db 665 FDSMCLESFTQGLPLSNFVPPPSDPSAPSDPSAPSDPSAPSDPSAPSDPSAPSDPSAPSL 724	RESULTS 4 t15200 hypothetical protein F12B6.1 - Caenorhabditis elegans C;Species: Caenorhabditis elegans C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 17-Mar-2000 C;Accession: T15200 R;Pauley, A.; Maggi, L. A;Description: The sequence of C. elegans cosmid F12B6. A;Reference number: Z18307 A;Accession: T15200 A;Status: preliminary; translated from GB/EMBL/DBJ A;Molecule type: DNA A;Residues: 1-147 <PAU> A;Cross-references: EMBL:AF003138; NID:92088708; PID:92088709; PIDN:AA54153.1; GSPDB A;Experimental source: strain Bristol N2; clone F12B6 C;Genetics:
Db 815 -----TAVRAAQVFVNNGK3HSMPTYLNSLNNAILLRNLPKS 852 Qy 252 E-NPSHYGITAFAHNPLNLTQOQLS-EVALMTVS 283 Db 853 KGPNPAAYGITVTHBMNKTSAASLSLDLYLQGTDV 886	Qy 132 GRNSDLYKTYQQIPIAKSLKNNKIWNEFRGGFSLGVSNNTQALPPSQEVNDAIKOMKKH 191 Db 769 GHNVSEYLLFTSDRF-----RLRYGAIFG -NVLKSIPIASEFTGTRAPPVMVRK- 814 Qy 192 LKLAKDSSADPFLNSLGRFMGTDTRNNKWWNNKGWAISSSLFVNNAILLRNLQKG 251 Db 815 -----TAVRAAQVFVNNGK3HSMPTYLNSLNNAILLRNLPKS 852 Qy 252 E-NPSHYGITAFAHNPLNLTQOQLS-EVALMTVS 283 Db 853 KGPNPAAYGITVTHBMNKTSAASLSLDLYLQGTDV 886
RESULT 3 ATP binding cassette transporter ABC2 - mouse (fragment) C;Species: Mus musculus (house mouse) C;Accession: B54774 R;Luciani, M.F.; Denizot, F.; Savary, S.; Mattei, M.G.; Chimini, G. A;Title: Cloning of two novel ABC transporters mapping on human chromosome 9. A;Reference number: A54774; MUID:94375008; PMID:808782 A;Accession: B54774 A;Molecule type: mRNA A;Residues: 1-1472 <LUC> A;Cross-references: GB:X75927; NID:9495258; PIDN:CA53531.1; PID:9495259 C;Superfamily: unassigned ATP-binding cassette proteins; ATP-binding cassette homology C;Keywords: ATP; nucleotide binding; P-loop F;44-234/Domain: ATP-binding cassette homology <ABC1> F;61-138/Region: nucleotide-binding motif A (P-loop) F;1108-1300/Domain: ATP-binding cassette homology <ABC2> F;1126-1133/Region: nucleotide-binding motif A (P-loop)	Qy 79 5PSLELQPWMYNEQYTFEVSN--DAPEDTGTELLNALTQDPGFGTRCMEG--NP1PDT---57 Db 605 PPLPLERSIMGNHSDFPVNSWNTDAENSTANDILHAMFSPTGPCKADKVPNLDDTMRR 664 Qy 58 -----PCQ -AGEEWT-----PCQ -AGEEWT-----TAPVPTIMDL- 78 Db 665 ELMFRNRYGEGRNKPKAPGVDKDSVDNEYOCQNIQGFEDIDISNATYNAPIYCCEDFG 724 Qy 79 -----FQNGNWTMQNPSACQCSSDKIKMFLPVCPGAGGLPPQPKONTADILQDGTGRN 134 Db 725 WNTLEDKWKNTN-----WLRNNTDRIFDLTGRN 755 Qy 135 ISDY-LYKTYQQIPIAKSLKNNKIWNEFRGGFSLGVSNNTQALPPSQEVND-----AI 185 Db 756 LTQFLRILTRFAQLANT'A-----PFELFGFSLGHVNQRA--QSQADITTSKRMLETI 806 Qy 186 KQMKHLKLN-----AKSSADPFLNSLGRFMGTDTRNNKWWNN 226 Db 807 KDTAQSHMIIINLNNTGIEPATPKVLDFFAQNTLQVNDL--LQNDYRENVKWN 863 Qy 247 KGRAISSFLVNNAILLRNLQKGEPHYGITAFAHNPLNLT-QQLESEVALMT 281 Db 864 KIWPGFPPIASNLNSNALLRQE-DYADPDELGILTMMHPMKTISQLDQNALKET 918
Query Match 16.9%; Best Local Similarity 24.9%; Matches 91; Conservative 40; Mismatches 98; Indels 136; Gaps 15;	Qy 2 GKPSLELQPWMYNEQY-----FVSNDAPE-----DTGLELLNALTQDPGFGT 46 Db 519 GDLPPLVLSPSOY-NYTOPRGNFIPYANEEFRQLRLSPASQQLVSTFLPSVGA 577 Qy 47 RCM-----EGNPI-----54 Db 578 TCVLKPANGSLGPMLNLSSGESRLAARFFDSMCLESFTQGLPLSNFVPPPSPAPSDS 637

RESULT 5
 T14292 glutamate-ammonia ligase (EC 6.3.1.2) - carrot
 N;Alternate names: glutamine synthetase
 C;Species: Daucus carota (carrot)
 C;Date: 20-Sep-1999 #sequence_revision 20-Sep-1999 #text_change 03-Jun-2002
 C;Accession: T14292
 A;Status: preliminary; translated from GB/EMBL/DDJB
 A;Molecule type: mRNA
 A;Residues: 1-322 <HIG>
 A;Cross-references: EMBL:AF019561; NID:92454632; PMID:92454633
 A;Experimental source: strain US-Harumakigosun; leaf
 C;Genetics:
 A;Gene: GS2
 C;Function:
 C;Superfamily: glutamate-ammonia ligase
 C;Keywords: ligase
 C;Description: catalyzes the formation of glutamine from ammonia and glutamic acid in the plant cell
 C;Sequence: catalyzes the formation of glutamine from ammonia and glutamic acid in the plant cell

Query Match 7 1%; Score 108 5; DB 2; Length 432;
 Best Local Similarity 24.5%; Pred. No. 0.42%;
 Matches 71; Conservative 26; Mismatches 110; Indels 83; Gaps 15;

Qy	3 KYPSELQPMWNEQYTFNSNDAPEDTGTELL-NALTKDGGG-----TRCMGN 52	Db	105 EHPS-ELPKWNYDGSSST--GQAQDDSEVILYQPAIKDPFRGGNNNIVICDTYTPQGE 160
Qy	53 PIPDTPCQ-----AGEEEWTTAQPOTIMDLFQNGNNNTMONSPACOCSKK 101	Db	161 PIPTNKRHKAAQIFSDAKVLGEPFWGTFEQETIMQ---QDVNW----- 201
Qy	102 KMLPLVCPGG--AGGLPPPPQRKONTADILQLDTGRNISDXLYVQIIAKSLKNK 159	Db	202 -----PLGVNVGGYGPQDPSYYCAAGDKSFRGDISAHYKACL----- 240
Qy	160 FRYGGFLSGVSNTQALPQQE--VNDAIK-QMKKHLKLAQDSSADRFLNSLGRFMGTLD 216	Db	245T --YAGTINISCTNGEVMPGQWEFQGPSVGIEADPHIWCAR-YLLERITQAVSVL-TDP 296
Qy	217 RNNVKVWNNGKWHIASSF-----INVINNAIRNLRLQKGEPNSHYG 258	Db	297 KPIDGDW-NGAGCHTNYSFKSMRREEGGFEVIKAILNLSLRKEHISAYG 345

Query Match 7 1%; Score 108 5; DB 2; Length 432;
 Best Local Similarity 24.5%; Pred. No. 0.42%;
 Matches 71; Conservative 26; Mismatches 110; Indels 83; Gaps 15;

Qy	3 KYPSELQPMWNEQYTFNSNDAPEDTGTELL-NALTKDGGG-----TRCMGN 52	Db	105 EHPS-ELPKWNYDGSSST--GQAQDDSEVILYQPAIKDPFRGGNNNIVICDTYTPQGE 160
Qy	53 PIPDTPCQ-----AGEEEWTTAQPOTIMDLFQNGNNNTMONSPACOCSKK 101	Db	161 PIPTNKRHKAAQIFSDAKVLGEPFWGTFEQETIMQ---QDVNW----- 201
Qy	102 KMLPLVCPGG--AGGLPPPPQRKONTADILQLDTGRNISDXLYVQIIAKSLKNK 159	Db	202 -----PLGVNVGGYGPQDPSYYCAAGDKSFRGDISAHYKACL----- 240
Qy	160 FRYGGFLSGVSNTQALPQQE--VNDAIK-QMKKHLKLAQDSSADRFLNSLGRFMGTLD 216	Db	245T --YAGTINISCTNGEVMPGQWEFQGPSVGIEADPHIWCAR-YLLERITQAVSVL-TDP 296
Qy	217 RNNVKVWNNGKWHIASSF-----INVINNAIRNLRLQKGEPNSHYG 258	Db	297 KPIDGDW-NGAGCHTNYSFKSMRREEGGFEVIKAILNLSLRKEHISAYG 345

RESULT 6
 AJBHQ glutamate-ammonia ligase (EC 6.3.1.2) 2 precursor, chloroplast - barley
 N;Alternate names: glutamine synthetase 2
 C;Species: Hordeum vulgare (barley)
 C;Date: 30-Sep-1991 #sequence_revision 30-Sep-1991 #text_change 03-Jun-2002
 C;Accession: S11865; S12687; S14893; A30468; S05371
 R;Stroman, P.; Bain, S.; Casadore, G.
 Plant Mol. Biol. 15, 161-163, 1990
 A;Title: A cDNA sequence coding for glutamine synthetase in *Hordeum vulgare* L.
 A;Reference number: S11865; PMID:91355050; PMID:1983297
 A;Accession: S11865
 A;Molecule type: mRNA
 A;Residues: 1-434 <STR>
 R;Casadore, G.
 submitted to the EMBL Data Library, June 1990

RESULT 7
 F90070 Clumping factor B [Imported] - *Staphylococcus aureus* (strain N315)
 C;Species: *Staphylococcus aureus*
 C;Date: 10-May-2001 #sequence_revision 10-May-2001 #text_change 22-Oct-2001
 C;Accession: F90070
 R;Kuroda, M.; Ohta, T.; Uchiyama, I.; Baba, T.; Yuzawa, H.; Kobayashi, I.; Cui, L.; Oma, A.; Mizutani-Uti, Y.; Kobayashi, N.; Sawano, T.; Inoue, R.; Kaito, C.; Sekimizu, K. C.; Shiba, T.; Hattori, M.; Ogasawara, N.; Hayashi, H.; Hiramatsu, K.
 Lancet 357, 1225-1240, 2001
 A;Title: Whole genome sequencing of *meticillin-resistant Staphylococcus aureus*.
 A;Reference number: A89758; PMID:21311952; PMID:11418146
 A;Accession: F90070
 A;Status: preliminary
 A;Molecule type: DNA
 A;Cross-references: GB:BA000018; PMID:913702586; PIDN:BAB43728.1; GSPDB:GN00149
 A;Experimental source: strain N315
 C;Genetics:
 A;Gene: clfB

Query Match 6.4%; Score 98; DB 2; Length 877;
 Best Local Similarity 21.7%; Pred. No. 7.8;
 Matches 61; Conservative 40; MisMatches 116; Indels 64; Gaps 12;

Qy	15	NEQYTFVSNDAPEDGTGTLERL-----LNAL-TKDPGEGTRCMEGNP.TPDTPCQCAGEEE	65	R; Lightfoot, D.A.; Green, N.K.; Cullimore, J.V.
Plant Mol. Biol.	11,	191-202, 1988		
A; Title:	The chloroplast-located glutamine synthetase of <i>Phaseolus vulgaris</i> L. : nucleic acid sequence			
A; Reference number:	504031			
A; Accession:	S04031			
A; Molecule type: mRNA				
A; Residues: 1-149 <LIG>				
A; Cross-references: GB:X12738; NID:921004; PIDN:CAA31234.1; PID:921005				
Db	152	NDANSIAATSELNSQTLDPQSSPOTISNAQTSKPSVTRSLAAEVPVNAADAK	211	
Qy	66	WTTA-----PVPQTMDLFONGNTMQNQSPACCCSDKIKR-----MLPICPG 110		
Db	212	GTVNNDKVTAATSNFKLEKTTFDPNOSGNTEM---AANFTVTDKVKSGDYETAKLPDSLTC	267	
Qy	111	AGGLPPPPORKQNT---ADILQ--DLTGRNISDYLVKVQTIASKLNKINWNEFRYGG	164	R; Cock, J.M.
Db	268	NGDV-DYSSNNTQALPPSEVNIAAIKOMKKHLKLAKDSSADREFLNSLGRFMGLDTRNNVYKWF	322	submitted to the EMBL Data Library, July 1991
Qy	165	FSLGVSNTOALPPSEVNIAAIKOMKKHLKLAKDSSADREFLNSLGRFMGLDTRNNVYKWF	224	
Db	323	FSLIPLFTDRAKPSKGTYDA-----NTIADEMENNNKTYNSPIAGIDKPGNGAN--	373	
Qy	225	NNKGWHAISSFLVNNAILRLANLQKGGENPSKHGKITAENHP	265	C; Superfamily: glutamate/ammonia ligase
Db	374	ISSQITIGVDTASGQNT--YKQTIVFVN P	398	C; Keywords: chloroplast; Ligase
				F:1-57/Domain: transit peptide (chloroplast) #status predicted <NP>
				F:58-429/Product: glutamate-ammonia ligase delta #status predicted <NP>
				Query Match Score 6.3%; Best Local Similarity 24.1%; Pred. No. 4.8; Matches 69; Conservative 26; Mismatches 116; Indels 75; Gaps 14;
				Query Match Score 95.5%; Best Local Similarity 24.1%; Pred. No. 4.8; Matches 69; Conservative 26; Mismatches 116; Indels 75; Gaps 14;
Db	106	KYPSLELOPWWNEYQXQTFVSNDAPEDTGTLALLKDPGFGRCM-----EGN 52		
Db	102	EIPS-ELPKWNNDGSST--GQAPGEDSEVILYPAQIFKDFERGGANNILVICDAYTPAGE 157		
Qy	53	PIPDTPCOAGEEEWT-----APVP-----QIMDLEFQNGNMTMQNSPACQCSDPIKKM 103		
Db	158	PIFTNKRHRAAEVFSNPRVIAEPWPGIEQEYTLLOTNVAMPGP-----	203	
Qy	104	LPVCPGGAGGLPQPKQONTADILQDITGRNISD-YLVKTYVQIIAKSLKNKIVNNEFR 161		
Db	204	----VGGYEGPGPYCSAGADKSFGRDTSADHYKACHFAGANISGTNGEVMPGQWE	256	
Qy	162	YG-GFSLVNSNTQALPPSQEVNDAIKOMKKHLKLAKDSSADREFLNSLGRFMGLDTRNNV 220		
Db	257	YQVGPSPVQI-----EAGDHIIWASRYL-----ERITEQAG-VVLSLDPKPIE 297		
Qy	221	KVWNFKNGWHAISSF-----LNVINNATLRLNQGENPSHYG 258		
Db	298	GDW-NGAGCHTNYSTKSMREDGEFEVTKATLNLRRKEHTSAYG 342		
				RESULT 10
				C64339
				hypothetical protein MJ0314 - Methanococcus jannaschii
				C; Species: Methanococcus jannaschii
				C; Description: 13-Sep-1996 #text_change 21-Jul-2000
				C; Accession: C64339
				C; Authors: Olsen, G.J.; Zhou, L.; Fleischmann, R.D.; Sutton, G.G.; Blakemore, R.; Bult, C.J.; White, O.; Weinstock, K.G.; Merrick, J.M.; Glodek, R.; Reich, C.I.; Overbeek, R.; Kirkness, E.F.; Haenni, M.C.; Cotton, M.D.; Roberts, K.M.; Hurst, M.A. ; Sadow, P.W.; Woessner, J.D.; Sadow, P.W.; Haenni, M.C.; Cotton, M.D.; Roberts, K.M.; Hurst, M.A.
				C; Title: Complete genome sequence of the methanogenic archaeon, <i>Methanococcus jannaschii</i>
				C; Reference number: A64300; PMID:96337999; PMID:8688087
				C; Accession: C64339
				C; Status: preliminary; nucleic acid sequence not shown; translation not shown
				A; Molecule type: DNA
				A; Residues: 1-263 <BUL>
				A; Cross-references: GB:U67486; GB:L77117; NID:91591031; PIDN:AAB98310.1; PID:91591031
				C; Genetics:
				A; Map position: FOR293501-294372
Qy	243	ILRNQGENPSHYGTAFNHPLNLTKQQLSEVA	277	
Db	342	V--SSSTTEQES--ALSATLDMSSPSLSTLA	372	

Db	43	PQEIKLYQNG-YTTEIAKIMKKSHETRRLI-----RNNNTDI-----81
Qy	132	GRTNSDYLVTKYQQLIAKSIKN- -KIWINNEFRYGGFSLGSNTQALPPSQEVN-----182
Db	82	-RKSESLSI-----IKNTKRKINLNPSESTAYLIGVLNGDSVKQESNVYIELKV 130
Qy	183	--DAIKOMKKHLAKDSSADPFLNSLGRFMTGLDTRANVKWVNNGK--WHIA---IS 233
Db	131	TDKFIEEIKRNL---ENIGFKVINEYVRKFENKKDQYVVVRV-RSKGFYWWKSLNWD 184
Qy	234	SFLAVNI-NNAILRANLQKG 251
Db	185	YYMMNVIGNNEKEKLM-SWLKG 203
RESULT 11		
Qy	818600	glutamate-ammonia ligase (EC 6.3.1.2) precursor, chloroplast (clone lambdaAtgs11) -
N;Alternate names:	glutamine synthetase	
C;Species:	Arabidopsis thaliana (mouse-ear cress)	
C;Date:	22-Nov-1993 #sequence_revision 12-May-1995 #text_change 03-Jun-2002	
C;Accession:	818600	
R;Peterman, T.K.; Goodman, H.M.		
Mol. Gen. Genet. 230, 145-154, 1991		
A;Title:	The glutamine synthetase gene family of Arabidopsis thaliana: light-regulation	
A;Reference number:	S18600; MUID:92079889; PMID:1684022	
A;Accession:	818600	
A;Molecule type:	mRNA	
A;Residues:	1-430 <PET>	
A;Cross-references:	EMBL:S69727; NID:9240069; PIDN:AAB20558.1; PID:9240070	
C;Experimental source:	Clone lambdaAtgs11	
C;Genetics:		
C;Genome:	nuclear	
C;Superfamily:	glutamate-ammonia ligase	
C;Keywords:	chloroplast; ligase	
F;1.51/Domain:	transit peptide (chloroplast) #status predicted <TNP>	
F;52-430/Product:	glutamate-ammonia ligase #status predicted <MAT>	
Query Match	6.28% Score 94.5; DB 2; Length 430;	
Best Local Similarity	23.18%; Pred. No. 5.9;	
Matches	67; Conservative 25; Mismatches 111; Indels 87; Gaps 14;	
Qy	5 PSLFQPMNQNEYQTFSNDAP-FDTGTLLENNALTDPGFG-----TRCMEGNPI 54	
Db	105 PS-ELPKNNDGSS---GQAPIPSEVTLYPQAIFDPRFRRGGNNILVICD1WTPAGEPI 160	
Qy	55 P-----DTPCQAGEEWEVTAPVQPTIMLDLFQNGNWTMQNPSPACQCSSDKIKM 103	
Db	161 PTNRKRAAEIFSNKKYSGEVPIFQIEOBYTLQ---QNKWKPLGWPM-----204	
Qy	104 LPVCPGGAGGLPPQRKQNTADILQLDTGRNISDLYLKTYVQTLAKS1KRN1WNEFRY 163	
Db	205 -----VGAFFPSQGPQPYCGNGADK1WGRD1SDAHYKACL-----YA 240	
Qy	164 GFSGIGVSNTQALPPSQEVN-----DAIKQMKKKHLAKDSSADRF1LN5LGRFMTGLD 216	
Db	241 GINTSGTNGEVMPQWFQVGPSVGIIDA---GDHVNRCAR-YLLERTEQAGVVLT-LDP 294	
Qy	217 RNNVKWVNNGKHAISSE-----LNVINN1LRANLQKGENSEPHYG 258	
Db	295 KPIEGDW-NGAGCHTNYSTKSMREGGFEVIKKAI1NLSLRHKHEHISAYG 343	
RESULT 12		
T42737	gp30 protein precursor - rat	
N;Alternate names:	megalin	
C;Species:	Rattus norvegicus (Norway rat)	
C;Date:	11-Jan-2000 #sequence_revision 11-Jan-2000 #text_change 04-Mar-2000	
C;Accession:	T42737	
R;Saito, A.; Pietromonaco, S.; Loo, A.R.C.; Farquhar, M.G.		
Proc. Natl. Acad. Sci. U.S.A. 91, 9725-9729, 1994		
A;Title:	Complete cloning and sequencing of rat gp330/megalin, a distinctive member	

A; Reference number: A58173; MUID:95024033; PMID:7937880	Qy 1 FGKYP -- LELOPWW-----YNEQYTFVSNDAPEDTGTLF	Db 4302 FGRENKEVVLVNNWLTQRIFHQLRYNQS -- VSNPCRCVCSHLCL
A; Accession: T42737	Qy 2 FVNNNGHAISSFLNVINNAILRNLQKGENDSHYGITAFNPHLN	Db 4309 FVNNNGHAISSFLNVINNAILRNLQKGENDSHYGITAFNPHLN
A; Status: preliminary; translated from GB/EMBL/DDJB	Qy 3 GGFSLGVNTQALPPSQEVNDAIKQMKHLKLAKDSADRFNSLIG	Db 4355 GGFSLGVNTQALPPSQEVNDAIKQMKHLKLAKDSADRFNSLIG
A; Molecule type: mRNA	Qy 4 4490 IGVSPFGPETIDRSMAAMNEHFV -- MEVGKQP --- VTFENPMY	Db 4490 IGVSPFGPETIDRSMAAMNEHFV -- MEVGKQP --- VTFENPMY
A; Residues: 1-4660 <SAI>	Qy 5 PSLEQPOWMNEQYTFVSNDAPED-TGTLWLLNALTKDPGFG--	Db 4491 PSLEQPOWMNEQYTFVSNDAPED-TGTLWLLNALTKDPGFG--
A; Cross-references: EMBL: T42409; NID:9561852; PID:9561852	Qy 6 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL	Db 4492 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
A; Experimental source: strain Sprague-Dawley; kidney	Qy 7 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4493 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----
C; Superfamily: alpha-2-macroglobulin receptor; EGF homologous domain	Qy 8 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG	Db 4494 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
F; 25-4660/Product: qp330 protein #status predicted #MAT	Qy 9 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4495 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG
Query Match Score 6.28; Score 94.5; DB 2; Local Similarity 23.6%; Pred. No. 1.4e+02; Mismatches 37; Mismatches 111; I	RESULT 13	AJRZQD
Best Local Similarity 23.6%; Pred. No. 1.4e+02; Mismatches 70; Conservative	Qy 10 450 --- RKTGSLIP-----LPKPLPSLSSLAKE-----NGNGC	N; Alternative names: glutamine synthetase delta
Qy 11 4490 IGVSPFGPETIDRSMAAMNEHFV -- MEVGKQP --- VTFENPMY	Db 450 --- RKTGSLIP-----LPKPLPSLSSLAKE-----NGNGC	C; Species: Oryza sativa (rice)
Qy 12 4491 PSLEQPOWMNEQYTFVSNDAPED-TGTLWLLNALTKDPGFG--	Db 4491 PSLEQPOWMNEQYTFVSNDAPED-TGTLWLLNALTKDPGFG--	C; Accession: S07471
Qy 13 4492 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL	Db 4492 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL	C; Accession: S07471
Qy 14 4493 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4493 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	A; Title: Three cDNA sequences coding for glutamine synthetase
Qy 15 4494 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG	Db 4494 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG	A; Reference number: S07469; MUID:91370845; PMID:2577497
Qy 16 4495 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4495 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	A; Accession: S07471
Qy 17 4496 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL	Db 4496 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL	A; Molecule type: mRNA
Qy 18 4497 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4497 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	A; Residues: 1-428 <SAI>
Qy 19 4498 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG	Db 4498 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG	A; Cross-references: GB:X14246; NID:920369; PIDN:CAA32462
Qy 20 4499 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4499 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	C; Keywords: chloroplast; ligase
Qy 21 4500 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL	Db 4500 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL	Query Match Score 6.1%; Score 92.5; DB 1; Local Similarity 23.6%; Pred. No. 8.5; Mismatches 30; Mismatches 112; I
Qy 22 4501 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4501 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 23 4502 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 23 4503 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4503 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 24 4504 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 25 4505 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4505 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 26 4506 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 26 4507 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4507 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 27 4508 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 27 4509 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4509 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 28 4510 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 28 4511 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4511 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 29 4512 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 29 4513 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4513 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 30 4514 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 30 4515 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4515 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 31 4516 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 31 4517 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4517 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 32 4518 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 32 4519 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4519 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 33 4520 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 33 4521 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4521 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 34 4522 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 34 4523 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4523 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 35 4524 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 35 4525 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4525 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 36 4526 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 36 4527 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4527 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 37 4528 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 37 4529 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4529 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 38 4530 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 38 4531 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4531 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 39 4532 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 39 4533 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4533 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 40 4534 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 40 4535 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4535 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 41 4536 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 41 4537 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4537 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 42 4538 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 42 4539 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4539 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 43 4540 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 43 4541 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4541 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 44 4542 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 44 4543 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4543 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 45 4544 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 45 4545 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4545 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 46 4546 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 46 4547 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4547 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 47 4548 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 47 4549 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4549 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 48 4550 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 48 4551 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4551 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 49 4552 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 49 4553 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4553 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 50 4554 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 50 4555 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4555 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 51 4556 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 51 4557 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4557 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 52 4558 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 52 4559 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4559 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 53 4560 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 53 4561 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4561 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 54 4562 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 54 4563 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4563 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 55 4564 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 55 4565 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4565 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 56 4566 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 56 4567 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4567 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 57 4568 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 57 4569 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4569 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 58 4570 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 58 4571 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4571 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 59 4572 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 59 4573 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4573 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 60 4574 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 60 4575 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4575 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 61 4576 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 61 4577 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4577 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 62 4578 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 62 4579 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4579 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 63 4580 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 63 4581 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4581 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 64 4582 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 64 4583 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4583 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 65 4584 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 65 4585 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4585 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 66 4586 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 66 4587 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4587 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 67 4588 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 67 4589 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4589 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 68 4590 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 68 4591 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4591 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 69 4592 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 69 4593 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4593 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 70 4594 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 70 4595 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4595 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 71 4596 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 71 4597 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4597 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 72 4598 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 72 4599 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4599 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 73 4600 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 73 4601 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4601 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 74 4602 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 74 4603 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4603 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 75 4604 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 75 4605 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4605 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 76 4606 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 76 4607 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4607 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 77 4608 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 77 4609 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4609 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 78 4610 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 78 4611 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4611 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 79 4612 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 79 4613 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4613 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 80 4614 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 80 4615 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4615 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 81 4616 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 81 4617 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4617 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 82 4618 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 82 4619 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4619 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 83 4620 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 83 4621 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4621 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 84 4622 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 84 4623 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4623 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 85 4624 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 85 4625 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4625 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 86 4626 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 86 4627 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4627 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 87 4628 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 87 4629 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4629 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 88 4630 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 88 4631 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4631 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 89 4632 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 89 4633 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4633 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 90 4634 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 90 4635 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4635 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 91 4636 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 91 4637 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4637 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 92 4638 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 92 4639 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4639 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 93 4640 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 93 4641 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4641 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 94 4642 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 94 4643 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4643 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 95 4644 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 95 4645 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4645 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 96 4646 166 SLGVNTQALPPSQE--VNDALKMKKHLKLAKDSADRFNSLIG
Qy 96 4647 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Db 4647 241 NISGTGNBVMGQWMEYQVGPSPVIEAGDHIWISH-YLLEIRITEQAG	Qy 97 4648 106 VCPGGAGGLPPQKRQNTADILDLTGRNISDLYKVYYQIAKSL
Qy 97 4649 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Db 4649 203 --- VGYGPQGPQPYCAVGSDFKSFRGDISAHYKAACL-----	Qy 98 4650 166 SLGVNTQALPPSQE--VND

Qy	223 WFNNGWHAISPF-----LNVINNAILANLOKGENPSHYG 258	Db	241 NISGTNGEVMPGQWEFQVGPSVGFAGDHWCAR-YLLERITEQAGVVLT-LDPKPIEGD 298
Db	299 W-NGAGCHTNYSTKSMEEDGGEVIRKAILNLSLRHDLHTSAYG 341	Qy	223 WFNNGWHAISPF-----LNVINNAILANLOKGENPSHYG 258
RESULT 14			
C:Species	Bacillus halodurans	Db	299 W-NGAGCHTNYSTKSMEEDGGEVIRKAILNLSLRHDLHTSAYG 341
C:Accession	B83793	Search completed: February 4, 2003, 09:40:38	
R:Takami, H.; Nakasone, K.; Takaki, Y.; Maeno, G.; Sasaki, R.; Masui, N.; Fuji, F.; Hirai	Job time : 25 secs		
A;Title	Complete genome sequence of the alkaliphilic bacterium Bacillus halodurans and		
A;Reference number	A03650; PMID:20512582; PMID:11058132		
A;Accession	B83793		
A;Status	preliminary		
A;Molecule type	DNA		
A;Cross-references	GB:AP001511; GB:BA0000004; NID:910173727; PID:BA04865.1; GSPPDB:GN00		
A;Experimental source	strain C-125		
C;Genetics			
A;Gene	BH1146		
Query Match	6.0%; Score 91; DB 2; Length 459;		
Best_Local_Similarity	33.3%; Pred. No. 12;		
Matches	32;保守性 29; Mismatches 29; Indels 24; Gaps 6;		
Qy	180 EVNDAIKOMKK--HIXKLAKDSSADRFLNLSGRFMIGLDTRNNVYWF---NNKGWHAITS 233	Db	366 EKHESVKRLKAOLSLATESDLDFIGEFG-EDLGID--ESEGVNLLEANSRPGRAI- 421
Qy	234 SFVINNAILANLORGEN----PSHYGTAFNH 264	Db	422 -----FRHPNLQKEERETLRLPHYGFLAKH 448
RESULT 15			
S32228	glutamate-ammonia ligase (EC 6.3.1.2) precursor - rape		
C:Species	Brassica napus (rape)		
C:Date	07-Dec-1994 #sequence_revision 10-Nov-1995 #text_change 03-Jun-2002		
C:Accession	S32228; S32686		
R:Ochs, G.; Schock, G.; Wild, A.			
R:Ochs, G.; Schock, G.; Wild, A.			
A;Description	Nucleotide sequence of a cDNA encoding chloroplastic glutamine synthetase		
A;Reference number	S32228		
A;Accession	S32228		
A;Molecule type	mRNA		
A;Residues	1-428 <OCH3>		
C:Cross-references	ENBL:X72751; NID:9296222; PID:CAA51280.1; PID:9296223		
C:Superfamily	glutamate-ammonia ligase		
C:Keywords	ligase		
Query Match	5.9%; Score 90.5; DB 2; Length 428;		
Best_Local_Similarity	23.9%; Pred. No. 12;		
Matches	68;保守性 28; Mismatches 113; Indels 75; Gaps 14;		
Qy	5 PSLELOPMMNEOYTFSNDAP-EDTGTLEILNALTQDKDGF-----TROMEGNPI 54	Db	103 PS-ELPKWNYDGSSST--GOAPGEDSEVILYPOAIFRDPERGNNNLIVCDTYTPAGEPI 158
Qy	55 P-DTPCQAGE-----EENNTTAPVQPTIMDLEQNGNWNTMQNNSPACQSSDKIKMLP 105	Db	159 PTNKRARAEEIFSNSKKVYNEEIPWFEGLQEYTLQGPVNPNPLGPW----- 202
Qy	106 VCPGAGGLPPQPKQNTADLQDTGRNISDYLVKTYYQIAKSLKNKIWNFRYGGF 165	Db	203 ----VGAYPEQGPQPYXCGVGAEKSGNRDISDAHKACL-----YAGI 240
Qy	166 SUGVSNTQALPPSQE--VNDIAK-OMKKHLKAKDSSADRFLNLSGRFTMTGDLTRNNVYK 222	Db	203 ----VGAYPEQGPQPYXCGVGAEKSGNRDISDAHKACL-----YAGI 240

Result No.	Score	Query	Match Length	DB	ID	Description
1	1513	99.2	2261	1	ABCI_HUMAN	O95477 homo sapien
2	1423	93.3	2261	1	ABCI_MOUSE	P41233 mus musculus
3	733.5	48.1	2273	1	ABCR_HUMAN	P98363 homo sapien
4	267	17.5	2436	1	ABC2_HUMAN	Q9bzC7 homo sapien
5	264	17.3	2434	1	ABC2_MOUSE	P41234 mus musculus
6	108.5	7.1	432	1	GLN2_DAUC	O22506 daucus carota
7	98.5	6.5	434	1	GLN2_HORVU	P13564 hordeum vulgare
8	98.5	6.5	2083	1	DYSE_MOUSE	Q9esd1 mus musculus
9	95.5	6.3	429	1	GLN4_PHAVO	P15102 phaeosilurus vittatus
10	94.5	6.2	263	1	Y314_MEJUA	O57762 methanococcus marcusii
11	94.5	6.2	430	1	GLN2_ARATH	C43127 arabidopsis thaliana
12	94.5	6.2	2080	1	DYSE_HUMAN	O75923 homo sapiens
13	94.5	6.2	4660	1	LRP2_RAT	P98158 rattus norvegicus
14	92.5	6.1	428	1	GLN2_ORYSA	P14655 oryza sativa
15	90.5	5.9	428	1	GLNC_BRANA	P04624 brassica napus
16	89.5	5.9	423	1	GLNC_MAIZE	P25462 zea mays
17	89.5	5.9	596	1	PPOB_LYCIS	C008304 lycopersicum esculentum
18	89	5.8	903	1	VGLB_HSVIF	P06436 herpes simplex virus
19	89	5.8	1597	1	GTFI_STRD0	P11001 streptococcus faecalis
20	88.5	5.8	363	1	YK57_YEAST	P36157 saccharomyces cerevisiae
21	88.5	5.8	982	1	HBL1_CAEEL	Q9xyd3 caenorhabditis elegans
22	88	5.8	678	1	VID5_AGRRL	P13463 agrobacteri
23	88	5.8	888	1	YGB4_YEAST	P25339 saccharomyces cerevisiae
24	87.5	5.7	428	1	GLN2_MEDSA	Q9xq94 medicago sativa
25	87.5	5.7	3148	1	HD_FUGRU	P51112 fusca rubripes
26	87	5.7	2766	1	THYG_HUMAN	P01266 homo sapiens
27	86.5	5.7	944	1	Y1665_UREPA	P99px7 ureaplasma urealyticum
28	86	5.6	633	1	BZZ1_YEAST	P38822 saccharomyces cerevisiae
29	86	5.6	1309	1	RAD9_YEAST	P14737 saccharomyces cerevisiae
30	85.5	5.6	430	1	GLN2_PEA	P08281 pisum sativum
31	85.5	5.6	2212	1	RRPL_EBOZM	Q05318 ebola virus
32	85.5	5.6	2329	1	YLJ6_CAEEL	P34369 caenorhabditis elegans
33	85	5.6	522	1	OCT1_MOUSE	P25425 mus musculus

Scoring table: BLOSUM62		Gapop 10.0 , Gapext 0.5		Alignments					
Searched:		112892 seqs, 41476328 residues							
Total number of hits satisfying chosen parameters:		112892							
Minimum DB seq length: 0									
Maximum DB seq length: 20000000000									
Post-processing: Minimum Match 0%		Maximum Match 100%							
Database :		SwissProt_40_*							
Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.									
SUMMARIES									
Result No.	Score	Query	Length	DB	ID				
1	1513	99.2	2261	1	ABCI_HUMAN				
2	1423	93.3	2261	1	ABCI_MOUSE				
3	733.5	48.1	2273	1	ABCR_HUMAN				
4	267	17.5	2436	1	ABC2_HUMAN				
5	264	17.3	2434	1	ABC2_MOUSE				
6	108.5	7.1	432	1	GLN2_DAUC				
7	98.5	6.5	434	1	GLN2_HORVU				
8	98.5	6.5	2083	1	DYSE_MOUSE				
9	95.5	6.3	429	1	GLN4_PHAVO				
10	94.5	6.2	263	1	Y314_MEJUA				
11	94.5	6.2	430	1	GLN2_ARATH				
12	94.5	6.2	2080	1	DYSE_HUMAN				
13	94.5	6.2	4660	1	LRP2_RAT				
14	92.5	6.1	428	1	GLN2_ORYSA				
15	90.5	5.9	428	1	GLNC_BRANA				
16	89.5	5.9	423	1	GLNC_MAIZE				
17	89.5	5.9	596	1	PPOB_LYCIS				
18	89	5.8	903	1	VGLB_HSVIF				
19	89	5.8	1597	1	GTFI_STRD0				
20	88.5	5.8	363	1	YK57_YEAST				
21	88.5	5.8	982	1	HBL1_CAEEL				
22	88	5.8	678	1	VID5_AGRRL				
23	88	5.8	888	1	YGB4_YEAST				
24	87.5	5.7	428	1	GLN2_MEDSA				
25	87.5	5.7	3148	1	HD_FUGRU				
26	87	5.7	2766	1	THYG_HUMAN				
27	86.5	5.7	944	1	Y1665_UREPA				
28	86	5.6	633	1	BZZ1_YEAST				
29	86	5.6	1309	1	RAD9_YEAST				
30	85.5	5.6	430	1	GLN2_PEA				
31	85.5	5.6	2212	1	RRPL_EBOZM				
32	85.5	5.6	2329	1	YLJ6_CAEEL				
33	85	5.6	522	1	OCT1_MOUSE				

RESULT 1		SEQUENCE FROM N.A.		SEQUENCE FROM N.A.	
ABC1_HUMAN		STANDARD; Q9UN06; Q9NQV4; Q9UN09; Q96G56;		STANDARD; Q9UN06; Q9NQV4; Q9UN09; Q96G56;	
ID	AC	AC		AC	
AC	AC	AC		AC	
OS	OS	SANTAMARINA_FOJO_S., PETERSON_K.M., KNAPPER_C.L., QIU_Y.,		SANTAMARINA_FOJO_S., PETERSON_K.M., KNAPPER_C.L., QIU_Y.,	
OT	OT	PETERSON_K.M., KNAPPER_C.L., QIU_Y.,		PETERSON_K.M., KNAPPER_C.L., QIU_Y.,	
CA	CA	PETERSON_K.M., KNAPPER_C.L., QIU_Y.,		PETERSON_K.M., KNAPPER_C.L., QIU_Y.,	
DB	DB	PETERSON_K.M., KNAPPER_C.L., QIU_Y.,		PETERSON_K.M., KNAPPER_C.L., QIU_Y.,	
DE	DE	ABC1_HUMAN		ABC1_HUMAN	
DT	DT	16-OCT-2001 (Rel. 40, Created)		16-OCT-2001 (Rel. 40, Last sequence update)	
DP	DP	Last annotation update		Last annotation update	
AA	AA	ABC1_HUMAN		ABC1_HUMAN	
GN	GN	ABC1_HUMAN		ABC1_HUMAN	
RA	RA	SANTAMARINA_FOJO_S., PETERSON_K.M., KNAPPER_C.L., QIU_Y.,		SANTAMARINA_FOJO_S., PETERSON_K.M., KNAPPER_C.L., QIU_Y.,	
RA	RA	PETERSON_K.M., KNAPPER_C.L., QIU_Y.,		PETERSON_K.M., KNAPPER_C.L., QIU_Y.,	
RA	RA	OSCARIO_J., REMALEY_A.T., YANG_X.-P.,		OSCARIO_J., REMALEY_A.T., YANG_X.-P.,	
RA	RA	CHIMININI_G., BLACKMON_E.E.,		CHIMININI_G., BLACKMON_E.E.,	
RA	RA	DUVERGER_N., RUBIN_E.M., ROSIER_M.,		DUVERGER_N., RUBIN_E.M., ROSIER_M.,	
RA	RA	Benefice_P.,		Benefice_P.,	
RA	RA	SEQUENCE FROM N.A.		SEQUENCE FROM N.A.	
RT	RT	MEDLINE-20345099; PubMed=10884428;		MEDLINE-20345099; PubMed=10884428;	
RA	RA	SANTAMARINA_FOJO_S., PETERSON_K.M., KNAPPER_C.L., QIU_Y.,		SANTAMARINA_FOJO_S., PETERSON_K.M., KNAPPER_C.L., QIU_Y.,	
RA	RA	PETERSON_K.M., KNAPPER_C.L., QIU_Y.,		PETERSON_K.M., KNAPPER_C.L., QIU_Y.,	
RA	RA	OSCARIO_J., REMALEY_A.T., YANG_X.-P.,		OSCARIO_J., REMALEY_A.T., YANG_X.-P.,	
RA	RA	CHIMININI_G., BLACKMON_E.E.,		CHIMININI_G., BLACKMON_E.E.,	
RA	RA	DUVERGER_N., RUBIN_E.M.,		DUVERGER_N., RUBIN_E.M.,	
RA	RA	Benefice_P.,		Benefice_P.,	
RA	RA	SEQUENCE FROM N.A.		SEQUENCE FROM N.A.	
RA	RA	Schwartz_K., Lawn_R.M., Wade_D.P.;		Schwartz_K., Lawn_R.M., Wade_D.P.;	
RA	RA	"Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ABCA1-mediated cholesterol efflux are regulated by LXR."		"Complete genomic sequence of the human ABCA1 gene: analysis of the human and mouse ABCA1-mediated cholesterol efflux are regulated by LXR."	
RA	RA	RT		RT	
RA	RA	RT		RT	
RA	RA	RT		RT	
RA	RA	RT		RT	
RA	RA	RN [1]		RN [1]	
RA	RA	SEQUENCE FROM N.A.		SEQUENCE FROM N.A.	
RA	RA	MEDLINE-21251004; PubMed=11352567;		MEDLINE-21251004; PubMed=11352567;	
RA	RA	QIU_Y., CAVEILLER_L., CHIU_S., YANG_X., RUBIN_E., CHENG_J.-F.,		QIU_Y., CAVEILLER_L., CHIU_S., YANG_X., RUBIN_E., CHENG_J.-F.,	
RA	RA	RT		RT	
RA	RA	RT		RT	
RA	RA	RT		RT	
RA	RA	RN [1]		RN [1]	
RA	RA	SEQUENCE FROM N.A.		SEQUENCE FROM N.A.	
RA	RA	MEDLINE-99104549; PubMed=10092505;		MEDLINE-99104549; PubMed=10092505;	
RA	RA	LAINGMANN_T., KLUCKEN_J., REIL_M., LIEBISCH_G., LUCIANI_M.F.,		LAINGMANN_T., KLUCKEN_J., REIL_M., LIEBISCH_G., LUCIANI_M.F.,	
RA	RA	RT		RT	
RA	RA	RT		RT	
RA	RA	RT		RT	
RA	RA	RN [1]		RN [1]	
RA	RA	Biochem. Biophys. Res. Commun. 257:29-33(1999).		Biochem. Biophys. Res. Commun. 257:29-33(1999).	
RA	RA	[6]		[6]	

- SEQUENCE OF 21-2261 FROM N.A.
MEDLINE=9364413; PubMed=10431238;
RP RX Rosier M., Funke H., Reai J., Amoura Z., Piette J.-C.,
RA Deleuze J.-F., Brewer H.B., Duverger N., Denetle P., Assmann G.,
RT "Tangier disease is caused by mutations in the gene encoding
ATP-binding cassette transporter 1";
RN Nat. Genet. 22:352-355(1999);
[7]
- VARIANTS FHA THR-1091 AND 1893-GLU-ASP-1894 DEL.
MEDLINE=0001430; PubMed=10533853;
RP RX Brooks-Wilson A., Clees S. M., Roomp K., Zhang L.-H., Yu L.,
RA Marchl M., Brooks-Wilson A., Clee S. M., Zhang L.-H., Roomp K.,
RA Collins J.A., van Dam M., Molhuizen H.O.F., Loubsler O.,
RA Ouellette B.F.P., Sensen C.W., Fichter K., Ashbourne-Excoffon K.J.D.,
RA Boucher B., Pimstone S., Genest J., Martindale D.,
RA Bouchard M.R., Morgan K., Koop B., Pimstone S., Kastelein J.J.P.,
RT "Mutations in the ABC1 gene in familial HDL deficiency with defective
RT cholesterol efflux";
RN Lancet 354:1341-1346(1999).
[8]
- VARIANTS TD ARG-597 AND ARG-1477, AND VARIANT FHA LEU-693 DEL.
MEDLINE=9364411; PubMed=10431236;
RP RX Brooks-Wilson A., Marchl M., Clee S. M., Zhang L.-H., Roomp K.,
RA van Dam M., Yu L., Brewer C., Collins J.A., Molhuizen H.O.F.,
RA Loubsler O., Ouellette B.F.P., Fichter K., Ashbourne-Excoffon K.J.D.,
RA Sensen C.W., Scheerer S., Mott S., Denis M., Martindale D.,
RA Frohlich J., Morgan K., Koop B., Pimstone S., Kastelein J.J.P.,
RA Hayden M.R.;
RT "Mutations in ABC1 in Tangier disease and familial high-density
RT lipoprotein deficiency";
RN Nat. Genet. 22:336-345(1999).
[9]
- VARIANTS TD SER-590; SER-935 AND VAL-937, AND VARIANTS ALA-399 AND
MET-83.
MEDLINE=9364412; PubMed=10431237;
RP RX Diezrich W., Dröbnik W., Klucken J., Langmann T., Boettcher A.,
RA Porsch-Ozquieremez M., Kaminski W.E., Hahmann H.W., Oette K.,
RA "The gene encoding ATP-binding cassette transporter 1 is mutated in
RT Tangier disease";
RN Genet. 22:347-351(1999).
[10]
- VARIANTS TD ILE-929; ARG-597 AND ARG-1477, AND VARIANTS FHA LEU-693
DEI; THR-1091; 1893-GLU-ASP-1894 DEL AND LEU-2150.
MEDLINE=054002; PubMed=11086027;
RP RX Clee S.M., Kastelein J.J.P., van Dam M., Marchl M., Roomp K.,
RA Zwarts K.Y., Collins J.A., Roelants R., Tamashita N., Stulic T.,
RA Suda T., Ceska R., Boucher B., Rondeau C., Desouich C.,
RA Hayden M.R.;
RT "Age and residual cholesterol efflux affect HDL cholesterol levels and
coronary artery disease in ABC1 heterozygotes.,"
J. Clin. Invest. 106:1263-1270(2000).
RN [11]
- VARIANTS TD ASN-1289 AND HIS-1800.
MEDLINE=0171564; PubMed=10706591;
RP RX Brousseau M.E., Schaefer E.J., Dupuis J., Eustace B.,
RA Van Erdewegh P., Goldkamp A.L., Thurston L.M., FitzGerald M.G.,
RA Yasek-McKenna D., O'Neill G., Eberhart G.P., Weiffenbach B.,
RA "Novel mutations in the gene encoding ATP-binding cassette 1 in four
RT tangier disease kindreds.,"
J. Lipid Res. 41:433-441(2000).
RN [12]
- VARIANT TD ASP-1046, VARIANT FHA CYS-230, AND VARIANTS LYS-219;
MEDLINE=20396633; PubMed=10938021;
RP RX Wang J., Burnett J.R., Near S., Young K., Zimmerman B., Hanley A.J.G.,
RA Connolly P.W., Harris S.B., Hegele R.A.;
RT "Common and rare ABCA1 variants affecting plasma HDL cholesterol.,"
Arterioscler. Thromb. Vasc. Biol. 20:1983-1988(2000).
RN [13]
- VARIANT TD TRP-587, AND VARIANT LEU-2168.
MEDLINE=21157002; PubMed=11257260;
- Bertolini S., Pisciotta L., Seri M., Cusano R., Cantafiora A.,
RA Caabresi L., Franceschini G., Ravazzolo R., Calandra S.;
RA "A point mutation in ABC1 gene in a patient with severe premature
RT coronary heart disease and mild clinical phenotype of Tangier
disease.,"
RT Atherosclerosis 154:599-605(2001).
RN [14]
- VARIANT LYS-219; MET-83 AND ASP-1172.
RP RX Brousseau M.E., Bodzioch K., Goldkamp A.L., Kielar D.,
RA Brousseau M.E., Bodzioch M., Schaefer E.J., Lackner K.J.,
RA Probst M., Ordovas J.M., Aslanidis C., Boettcher A., Hubacek J.,
RA Bloomfield Rubins H., Collins D., Robins S.J., Wilson P.W.F.,
RA Schmitz G.;
RT "Common variants in the gene encoding ATP-binding cassette transporter
1 in men with low HDL cholesterol levels and coronary heart disease.,"
RL Athrosclerosis 154:607-611(2001).
RN [15]
- VARIANT TD LEU-1506.
RP RX Lapicka-Bodzioch K., Bodzioch M., Kielar D., Probst M.,
RA Kielar B., Andrikovic H., Boettcher A., Hubacek J., Aslanidis C.,
RA Suttorp N., Schmitz G.;
RT "Homogeneous assay based on 52 primer sets to scan for mutations of
the ABCA1 gene and its application in genetic analysis of a new
patient with familial high-density lipoprotein deficiency syndrome.,"
RL Biochim. Biophys. Acta 1537:42-48(2001).
RN [16]
- VARIANT TD ASN-1289 AND TRP-2081, AND VARIANT LYS-219.
RP RX Huang W., Moriyama K., Koga T., Hua H., Ageta M., Kawabata S.,
RA Matavari K., Inamura T., Eto T., Kawamura M., Teramoto T., Sasaki J.;
RA "Novel mutations in ABCA1 gene in Japanese patients with Tangier
disease and familial high density lipoprotein deficiency with
RT coronary heart disease.,"
RL Biochim. Biophys. Acta 1537:71-78(2001).
RN [17]
- VARIANT LYS-219; ALA-399; MET-771; PRO-774; ASN-776; ILE-825;
RP MET-883; ASN-1177; LYS-1587 AND CYS-1731.
RP MEDLINE=21138379; PubMed=11238061;
RX Clee S.M., Zwinger A.H., Engert J.C., Zwarts K.Y.,
RA Molhuizen H.O.F., Roomp K., Jukema J.W., van Wijland M., van Dam M.,
RA Hudson T.J., Brooks-Wilson A., Genest J., Jr., Kastellien J.J.P.,
RA Hayden M.R.;
RT "Common genetic variation in ABCA1 is associated with altered
RT lipoprotein levels and a modified risk for coronary artery disease.,"
RL Circulation 103:1198-1205(2001).
RN [18]
- VARIANT TD THR-255, AND VARIANT ATHEROSCLEROSIS ASP-1611.
RP RX Nishida Y., Hirano K., Tsukamoto K., Nagano M., Ikegami C., Roomp K.,
RA Matsuuwa F., Ishigami M., Sakane N., Zhang Z., Tsujii K., Matsuyama A., Ohama T.,
RA Wellington C., Yoshida Y., Misugi S., Hayden M.R., Egashira T.,
RA Yamashita S., Matsuzawa Y.;
RA "Expression and functional analyses of novel mutations of ATP-binding
RT cassette transporter-1 in Japanese patients with high density
RT lipoprotein deficiency.,"
RL Biochem. Biophys. Res. Commun. 290:713-721(2002).
CC -1 FUNCTION: CAMP-DEPENDENT AND SULFONYLUREA-SENSITIVE ANION
TRANSPORTER. KEY GATEKEEPER INFLUENCING INTRACELLULAR CHOLESTEROL
TRANSPORT.
CC -1 TISSUE SPECIFICITY: WIDELY EXPRESSED, BUT MOST ABUNDANT IN
CC MACROPHAGES.
CC -1 DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES,
EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN
ATP BINDING CASSETTE (ABC) DOMAIN.
- 1 DISEASE: DEFECTS IN ABCA1 ARE A CAUSE OF HIGH DENSITY LIPOPROTEIN
DISORDERS. TYPE I (HDL1), ALSO KNOWN AS TANGIER DISEASE (TD). TD
IS A RECESSIVE DISORDER CHARACTERIZED BY ABSENCE OF HIGH DENSITY
LIPOPROTEIN (HDL) CHOLESTEROL FROM PLASMA, HEPATOSPLENOMEGLY,
PERIPHERAL NEUROPATHY, AND FREQUENTLY PREMATURE CORONARY ARTERY
DISEASE (CAD).
- 1 DISEASE: Defects in ABCA1 are a cause of high density lipoprotein

Query Match 99.2%; Score 1513; DB 1; Length 2261;
 Best Local Similarity 99.3%; Pred. No. 7.5e120; Gaps 0;
 Matches 282; Conservative 0; Mis matches 2; Indels 0;

Qy 1 FGKYSPELQWMMYNEQTYFVSNDAPEDTGTLELNALTICKMLPVCPPGAGGLPPQRK 120
 Db 1371 FGKYSPELQWMMYNEQTYFVSNDAPEDTGTLELNALTICKMLPVCPPGAGGLPPQRK 1430

Qy 61 AGEERWTTAPVPTIMDFQNGWTMNPSPACQCSSDKIKRMLPVCPPGAGGLPPQRK 120
 Db 1431 AGEERWTTAPVPTIMDFQNGWTMNPSPACQCSSDKIKRMLPVCPPGAGGLPPQRK 1490

Qy 121 QNTADILQDGTGRNISDYLVKTQVQITAKSLANKIWIINFERYGGFSLGVSNTQALPPSQE 180
 Db 1491 QNTADILQDGTGRNISDYLVKTQVQITAKSLANKIWIINFERYGGFSLGVSNTQALPPSQE 1550

Qy 181 VNDATKOMKKHLKLAKDSSADFLNSLGRMTGLDTRNNVKWVNNGWHAISSFLNVIN 240
 Db 1551 VNDATKOMKKHLKLAKDSSADFLNSLGRMTGLDTRNNVKWVNNGWHAISSFLNVIN 1610

Qy 241 NAILRNLQKGPNPSHGTATFHPLNLTQOOLSEYAPMTTSVD 284
 Db 1611 NAILRNLQKGPNPSHGTATFHPLNLTQOOLSEYAPMTTSVD 1654

RESULT 2

ABC1_MOUSE

ID ABC1_MOUSE STANDARD; PRT; 2261 AA.

AC P41253; DT 01-FEB-1995 (Rel. 31, Created)
 DT 16-OCT-2001 (Rel. 40, Last sequence update)
 DT 15-JUN-2002 (Rel. 41, Last annotation update)

DE ATP-binding cassette, sub-family A, member 1 (ATP-binding cassette, DE transporter 1) (ATP-binding cassette 1) (ABC-1).
 ABC1 OR ABC1.

GN OS Mus musculus (Mouse).

OC Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus .

OX NCB_1_TAXID=10090; RN [1]

RP SEQUENCE FROM N.A.
 STRAIN=0BA/2; TISSUE=Macrophage;
 MEDLINE=94375008; PubMed=8088782;

RX Luciani M.F., Savary S., Mattei M.-G., Chimini G.; RT 9.;
 RT Cloning of two novel ABC transporters mapping on human chromosome RT 9.;
 RL Genomics 21:150-159 (1994).

RP SEQUENCE FROM N.A.
 RC STRAIN=C57BL/6J; RA Liu Y., Cavelier L., Chiu S., Rubin E., Cheng J.-F.; RT Identify potential regulatory sequences.";
 RL Submitted (JUL-2000) to the EMBL/GenBank/DBJ databases.

CC -1- FUNCTION: CAMP-DEPENDENT AND SULFONYLUREA-SENSITIVE ANION TRANSPORTER. KEY GATEKEEPER INFLUENCING INTRACELLULAR CHOLESTEROL TRANSPORT (BY SIMILARITY).

CC -1- TISSUE SPECIFICITY: WIDELY EXPRESSED IN ADULT TISSUES. HIGHEST LEVELS ARE FOUND IN PREGNANT UTERUS AND UTERUS.

CC -1- DOMAIN: MULTIFUNCTIONAL POLYPEPTIDE WITH TWO HOMOLOGOUS HALVES, EACH CONTAINING AN HYDROPHOBIC MEMBRANE-ANCHORING DOMAIN AND AN ATP BINDING CASSETTE (ABC) DOMAIN.

CC -1- SIMILARITY: BELONGS TO THE ABC TRANSPORTER FAMILY. ABCA SUBFAMILY.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see <http://www.isb-sib.ch/announce/> or send an email to license@isb-sib.ch).

DR EMBL; X75926; CAA53530.1; ALT_INIT.
 DR EMBL; AF281263; AAG33073.1; ALT_INIT.
 DR MGI; 98607; Abca1.
 DR InterPro; IPR003593; AAA_ATPase.
 DR InterPro; IP000439; ABC_Transporter.
 DR Pfam; PF00005; ABC_Transport; 2.
 DR ProDom; PD000006; ABC_transport; 2.
 DR SMART; SM00382; AAA_1.
 DR PROSITE; PS00211; ABC_Transporter; 1.
 DR ATP-binding; Glycoprotein; Transmembrane; Transport.
 DR KW ATP-binding; Glycoprotein; Transmembrane; Transport.
 FT TRANSEM 26 42 POTENTIAL.
 FT TRANSEM 640 656 POTENTIAL.
 FT TRANSEM 690 706 POTENTIAL.
 FT TRANSEM 717 733 POTENTIAL.
 FT TRANSEM 749 765 POTENTIAL.
 FT TRANSEM 771 787 POTENTIAL.
 FT TRANSEM 1041 1057 POTENTIAL.
 FT TRANSEM 1351 1367 POTENTIAL.
 FT TRANSEM 1661 1677 POTENTIAL.
 FT TRANSEM 1708 1724 POTENTIAL.
 FT TRANSEM 1732 1753 POTENTIAL.
 FT TRANSEM 1775 1791 POTENTIAL.
 FT TRANSEM 1854 1870 POTENTIAL.
 FT NP_BIND 933 940 ATP (POTENTIAL).
 FT CARBOHYD 1946 1953 ATP (POTENTIAL).
 FT CARBOHYD 14 14 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 98 98 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 151 151 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 161 161 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 196 196 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 244 244 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 292 292 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 337 337 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 349 349 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 400 400 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 478 478 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 489 489 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 521 521 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 820 820 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 1144 1144 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 1294 1294 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 1453 1453 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 1499 1499 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 1504 1504 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 1637 1637 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CARBOHYD 2044 2044 N-LINKED (GLCNAC. . .) (POTENTIAL).
 FT CONFLICT 2238 2238 MISSING (IN REF. 2).
 FT CONFLICT 1567 1568 MISSING (IN REF. 2).
 SQ SEQUENCE 2261 AA; 254011 MW; FAE62B21FD1D09F9 CRC64;

Query Match 93.3%; Score 1423; DB 1; Length 2261;
 Best Local Similarity 93.0%; Pred. No. 3.2e-112;
 Matches 264; Conservative 10; Mismatches 10; Indels 0; Gaps 0;

Qy 1 FGKYSPELQWMMYNEQTYFVSNDAPEDTGTLELNALTICKMLPVCPPGAGGLPPQRK 60
 Db 1371 FGKYSPELQWMMYNEQTYFVSNDAPEDTGTLELNALTICKMLPVCPPGAGGLPPQRK 1430

Qy 61 AGEERWTTAPVPTIMDFQNGWTMNPSPACQCSSDKIKRMLPVCPPGAGGLPPQRK 120
 Db 1431 AGEERWTTAPVPTIMDFQNGWTMNPSPACQCSSDKIKRMLPVCPPGAGGLPPQRK 1490

Qy 121 QNTADILQDGTGRNISDYLVKTQVQITAKSLANKIWIINFERYGGFSLGVSNTQALPPSQE 180
 Db 1491 QNTADILQDGTGRNISDYLVKTQVQITAKSLANKIWIINFERYGGFSLGVSNTQALPPSQE 1550

Qy 181 VNDAIKOMKKHLKLAKDSSADFLNSLGRMTGLDTRNNVKWVNNGWHAISSFLNVIN 240
 Db 1551 VNDAIKOMKKHLKLAKDSSADFLNSLGRMTGLDTRNNVKWVNNGWHAISSFLNVIN 1610

Qy 241 NATURANLQGENPSHGTATFHPLNLTQOOLSEYAPMTTSVD 284
 Db 241 NATURANLQGENPSHGTATFHPLNLTQOOLSEYAPMTTSVD 1550

RP	I-959; K-1036; V-1038; P-1063; D-1087; C-1097; C-1108; L-1380; K-1399;	Db	1516 QRSTEILQDLTDRISDELVKTYPAIIRRSSKSKFVNNEORYGGTSIG---GKLPVVPI 1571
RP	P-1440; V-1440; H-1443; L-1486; Y-1488; M-1537; P-1689; L-1705;		
RP	T-1733; R-1748; P-1763; K-1885; H-1998; E-1996; I-1975; S-1977; G-2077	Qy	181 VNDAIKQMKKKHLAKDGSADRFLNSGR-----PMTGLDTRNWK 221
RP	W-2077 AND V-2241; AND VARIANTS Q-132; H-212; R-423; I-552; R-914;		
RP	Q-943; T-1562; I-1868; M-1521; L-1948; F-1970; A-2059; N-2177 AND	Db	1572 TGEALV-----GFLSDGRIMNVSGGPITREASKEIPDELKHLTEDNIK 1616
RP	V-2216.		
RX	MDLINE-20442027; PubMed=10958763;		
RA	Rivera A., White K., Stoehr H., Steiner K., Hemmrich N., Grimm T.,	Qy	2222 WFNNGWHAISSEPLVNTINNATRANQKGENPSHYGITAFNHPLNLTKQQLSEVALMATT 281
RA	Jurklies B., Lorenz B., Scholl H.P.N., Apelstedt-Sylla E.,		
RA	Weber B.H.F.;	Db	1617 WFNNGWHALVSFLNVAHNAILRASSLPKDRSPEEYGTIVSQPLNLTKEQLSEITVLT 1676
RT	A comprehensive survey of sequence variation in the ABCA4 (ABCR) gene	Qy	282 SVT 284
RT	in Stargardt disease and age-related macular degeneration.;		
RL	Am. J. Hum. Genet. 67:800-813(2000).	Db	1677 SVT 1679
RN	[15]		
RP	VARIANT CORD3 GLU-65; CYS-212; PRO-541; ALA-863; GLY-863 DEL;		
RP	VAL-1038; LYS-1122; TYR-1490 AND ASP-1598.		
RX	MDLINE-20442040; PubMed=10958761;	RESULT 4	
RA	Maugeri A., Klevering B.J., Rohrschneider K., Blankenagel A.,	ABC_HUMAN	
RA	Brunner H.G., Deutman A.F., Hoyng C.B., Creemers F.P.M.;	ID	
RT	"Mutations in the ABCA4 (ABCR) gene are the major cause of autosomal recessive cone-rod dystrophy.";	AC	
RL	Am. J. Hum. Genet. 67:960-966 (2000).	99BZC';	
RN	[16]	DT	
RP	VARIANTS STGD ASP-340; GLN-572; ALA-863; SER-965; VAL-1038; ALA-1780	16-OCT-2001 (Rel. 40, Created)	
RP	AND HIS-1898, AND VARIANT GLN-943;	DT	
RP	AND HIS-1898, AND VARIANT GLN-943;	15-JUN-2002 (Rel. 41, Last annotation update)	
RX	MDLINE=20442056; PubMed=10746567;	DE	
RA	Shroyer N.F., Lewis R.A., Lupski J.R.;	DE-transporter 2 (ATP-binding cassette 2).	
RT	Complex inheritance of ABCR mutations in Stargardt disease: linkage disequilibrium, complex alleles, and pseudodominance.;	DE	
RT	Am. J. Hum. Genet. 106:244-248(2000).	ABC2.	
RN	[17]	GN	
RP	VARIANTS STGD.	ABCA2 OR ABC2.	
RX	MDLINE=20442082; PubMed=10634594;	OS	
RA	Papaiannou M., Ocaka L., Bessant D., Bird A.C., Payne A.,	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;	
RA	Bhattacharya S.S.;	OC	
RT	"An analysis of ABCR mutations in British patients with recessive retinal dystrophies.";	Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.	
RT	Invest. Ophthalmol. Vis. Sci. 41:16-19(2000).	OX	
RN	[18]	NCBI_TaxID=9606;	
RP	VARIANTS STGD C-212; D-767; I-897; V-1038; K-1399; Q-1640 AND	RN	
RP	R-1961, AND VARIANT HIS-212.	SEQUENCE FROM N.A.	
RX	MDLINE=20442052; PubMed=1071170;	RP	
RA	Simionelli F., Testa F., de Crecchio G., Rinaldi E., Hutchinson A.,	PubMed=1178938;	
RA	Atkinson A., Dean M., D'Urso M., Allickets R.;	RA	Kaminski W.E., Piehler A., Pullmann K., Porsch-Ozcurumez M., Duong C.,
RT	"New ABCR mutations and clinical phenotype in Italian patients with	RA	Bared G.M., Buchler C., Schmitz G.;
RT	Stargardt disease.";	RT	"Complete coding sequence, promoter region, and genomic structure of the human ABCA2 gene and evidence for sterol-dependent regulation in macrophages.";
RL	Invest. Ophthalmol. Vis. Sci. 41:892-897(2000).	RT	RL Biochem. Biophys. Res. Commun. 281:249-258(2001).
RN	[19]	CC	"- FUNCTION: PROBABLE TRANSPORTER. ITS NATURAL SUBSTRATE HAS NOT BEEN FOUND YET. MAY HAVE A ROLE IN MACROPHAGE LIPID METABOLISM AND NEURAL DEVELOPMENT."
RP	CHARACTERIZATION OF VARIANTS, AND MUTAGENESIS OF GLY-966; LYS-969;	CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions. Long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
RX	MDLINE=20442331; PubMed=11017087;	CC	CC
RA	Sun H., Snailwood P.M., Nathans J.;	DR	DR EMBL; AF327705; AAK14335.1;
RT	"Biochemical defects in ABCR protein variants associated with human retinopathies";	DR	DR EMBL; AF327705; AAK14335.1; JOINED.
RL	Genet. 26:242-246(2000).	DR	DR EMBL; AF327658; AAK14335.1; JOINED.
RN	[20]	DR	DR EMBL; AF327659; AAK14335.1; JOINED.
RP	VARIANT STGD ASN-972, AND VARIANTS GLN-943; ILE-1868 AND LEU-1948.	DR	DR EMBL; AF327660; AAK14335.1; JOINED.
RX	MDLINE=21478161; PubMed=11594933;	DR	DR EMBL; AF327661; AAK14335.1; JOINED.
RA	Ekstrand L., Ekstroem U., Abrahamson M., Bauer B., Andreasson S.;	DR	DR EMBL; AF327662; AAK14335.1; JOINED.
Query Match	48.1%; Score 733.5; DB 1; Length 2273;	DR	DR EMBL; AF327663; AAK14335.1; JOINED.
Best Local Similarity	48.2%; Pred. No. 9.1e-34;	DR	DR EMBL; AF327664; AAK14335.1; JOINED.
Matches	Conservative 35; Mismatches 83; Indels 39; Gaps 4;	DR	DR EMBL; AF327665; AAK14335.1; JOINED.
Qy	1 FGKYSLEQPMYNEQQTFVSNDAPETGTILELNALTRDPGFTRCMEGNP LPDTPO Q 60	DR	DR EMBL; AF327666; AAK14335.1; JOINED.
Db	1397 FGEYALTLIPWIGQTFNSDEPGESEQFVLAIVLNRPGFNRCKREGWPEYCG- 1455	DR	DR EMBL; AF327667; AAK14335.1; JOINED.
Qy	61 AGEEEWTTAVPQTMDLFQNGWTMONSPACQCSSDKKKMLPVCPGAGLPPORK 120	DR	DR EMBL; AF327671; AAK14335.1; JOINED.
Db	1456 GNSTWKTPSVSPNITQFLQKQKWTQNPSPCRCSRETRKUTMLPECPGAGLPPQR 1515	DR	DR EMBL; AF327675; AAK14335.1; JOINED.
Qy	121 QNTADILQDLTGRNISDVLVKTVQIIAKSLKNK1WVNFRYGGFSLGVNSNTQALPPSQE 180	DR	DR EMBL; AF327676; AAK14335.1; JOINED.

Query Match		Score 267; DB-1; Length 2436;	
Best Local Similarity 29.2%; Pred. No. 3.5e-14;		Matches 35; Mismatches 73; Indels 86; Gaps 12;	
Best Local Similarity 80; Conservative Matches 80;			
QY	44	FGTRCMEG-----NPIT-DTPCQ-----AGREEWHTAP-Y 71	
Db	1572	EDNCLESFTQGQLPLSNFVPPPSDPSASPDSPDQLQANNVSLSDPTAEGMWISAPS1 1631	
QY	72	PQTIMDLFQNGNWTMQNPSPACOCSDDKIKMLPVPGAGLPPQPKONTADILQDIT 131	
Db	1632	PRIVREPYR-----CTCAQGTGFS---CPSSVG-HPQMRRVTGDLTDIT 1675	
QY	132	GRNISDLYKTYWQIQLSKLKWNEFRYGGESVNTQALPPSQEVNDAIKOMKKH 191	
Db	1676	GHVSEYUFLTSDFR-----RLHRYCAITFG-NVLKSTIASFGTRAPPVRK 1721	
QY	192	LKAKDSSADRFNLNSLGRMTGLDTRNWKVWNKNCKWAISSPFLAVINAILRNQKG 251	
Db	1722	-----TAVRAAQYFVNNGKYHSAPTYLNSLNAILRNLPKS 1759	
QY	252	E-NPSHYGTTAFNHPLNLTKOQLS-EVALMWTSV 283	
Db	1760	KGNPAAYGTVTHPMNKTSASLSLDYLLQGTDV 1793	
RESULT 5			
ABC2_MOUSE			
ID	ABC2_MOUSE	STANDARD;	PRT;
AC	P41234;		2434 AA.
DT	01-FEB-1995	(Rel. 31, Created)	
DT	16-OCT-2001	(Rel. 40, Last sequence update)	
DT	15-JUN-2002	(Rel. 41, Last annotation update)	
DE	ATP-binding cassette, sub-family A, member 2 (ATP-binding cassette 2).		
DE	DE transporter 2 (ATP-binding cassette 2).		
GN	ABC2 OR ABC2.		
OS	Mus musculus (Mouse).		
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Rodentia; Sciurognathi; Muridae; Murinae; Mus .		
RN	[1]		
RP	SEQUENCE FROM N.A.; AND REVISIONS.		
RC	STRAIN=dba/2;		
RA	Chilini G.;		
RL	Submitted (DEC-2000) to the EMBL/GenBank/DBJ databases.		
RN	[2]		
RP	SEQUENCE OF 964-2434 FROM N.A.		
RC	STRAIN=dba/2; TISSUE=Macrophage;		
RX	Medline-94375008; PubMed-8088782;		
RA	Luciani M.F.; Denizot F.; Savary S.;		
CC	"Cloning of two novel ABC transporters mapping on human chromosome 9."		
RT	Gentomics 21:150-159 (1994).		
RT	-!- FUNCTION: PROBABLE TRANSPORTER, ITS NATURAL SUBSTRATE HAS NOT BEEN FOUND YET. MAY HAVE A ROLE IN MACROPHAGE LIPID METABOLISM AND NEURAL DEVELOPMENT.		
CC	-!- SUBCELLULAR LOCATION: Integral membrane protein (potential).		
CC	-!- TISSUE SPECIFICITY: WIDELY EXPRESSED IN ADULT TISSUES. HIGHEST LEVELS ARE FOUND IN BRAIN AND PREGNANT UTERUS.		
CC	-!- SIMILARITY: BELONGS TO THE ABC TRANSPORTER FAMILY. ABCA SUBFAMILY.		
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL Outstation - European Bioinformatics Institute. There are no restrictions on its use by non profit institutions as long as its content is in no way modified and its dissemination is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).		

RESULT 7									
Db	241	-YAGINISSTNGEVMPGOMEFQVGSVIEAGDHINCAYYLLEITEAGVVLT-LDP	296						
	GLN2-HORVU	STANDARD;	PRT;	434	AA.				
ID	GLN2_HORVU								
AC	P13564_;								
DT	01-JAN-1990	(Rel. 13, Created)							
DT	01-NOV-1990	(Rel. 16, Last sequence update)							
DT	15-JUN-2002	(Rel. 41, Last annotation update)							
DE	Glutamine synthetase leaf isozyme, chloroplast precursor (EC 6.3.1.2)								
DE	(Glutamate + ammonia ligase) (Chloroplast GS2).								
OS	Hordeum vulgare (Barley).								
OC	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;								
OC	Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae; Pooidae;								
OC	Triticeae; Hordeae; Hordeum.								
OX	[11]								
RN	RP	SEQUENCE FROM N.A.							
RX	MEDLINE=91355830;	PubMed=1983297;							
RA	Stroman P., Baima S., Casadoro G.;								
RT	"A cDNA sequence coding for glutamine synthetase in <i>Hordeum vulgare</i> L."								
RT	Plant Mol. Biol. 15:161-163 (1990).								
RN	[12]								
RP	SEQUENCE OF 9-434 FROM N.A.								
RX	STRAIN-NCV, Maris Wark, TISSUE-Leaf;								
RC	MDLNB=91346638; PubMed=1983286;								
RA	Freeman J., Marquez A.J., Wallsgrove R.M., Saarelaisten R., Forde B.G.;								
RA	"Molecular analysis of barley mutants deficient in chloroplast glutamine synthetase."								
RT	glutamine synthetase."								
RL	Plant Mol. Biol. 14:297-311 (1990).								
RN	[13]								
RP	SEQUENCE OF 48-434 FROM N.A.								
RX	MDLNB=83322552; PubMed=2473765;								
RA	Baima S., Haegi A., Stroman P., Casadoro G.;								
RT	"Characterization of a cDNA clone for barley leaf glutamine synthetase."								
RT	Carlsherg Res. Commun. 54:1-9 (1989).								
CC	-1- FUNCTION: THE LIGHT MODULATED CHLOROPLAST ENZYME, ENCODED BY A NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR THE REAESTERILATION OF THE AMMONIA GENERATOR BY PHOTORESPARATION.								
CC	-1- CATALYTIC ACTIVITY: ATP + L-glutamate + NH ₃ (3) = ADP + phosphate + L-glutamine.								
CC	-1- SUBUNIT: HOMOCTAMER.								
CC	-1- SUBCELLULAR LOCATION: Chloroplast.								
CC	-1- MISCELLANEOUS: IN BARLEY, THERE ARE DISTINCT ISOZYMES IN THE CHLOROPLAST, AND CYTOPLASM.								
CC	-1- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.								
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement. (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).								
DR	X53580; QAA37643_1;								
DR	EMBL: X16000; QAA37643_1;								
DR	PIR: S11865; ABBQ.								
DR	InterPro: IPR01691; GLN_synth.								
DR	pfam: PF00120; gln_synth_1;								
DR	PROSITE: PS00100; GINA_1_1;								
DR	DRUG: Multigene family; Chloroplast; Transit peptide.								
KW	CHLOROPLAST.								
ET	TRANSIT								
CC	CHLOROPHYLL								
CC	CHLOROPHYLL-COMPLEX-II								
CC	CHLOROPHYLL-A								
CC	CHLOROPHYLL-B								
CC	CHLOROPHYLL-A+B								
CC	CHLOROPHYLL-COMPLEX-I								
CC	CHLOROPHYLL-COMPLEX-III								
CC	CHLOROPHYLL-COMPLEX-IV								
CC	CHLOROPHYLL-COMPLEX-V								
CC	CHLOROPHYLL-COMPLEX-VI								
CC	CHLOROPHYLL-COMPLEX-VII								
CC	CHLOROPHYLL-COMPLEX-VIII								
CC	CHLOROPHYLL-COMPLEX-IX								
CC	CHLOROPHYLL-COMPLEX-X								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								
CC	CHLOROPHYLL-COMPLEX-XIX								
CC	CHLOROPHYLL-COMPLEX-XX								
CC	CHLOROPHYLL-COMPLEX-XI								
CC	CHLOROPHYLL-COMPLEX-XII								
CC	CHLOROPHYLL-COMPLEX-XIII								
CC	CHLOROPHYLL-COMPLEX-XIV								
CC	CHLOROPHYLL-COMPLEX-XV								
CC	CHLOROPHYLL-COMPLEX-XVI								
CC	CHLOROPHYLL-COMPLEX-XVII								
CC	CHLOROPHYLL-COMPLEX-XVIII								

CC -!- SIMILARITY: CONTAINS 5 C2 DOMAINS.
 CC -!- CAUTION: The submitted sequence from Ref. 1 differs from that shown
 CC in a number of positions. We use the sequence obtained by direct
 CC sequencing which is cited in figure 1 of that reference.

CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announce/>
 CC or send an email to licensee@isb-sib.ch).

CC EMBL; AF188290; AAC17066.2; ALT_SEQ.

DR HSPP; AJ242954; CAB63111.1; -.

DR MGII; MGI:1349385; DYSF.

DR InterPro; IPR000008; C2.

DR Pfam; PF00168; C2; 7.

DR SMART; SM00239; C2; 7.

DR PROSITE; PS00099; C2_DOMAIN_1; FALSE_NEG.

DR PROSITE; PS50004; C2_DOMAIN_2; 5.

KW Transmembrane; Repeat.

FT DOMAIN 1 2049 CYTOPLASMIC (POTENTIAL).
 FT TRANSHEM 2 2050 2070 EXTRACELLULAR (POTENTIAL).
 FT DOMAIN 1 2071 2083 EXTRACELLULAR (POTENTIAL).
 FT DOMAIN 1 86 C2 DOMAIN 1.
 FT DOMAIN 210 305 C2 DOMAIN 2.
 FT DOMAIN 369 487 C2 DOMAIN 3.
 FT DOMAIN 1142 1247 C2 DOMAIN 4.
 FT DOMAIN 1568 1666 C2 DOMAIN 5.
 FT DOMAIN 1041 1100 ARG-RICH.
 FT CONFLICT 468 468 D->G (IN REF. 2).
 FT CONFLICT 502 509 AVRPSKAS->VLSKQAT (IN REF. 2).
 FT CONFLICT 1687 1694 C->Y (IN REF. 2).
 FT CONFLICT 1694 1694 K->O (IN REF. 2).
 FT CONFLICT 1698 1698 K->Q (IN REF. 2).
 FT CONFLICT 1799 1799 Q->R (IN REF. 2).
 FT CONFLICT 1847 1853 MVGEEH->ISGSEEN (IN REF. 2).
 FT CONFLICT 1865 1886 G->D (IN REF. 2).
 FT CONFLICT 1886 1888 VCA->LCI (IN REF. 2).
 FT CONFLICT 1893 1894 DA->EH (IN REF. 2).
 FT CONFLICT 1897 1911 RLDKTEISKPARV -> SIDQTEFRVPPLRII (IN
 REF. 2).
 FT CONFLICT 1921 1921 F->L (IN REF. 2).
 FT CONFLICT 1924 1924 F->Y (IN REF. 2).
 FT CONFLICT 1927 1929 SLQ->FILE (IN REF. 2).
 FT CONFLICT 1933 1937 NRKPK->HRTLI (IN REF. 2).
 FT CONFLICT 1942 1942 A->S (IN REF. 2).
 FT CONFLICT 1949 1960 QLDKTEISKPARV -> MIPDLKAMDPPLKARTA (IN REF.
 2).
 FT CONFLICT 1966 1968 KTV->PSM (IN REF. 2).
 FT CONFLICT 1975 1984 VTEGEGKML->YAKUDGPVRM (IN REF. 2).
 FT CONFLICT 1988 1988 L->V (IN REF. 2).
 FT CONFLICT 1994 2001 TVESEHE->VLFNEEAD (IN REF. 2).
 FT CONFLICT 1993 1937 Q->K (IN REF. 2).
 FT CONFLICT 2007 2007 D->S (IN REF. 2).
 FT CONFLICT 2010 2020 EDPRPD->DPPNRPE (IN REF. 2).
 FT CONFLICT 2019 2025 SPY->NPC (IN REF. 2).
 FT CONFLICT 2033 2035 L->R (IN REF. 2).
 FT CONFLICT 2039 2042 L->V (IN REF. 2).
 FT CONFLICT 2042 2042 RCAILFILF->KIVIGULLL (IN REF. 2).
 FT CONFLICT 2047 2057 LGVFEYAF->VAVLYSL (IN REF. 2).
 FT CONFLICT 2063 2070 AA->LS (IN REF. 2).
 FT CONFLICT 2074 2075 LYRPER -> TVRPA (IN REF. 2).
 FT CONFLICT 2078 2083 Score 98.5%; DB 1; Length 2083;
 SQ SEQUENCE 6.5%; Best Local Similarity 18.5%; Pred. No. 5.; Mismatches 43; Indels 157; Gaps 15;

Query Match 1 FGKPSL-----ELQPWMYNEQYTFSNDAPEDTGTELLNALTKEFGFTRCMEGN 52

Best Local Similarity 67; Conservative Matches 67; Sequence Score 98.5%; Pred. No. 5.; Mismatches 43; Indels 157; Gaps 15;

Db 1630 FGKMFELTCTPLEKDDKLTLYD--YDLSKDEKIGETVIDLENRLSK --FGARC--- 1681
 Qy 53 PIPDTPCQAGEEEM-----TTAVPQPTIMDLEQNGNTMQN---- 88
 Db 1682 GLPONTCVGSGPNKWRDKLRLPSQLLHLCQOHRRIKAPYRDRVTDQKDTIEERGRL 1741
 Qy 89 PSPA-----QCSSD1KKMLPVCPGAGGLP 115
 Db 1742 PNPHGGPVVERLAHVHQGQLYPEH/ESRPLYSPIQDQEKGKLOMWIDIFPKVLGGPG 1801
 Qy 116 PP---QRKQ-----NPAIDLQD--LGGRNISDYLVKTIVV----- 144
 Db 1802 PPFNITPPKARRFFLRCLIWNTKDVLDLSTGTGERMSDIYVKGMGVFEEHKOKTDVHY 1861
 Qy 145 -----OIIKS1KNIKWIUNEFYGGFSIGVSNTQALPPSOY 181
 Db 1862 RSLGEGNFNNWRVVFPPFDYLPAEQVCAYAKDAFW-----RLDKTEISKPARV 1910
 Qy 182 -----NA-----IKQMKGHLKLADSSADRFELNSL-GRFMTGGLDTRNNYKV 222
 Db 1911 FQIWNNDKFSDDFLGSQLQDINRNMPKPAKTAEKCSLDQDDTFRPEWVSLFQKTVKG 1970
 Qy 223 WF 224
 Db 1971 WW 1972

RESULT 9
 GLN4_PHAVU ID GLN4_PHAVU STANDARD; PRT; 429 AA.
 AC F1510; DT 01-APR-1980 (Rel. 14, Created)
 DE (Isozyme delta) Glutamate synthetase, chloroplast precursor (EC 6.3.1.2)
 DE (Isozyme delta) Glutamate synthetase, chloroplast precursor (EC 6.3.1.2)
 OS Phaseolus vulgaris (Kidney bean) (French bean).
 OC Phukkaryota; Viridiplantae; Streptophytina; Embryophytina; Tracheophytina;
 OC Spermatozoo; Magnoliophytina; eu dicots; Rosidae;
 OC eurosids I; Fabales; Fabaceae; Papilionoideae; Phaseoleae; Phaseolus.
 OC NCBI_TaxID:3885; RN [1]
 RN NCBI_TaxID:3885; RN [1]
 RP SEQUENCE FROM N.A.
 RC STRAIN=cv. Tendergreen; TISSUE=Leaf;
 RA Lightfoot D.A.; Green N.K.; Culimore J.V.;
 RT DE the chloroplast-located glutamine synthetase of Phaseolus vulgaris
 RT DE nucleotide sequence, expression in different organs and uptake
 RT DE into isolated chloroplasts;
 RL Plant Mol. Biol. 11:191-202 (1988).
 CC -!- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A
 CC NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR
 CC THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPIRATION.
 CC -!- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +
 CC L-glutamine.
 CC -!- SUBCELLULAR LOCATION: Chloroplast.
 CC -!- MISCELLANEOUS: THERE ARE AT LEAST FOUR ISOZYMES OF THIS ENZYME IN
 CC P. VULGARIS.
 CC -!- MISCELLANEOUS: IRREVERSIBLE INHIBITED BY THE HERBICIDE
 CC L-PHOSPHINOTHRICIN (PPT).
 CC -!- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.
 CC This SWISS-PROT entry is copyright. It is produced through a collaboration
 CC between the Swiss Institute of Bioinformatics and the EMBL outstation -
 CC the European Bioinformatics Institute. There are no restrictions on its
 CC use by non-profit institutions as long as its content is in no way
 CC modified and this statement is not removed. Usage by and for commercial
 CC entities requires a license agreement (See <http://www.isb-sib.ch/announces/>
 CC or send an email to licensee@isb-sib.ch).
 DR RMBL: X12738; CAA31234.1; -.
 DR PIR: S04031; AsPBOD.
 DR InterPro: IPR001691; GLN_synth.

DR	EMBL; 067486; AAB98310.1;
DR	TIGR; MJ0314;
DR	InterPro; IPR00120; glnA_synt; 1;
DR	PROSITE; PS00180; GINA_1; 1;
DR	PROSITE; PS00181; GINA_Atp; 1;
KW	Nitrogen fixation; Ligase; Multigene family; Chloroplast;
KW	Transit peptide.
FT	CHLOROPLAST.
FT	TRANSIT 1 57
SEQ	SEQUENCE 429 AA; 429 AA; 47246 MW; 0CA5624B1118AF8 CRC64;
Query Match	6.38; Score 95.5; DB 1; Length 429; Best Local Similarity 24.6%; Pred. No. 1.;2; Matches 69; Conservative 26; Mismatches 116; Indels 75; Gaps 14;
Qy	3 KYPSELQWPMYNEQTYFVSNDAP-EDTGTELLNAA-TKDPGFTRCM-----EGN 52
Db	102 EHPS-ELPKWNNDGSST--GQAPEGDSEVILYPKQIAFKDPFRGGNNLVICDAYPAGE 157
Qy	53 PPTDPQAGAEPEWTT----APV-----QTIMDLFGNTWMQNPSPACCSDUKKKM 103
Db	158 PPTPNKHRAAEVFSPPRVAEVPPWEGIELEYTLLQTWNWNPQWP----- 203
Qy	104 LPVCPGAGGLPPORKQNTADILQLDTGRNISD--YLKVTKYVQIAKSLSKNNKINNEFR 161
Db	204 YG-VGGFPGPQPYYSAGAKSFGRDISAHAYACLAGINISGTGEVMFGQWE 256
Qy	162 YG-GFSTLGVSNTOALPPSQVNDAIKOMKHLKLAKDSSADRFELNSLIGREMTGLOTRNVY 220
Db	257 YQVPGSVI-----EAGDHIIWASRYL-----ERTEQAG--VVSLSDLKPIE 297
Qy	221 KYNENNGWHAISS-----INVNNIALPBNLQKGENSESHYG 258
Db	298 GDW-NGACHTNYSKSMRDEGGFEVIKKAILNLSRKEHITSAYG 342
RESULT 10	Y314_METJA STANDARD; PRT: 263 AA.
ID	Y314_METJA ID: Q57762; AC: DT: 01-NOV-1997 (Rel. 35, Created) DT: 01-NOV-1997 (Rel. 35, Last sequence update) DT: 16-OCT-2001 (Rel. 40, Last annotation update) DE: Hypothetical protein MJ014. GN: MJ0314.
OS	Methanococcus jannaschii
OC	Archaea; Euryarchaeota; Methanococcales; Methanococcaceae; Methanococcaceae; Methanococcus.
OX	NCBI_TAXID=2190; NCBI_TAXID=3702;
RN	RP: SEQUENCE FROM N.A. STRAIN-JAL-1 / DSM 2661 / ATCC 43067; MEDLINE:96337999; PubMed:8688087;
RX	RA: Bult C.J., White O., Olsen G.J., Zhou L., Fleischmann R.D., Sutton G., Blattke J.A., Fitzgerald L.M., Clayton R.A., Gocayne J.D., Kerlavage R., Dougherty B.A., Tomb J.-F., Reich C.T., Overbeek R., Kirkness E.F., Weinstock K.G., Merrick J.M., Grolek A., Scott J.L., Geoghanen S.M., Weidman J.F., Fuhrmann J.L., Nguyen D., Overbbeck T.R., Kelley J.M., Peterson D., Sadow P.W., Hanna M.C., Carlton M.D., Roberts K.M., Hurst M.A., Kaine B.P., Borodovsky M., Klenk H.-P., Fraser C.M., Smith H.O., Woese C.R., Venter J.C.; RT: "Complete genome sequence of the methanogenic archaeon, Methanococcus jannaschii"; Science 273;1058-1073 (1996).
RL	- SIMILARITY: SOME, TO M.JANNASCHII MJ0398.
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (see http://www.isb-sib.ch/announce/ or send an email to licensed@isb-sib.ch).
DR	EMBL; 067486; AAB98310.1; -
DR	TIGR; MJ0314; -
DR	InterPro; IPR00120; glnA_synt; 1;
DR	PROSITE; PS00180; GINA_1; 1;
KW	Nitrogen fixation; Ligase; Multigene family; Chloroplast;
KW	Transit peptide.
FT	HYPOTHETICAL protein; Complete proteome.
SEQ	SEQUENCE 263 AA; 30804 MW; A7520A3BEBE0CC5CD CRC64;
Query Match	6.28; Score 94.5; DB 1; Length 263; Best Local Similarity 24.6%; Pred. No. 0.73; Matches 49; Conservative 32; Mismatches 61; Indels 57; Gaps 11;
Qy	72 PQTIMDLFQNGNWTHMNPSPACQCSSDKIKKMLPVCPPGAGGLPPORKQNTADILQDLT 131
Db	43 PQEIILKIQNG-YTTEILAKMKCSHETLIRRIL-----RNNNNIDI----- 81
Qy	132 GRNISDLYLKTYVQIATSKLNK--KIWNNEFRYGGFSLGSVNTQALPPSQEVN----- 182
Db	62 -RKSSESLI-----1KNTKVNKLINIPSESTLAYLVLNGDGSVNVYIELKVY 130
Qy	183 --DAIKQMKKHLKLAKDSSADRFELNSLGRMTGLDTPNVEVWNNKKG--WHA---IS 233
Db	131 TDKDFEEFKNL---ENIGKVLNEYKRFKENKKDQYVVR- -RSKGFYYWYKSLNDV 184
RESULT 11	GLN2_ARATH STANDARD; PRT: 430 AA.
ID	GLN2_ARATH ID: Q43127; AC: DT: 04-DEC-2001 (Rel. 40, Created) DT: 16-OCT-2001 (Rel. 40, Last sequence update) DT: 15-JUN-2002 (Rel. 41, Last annotation update)
DE	Glutamine synthetase, chloroplast precursor (EC 6.3.1.2) (Glutamate--ammonia ligase) (GS2).
GN	GLN2 OR GS2L OR ATSG35630 OR MJ4E4.9.
OS	Arabidopsis thaliana (Mouse-ear cress).
OC	Eukaryota; Viridiplantae; Streptophytina; Embryophyta; Spermatophytina; Magnoliophytina; eudicots; core eudicots; Rosidae; eurosids II; Brassicales; Brassicaceae; Arabidopsis.
OC	NCBI_TAXID=3702;
RN	[1] SEQUENCE FROM N.A. RX: MEDLINE:92079889; PubMed:1684022; RA: Peterman T.K., Goodman H.M.; RT: The glutamine synthetase gene family of Arabidopsis thaliana: light-regulation and differential expression in leaves, roots and seeds.; RL: Mol. Gen. Genet. 230:145-154 (1991).
RP	SEQUENCE FROM N.A. RX: MEDLINE:92079889; PubMed:1684022; RA: Peterman T.K., Goodman H.M.; RT: The glutamine synthetase gene family of Arabidopsis thaliana: light-regulation and differential expression in leaves, roots and seeds.; RL: Mol. Gen. Genet. 230:145-154 (1991).
RP	SEQUENCE FROM N.A. RX: MEDLINE:92079889; PubMed:1684022; RA: Kotani H., Nakamura Y., Sato S., Asamizu E., Kaneko T., Miyajima N., Tabata S.;
RT	"Structural analysis of Arabidopsis thaliana chromosome 5. VI. Sequence features of the regions of 1.367,185 bp covered by 19 physically assigned P1 and TAC clones.";
RT	RT: DNA Res. 5:203-216 (1998). CC: -1 FUNCTION: THE LIGHT MODULATED CHLOROPLAST ENZYME, ENCODED BY A NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPARATION (BY SIMILARITY).
CC	-1 CATALYTIC ACTIVITY: ATP + L-glutamate + NH ₃ = ADP + phosphate +

CC	L-glutamine.
CC	-1- SUBUNIT: HOMOCTAMER (BY SIMILARITY).
CC	-1- SUBCELLULAR LOCATION: Chloroplast.
CC	-1- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.
CC	-----
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration between the Swiss Institute of Bioinformatics and the EMBL outstation - the European Bioinformatics Institute. There are no restrictions on its use by non-profit institutions as long as its content is in no way modified and this statement is not removed. Usage by and for commercial entities requires a license agreement (See http://www.isb-sib.ch/announce/ or send an email to license@isb-sib.ch).
CC	-----
DR	EMBL; S69727; AAB0558-1; .
DR	EMBL; AB015045; BAA887_61; .
DR	EMBL; AB013393; BAB09304; .
DR	SWISS-PROT; Q43127; ARATH.
DR	InterPro; IPR001691; GLN_Synth.
DR	Pfam; PF00120; gln-synth; 1.
DR	PROSITE; PS00180; GLNA_1; .
DR	PROSITE; PS00181; GLNA_ATP; 1.
KW	Ligase; Multigene family; Chloroplast; Transit peptide.
FT	TRANSIT 1 51 CHLOROPLAST (POTENTIAL).
FT	CHAIN 52 430 AA; 47410 MW; 664059BC0672295 CRC64;
SQ	SEQUENCE 430 AA; -----
Query Match	6.28; Score 94.5; DB 1; Length 430;
Best Local Similarity	23.1%; Pred. No. 1.4;
Matches	67; Conservative 25; Mismatches 111; Indels 87; Gaps 14;
Qy	5 PSLLEQPMVYNOQTYFSNDAP-EDIGTLELLINALTRKDPGFG-----TRCMEGNP1 54
Db	105 PS-ELPKWNYDGSST-----GQAFGEDSEVILYLPQAIRDPPFGNNILIVICDTWT PAGEP1 160
Qy	55 P-----DTPCQAGEEWTTATPVQPTMDLFQNGNTWMONPSACOCSSDKIKM 103
Db	161 PTNKRAAEIFSNKKVSGEPWFGEQEYFTLQQ--QNVKWLPGW-----204
Qy	104 LPVCPGGAGLPPQPKRONTADILQDLTGRNISDYLVKTYQITAKSLKKNIWVNNEFRYG 163
Db	205 -----VGAFFPGQGPQYYCGVADKIQWGRDTSDAHYKACL-----YA 240
Qy	164 GFSLGVSNTQALPPSOEVN-----DAIKMKKHIIKLAQDSADRFLNSIGREMTGLDP 216
Db	241 GINISGTNGEYMPQWEEFQVGPSPVGIDA----GDHWWCAR-YLLERITEAGVVLT-LDP 294
Qy	217 RNNVKVFNKGQWHASSE-----LNTVNNALRLANLOKGENPSHYC 258
Db	295 KPIEGDW-NGAGCHTNYSTKSMEREGGFEVTKKATLNLSRHKHEITSAYG 343
RESULT 12	-----
DYSF_HUMAN	SEQUENCE FROM N.A., VARIANTS MM V-1298; R-1857 AND C-2042, AND
ID	DYSF_HUMAN STANDARD; PRT; 2080 AA.
AC	Q75923; Q75696; Q9UNEN;
DT	15-JUN-2002 (Rel. 41, Last sequence update)
DT	15-JUN-2002 (Rel. 41, Last annotation update)
DE	dysferin (dystrophy associated fer-1-like protein) (Fer-1 like protein 1)
GN	DYSF OR FER1LI.
OS	Homo sapiens (Human).
OC	Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; Eutheria; Primates; Catarrhini; Hominidae; Homo.
OC	Urtilaeae J.A.; Aoki M.; Iwata I.; Wu C.; Fardeau M.; Angelini C.; Serrano C., Amato A.A.; Bossio K.; Oeltjen J.; Bejaoui K.; Boileau S.; Urtizere J.A.; McKenna Yasek D.,
RN	[1]
RP	SEQUENCE FROM N.A., VARIANTS MM V-1298; R-1857 AND C-2042, AND
RP	VARIANTS LGMD2B V-1288 AND C-2042.
RC	TISSUE-Skeletal muscle.
RX	MEDLINE=98400252; PubMed=973126;
RA	Li J.; Aoki M.; Iwata I.; Wu C.; Fardeau M.; Angelini C.; Serrano C.,
RA	Urtizere J.A.; Boileau S.; McKenna Yasek D.,
RA	Amato A.A.; Bossio K.; Oeltjen J.; Bejaoui K.; Boileau S., Urtizere J.A.; Aoki M.; Iwata I.; Wu C.; Fardeau M.; Angelini C., Serrano C.,

Hosler B.A., Schurr E., Arahatka K., de Jong P.J., Brown R.H. Jr.; "Dysferlin, a novel skeletal muscle gene, is mutated in Miyoshi myopathy and limb-girdle muscular dystrophy." ; Natl. Genet. 20:31-36(1998). [2]

RN RP SEQUENCE OF 303-2080 FROM N.A.
RC TISSUE-SKELETAL muscle, and Placenta;
RX MEDLINE=98400253; PubMed=97131527;
RA Bashir R., Britton S., Strachan T., Keers S., Vafiadaki E., Lako M., Richard T., Marchand S., Bourg N., Argov Z., Sadeh M., Mahjneh I., Marconi G., Passos-Bueno M.R., de Sa Moreira E., Zatz M., Beckmann J.S., Bushby K.M.D.; "A gene related to Cenorhabditis elegans spermatogenesis factor fer-1 is mutated in limb-girdle muscular dystrophy type 2B." ; Natl. Genet. 20:37-42(1998). [3]

RN RP SUBCELLULAR LOCATION, AND TISSUE SPECIFICITY.
RX MEDLINE=92244026; PubMed=1019675;
RA Anderson L.V.B., Davison K., Moss J.A., Young C., Cullen M.J., Walsh J., Johnson M.A., Bashir R., Britton S., Keers S., Argov Z., Mahjneh I., Fougerousse F., Beckmann J.S., Bushby K.M.D.; "Dysferlin is a plasma membrane protein and is expressed early in human development." ; Hum. Mol. Genet. 8:855-861(1999). [4]

RN RP ERRATUM.
RA Walsh J., Johnson M.A., Bashir R., Britton S., Keers S., Argov Z., Mahjneh I., Fougerousse F., Beckmann J.S., Bushby K.M.D.; "Dysferlin is a plasma membrane protein and is expressed early in human development." ; Hum. Mol. Genet. 8:1141-1141(1999). [5]

RN RP SUBCELLULAR LOCATION.
RX MEDLINE=99124566; PubMed=10496277;
RA Matsuda C., Aoki M., Hayashi Y.K., Ho M.F., Arahatka K., Brown R.H. Jr.; "Dysferlin is a surface membrane-associated protein that is absent in Miyoshi myopathy." ; Neurology 53:1119-1122(1999). [6]

RN RP SUBCELLULAR LOCATION, AND VARIANT MM AND LGMD2B ARG-791.
RX MEDLINE=99214028; PubMed=10193377;
RA Weiller T., Bashir R., Anderson L.V.B., Davison K., Moss J.A., Britton S., Nylen E., Keers S., Vafiadaki E., Greenberg C.R., Bushby K.M.D., Wrogemann K.; "Identical mutation in patients with limb girdle muscular dystrophy type 2B or Miyoshi myopathy suggests a role for modifier gene(s)." ; Hum. Mol. Genet. 8:871-877(1999). [7]

-1- SUBCELLULAR LOCATION: TYPE II membrane protein (Probable).
-1- TISSUE SPECIFICITY: HIGHLY EXPRESSED IN SKELETAL MUSCLE. ALSO FOUND IN HEART, PLACENTA AND AT LOWER LEVELS IN LIVER, LUNG, KIDNEY AND PANCREAS.
-1- DEVELOPMENTAL STAGE: Expression in limb tissue from 5-6 weeks embryo; persists throughout development.
-1- DISEASE: DEFECTS IN DYSF ARE THE CAUSE OF AUTOSOMAL RECESSIVE LIMB GIRDLE MUSCULAR DYSTROPHY TYPE 2B (LGMD2B). TYPE 2 LIMB GIRDLE MUSCULAR DYSTROPHIES REPRESENT A GENETICALLY HETEROGENEOUS GROUP OF DISEASES WITH VARYING DEGREES OF SEVERITY, DEPENDING ON AGE AT ONSET AND RATE OF PROGRESSION. LGMD2B IS CHARACTERIZED BY WEAKNESS AND ATROPHY STARTING IN THE PROXIMAL PELVIFEMORAL MUSCLES, WITH ONSET IN THE LATE TEENS OR LATER. MASSIVE ELEVATION OF SERUM CREATINE KINASE LEVELS AND SLOW PROGRESSION. SCAPULAR MUSCLE INVOLVEMENT IS MINOR AND NOT PRESENT AT ONSET. UPPER LIMB GIRDLE INVOLVEMENT Follows SOME YEARS AFTER THE ONSET IN LOWER LIMBS.
-1- DISEASE: DEFECTS IN DYSF ARE THE CAUSE OF MIYOSHI MYOPATHY (MM). THIS TYPE OF AUTOSOMAL RECESSIVE DYSTROPHY INVOLVES THE DISTAL LOWER LIMB MUSCULATURE. IT IS CHARACTERIZED BY WEAKNESS THAT INITIALLY AFFECTS THE GASTROCNEMIUS MUSCLE DURING EARLY ADULTHOOD. OTHERWISE THE PHENOTYPE OVERLAPS WITH LGMD2B,
-1- SIMILARITY: BELONGS TO THE FERLIN FAMILY.
-1- SIMILARITY: CONAINS 5 C2 DOMAINS. NOTE=Dysferlin
!! DATABASE: NAME=Dysferlin
!! DOMAIN: NAME=C2
!! DOMAIN: NAME=C2
!! DOMAIN: NAME=C2
!! DOMAIN: NAME=C2

CC	WWW="http://www.dndb.nl/dsfsf.home.html"
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation -
CC	the European Bioinformatics Institute. There are no restrictions on its
CC	use by non profit institutions as long as its content is in no way
CC	modified and this statement is not removed. Usage by and for commercial
CC	entities requires a license agreement (See http://www.isb-sib.ch/announce.
CC	or send an email to license@isb-sib.ch).
CC	
DR	EMBL; AF075575; AAC63519.1; -;
DR	EMBL; AJ007670; CAA06303.1; ALT_SEQ.
DR	EMBL; AJ007973; CAA07800.1; -;
DR	HSSP; P21707; 1RSY.
DR	GeneID; HGNC:3097; DSFSF.
DR	Gene; HGNC:3097; DSFSF.
DR	MIM; 603009; -;
DR	MIM; 253601; -;
DR	MIM; 254130; -;
DR	MIM; 606768; -;
DR	InterPro; IPR000008; C2.
PFAM	PF00168; C2; 7.
SMART	SM00239; C2; 7.
DR	PROSITE; PS00439; C2_DOMAIN_1; FALSE_NEG.
DR	PROSITE; PS50004; C2_DOMAIN_2; 5
KW	Transmembrane; Repeat; Disease mutation.
FT	DOMAIN 1 2046 CYTOPLASMIC (POTENTIAL).
FT	TRANSMEM 2047 POTENTIAL.
FT	DOMAIN 2068 EXTRACELLULAR (POTENTIAL).
FT	DOMAIN 1 2077 C2 DOMAIN 1.
FT	DOMAIN 207 302 C2 DOMAIN 2.
FT	DOMAIN 366 479 C2 DOMAIN 3.
FT	DOMAIN 1139 1244 C2 DOMAIN 4.
FT	DOMAIN 1565 1663 C2 DOMAIN 5.
FT	DOMAIN 1038 1097 ARG-RICH.
FT	VARIANT 791 791 P -> R (IN MM AND LGMD2B).
FT	VARIANT 1298 1298 /FTID=VAR_0123108.
FT	VARIANT 1857 1857 I -> V (IN MM AND LGMD2B).
FT	VARIANT 2042 2042 H -> R (IN MM).
FT	VARIANT 2080 2080 /FTID=VAR_012310.
SQ	SEQUENCE 2080 AA; 23793 MW; 376E22A5AB9BE398 CRC64;
Query	Match 6.2%; Score 94.5%; DB 1; Length 2080;
Best	Local Similarity 18.0%; pred. No. 12;
Matches	Conservative 45; Mismatches 95; Indels 157; Gaps 15
Qy	1 FGKPSL-----ELQPHMYNEQTYFISNDADFTGTLLELNALTDPGFETRCMEGN 52
Db	1627 FGKMFELTCFLPLEKIKLTIYD-YDLLSKDEKEIGTYVDLNRLLSK--FGARC---- 1678
Qy	53 PIPDTPCQAGEEW-----TIAAPVQTIDLFQNQNTWMQ----- 88
Db	1679 GLFQTRVSGPQWRDQLRPSQLLHFCQOHRVKAPVYRDFVNQFDKEYSIEIAGRI 1738
Qy	89 PSPAC-----QCSSDKKKMLPVCPGAGGLP 115
Db	1739 PNPHLGPVVEERLALAHYLQQQGLVPHEVESRPLSPYSLQPDTEQGKLQMWVDFLPKALGRGP 1798
Qy	116 P-----PORKQ-----NTADILQD--LTGARNISDYLVKTYV----- 144
Db	1799 PPENITPRARRFFRLCIIWTRDYLDDLSLTGEKMSDLYVKGWMIGFEHHQKTDHY 1858
Qy	145 -----QIAKASLRKRNKAVNNEFRGGFSLGVSNQLPAQPQEV 181
Db	1859 RSLGEGGENWRFIFPDYLPAAEQVCTIAKKDAFW-----RLDKTESKIPARVV 1907
Qy	182 -----NDA-----IKOMKKHLKLAKDSSADRFNLNL-GRFMTGLDTRNNYKV 222
Db	1908 EQIWMDKNEFSDDFLGSIQLDINRMPKPAKAKCSLDQDAAFPWVSLFEOQTKYKG 1967

QY	104	LPVCPG-AGGLPPORKONTADILQLDTGRNISDYLKYVOLIAKSLKNKIWNEFRY	162
Db	4411	-YCVGVLSGRIPP-----	1
Db	163	GFFSLSVNTQALPSSQEVDIAKOMKKHLAKDSSADREFLNSIG-RPMTGLDTRNNVK	221
Qy	4450	RKTGSLLFET-----LPPLPSLSSLAKSE-----NGNGVTRSGADV-----NMD	4489
Db	222	WVFNNKGWHASSTFVNINNAILNLQRGENPSYGTIAFNHPLUNLTKQQLSEVA	278
Qy	4490	IGVSPFGPETIDDRSMAMNHFV---MEVGKQP-----VIFENNYAAARDNTSKVAL	4538
RESULT 14			
GLN2-ORYSA			
ID	GLN2-ORYSA	STANDARD;	PRT;
AC	P14655;		428 AA.
DT	01-APR-1990 (Rel. 14, Created)		
DT	01-APR-1990 (Rel. 14, Last sequence update)		
DT	16-OCT-2001 (Rel. 40, Last annotation update)		
DE	Glutamine synthetase shoot isozyme, chloroplast precursor (EC 6.3.1.2)		
DE	(Glutamate + ammonia ligase) (Clone lambda-GS31).		
OS	Oryza sativa (Rice)		
OC	Eukaryota; Viridiplantae; Streptophyta; Embryophyta; Tracheophyta;		
OC	Spermatophyta; Magnoliophyta; Liliopsida; Poales; Poaceae;		
OC	Eurhartoideae; Oryzeae; Oryzae.		
OX	NCBI_TAXID=4530;		
RN	[1]		
RP	SEQUENCE FROM N.A.		
RC	STRAIN=cV_Kinnow; TISSUE=Shoot;		
RA	PubMED=91370845; PubMed=2577497;		
RA	Sakamoto A., Ogawa M., Masumura T., Shibata D., Takeba G.,		
RA	Tanaka K., Fujii S.;		
RT	"Three cDNA sequences coding for glutamine synthetase polypeptides in		
RT	Oryza sativa L."		
RL	Plant Mol. Biol. 13:611-614 (1990).		
CC	-!- FUNCTION: THE LIGHT-MODULATED CHLOROPLAST ENZYME, ENCODED BY A		
CC	NUCLEAR GENE AND EXPRESSED PRIMARILY IN LEAVES, IS RESPONSIBLE FOR		
CC	THE REASSIMILATION OF THE AMMONIA GENERATED BY PHOTORESPARATION.		
CC	-!- CATALYTIC ACTIVITY: ATP + L-glutamate + NH(3) = ADP + phosphate +		
CC	L-glutamine.		
CC	-!- SUBUNIT: HOMOOCOTAMER.		
CC	-!- SUBCELLULAR LOCATION: Chloroplast.		
CC	-!- SIMILARITY: BELONGS TO THE GLUTAMINE SYNTHETASE FAMILY.		
CC	-----		
CC	This SWISS-PROT entry is copyright. It is produced through a collaboration		
CC	between the Swiss Institute of Bioinformatics and the EMBL outstation		
CC	the European Bioinformatics Institute. There are no restrictions on		
CC	use by non-profit institutions. The content is in no		
CC	modified and this statement is not removed. Usage by and for commercial		
CC	entities requires a license agreement. (See http://www.isb-sib.ch/announcements.html or send an email to license@isb-sib.ch).		
CC	-----		
DR	EMBL; X11246; CAA2462.1; -		
DR	PIR; S07471; AJRZ00.		
DR	InterPro; IPR001691; GLN_synth.		
DR	PFAM; PF00120; gln synth; 1.		
DR	PROSITE; PS00180; GLNA_;		
DR	PROSITE; PS00181; GLNA_ATP; 1.		
KW	LIGASE; Multigene family; Chloroplast; Transit peptide.		
FT	TRANSIT 1 56	CHLOROPLAST (POTENTIAL),	
FT	CHAIN 57 428 MW; DFF1B39BFC5921FE CRC64;	GLUTAMINE SYNTHETASE SHOOT ISOZYME.	
SQ	SEQUENCE 428 AA;	465442 MW;	
Query Match	6.1%	Score 92.5;	Length 428;
Best Local Similarity	23.6%	Pre. No. 2.1;	
Matches 67;	Conservative 30;	Mismatches 112;	Indels 75;
			Gaps
Qy	5 PSLLEQPNMNEQTYTFVSNDAP-BDTGTLELNNTKDPFGF-----TROMEGNPI 54		
Db	103 ps-ELPKWNWDGSS-----GQAPGDESEVLYPQAIKFDPFRGGMNILYWCDFYTPGEP1 158		
Qy	55 P----DTPCQAGEEWEHTAPV-----QTIMDLFQNGNYTMONSPACOCSSDIKKMLP 105		

```

FT CONFLICT      82          82          I -> Y (IN REF. 2).
FT CONFLICT      263         263         G -> R (IN REF. 2).
FT CONFLICT      338         338         S -> I (IN REF. 2).
SQ SEQUENCE     4.28 AA: 47344 MW: A0558C64FD9B18A CRC64;

Query Match      5 98; Score 90.5; DB 1; Length 428;
Best Local Similarity 23.9%; Pred. No. 3.1;
Matches 68; Conservative 28; Mismatches 113; Indels 75; Gaps 14;

Qy  5 PSLELOPMMNEQQTTFVSNDAP-EDTGTLNALTQDGFG-----TRCMEGNP 54
Db  103 PS-ELPKWNYDGSST---GAOPGEDSEVLYPQALFRDFERGGNNILVCDTYPAGEPI 158
Qy  55 P-DTPCQAGE-----EEMTTAPVPOITMDLFQONGNTWMONPSACQCSSDKIKMMP 105
Db  159 PTINKARAETFSNKKVNEIIPWFGIEQEXTLLOPNVNPPLGP----- 202
Qy  106 VCPPGAGGLPPQRKQNTADILQDLTGRHISDLVVKTYQIAKSLKNKTIWNEFRYGGF 165
Db  203 -----VGAEPGPQGPQYYCCGAEKSWGRDSDAHYKACI-----YAGI 240
Qy  166 SLGVSNTOALPPSQE- -VANDAIK-QMKKHLKLAKDSSADRFMSLGRPMTGLDTRNNVK 222
Db  241 NISGTNGEMPGQWEFQVQGPSVGTEAGDHWCAR-YLLERITEQAGVWLT-LDPKPIEGD 298
Qy  223 WFNNGKWHAISSF-----INVNNAILRANLQKGENPSHKG 258
Db  299 W-NGAGCHTNYSTKSMREOGGFEVIKKALLNLSLRHMEHISAYG 341

```

Search completed: February 4, 2003, 09:39:35
 Job time : 19 secs



	result	No.	Score	Query Match	Length	DB ID	Description
1:	sp_archaea:*	1	1235.5	81.0	2260	13	Q8uvv4 gal
2:	sp_bacteria:*	2	731.5	48.0	2281	6	Q02698 gallus tauru
3:	sp_fungi:*	3	724.5	47.5	2310	11	Q035600 mus muscu
4:	sp_humai:*	4	664.4	43.5	2159	11	Q91v24 mus musculi
5:	sp_invertebrate:*	5	662.5	43.5	2146	4	Q9bzc4 homo sapien
6:	sp_mammal:*	6	658.5	43.2	2008	4	Q96588 homo sapien
7:	sp_mhc:*	7	658.5	43.2	2146	4	Q9nr13 homo sapien
8:	sp_organelle:*	8	267	17.5	1529	4	Q9up10 homo sapien
9:	sp_phage:*	9	267	17.5	2436	4	Q9hc28 homo sapien
10:	sp_plant:*	10	267	17.2	867	4	Q96ic2 homo sapien
11:	sp Rodent:*	11	259.5	17.0	2434	11	Q9esr9 rattus norvegicus
12:	sp_viruse:*	12	250	16.4	2277	4	Q96fT3 homo sapien
13:	sp_unguiculat:*	13	215.5	14.1	1547	5	Q01790 caenorhabditis elegans
14:	sp_virus:*	14	114.5	7.5	961	5	Q8wX4 drosophila melanogaster
15:	sp_bacteriopl:*	15	114.5	7.5	1878	5	Q9vb66 drosophil
16:	sp_archeap:*	16	114	7.5	1500	5	Q9vz41 archeamoebae

17	1.02	6.7	9.04	12	Q9IWU4	human herpe
18	1.00	6.6	3.45	17	Q8TUM6	methanoarc
19	9.8	6.4	8.77	16	Q9R07	staphylococ
20	9.8	6.4	9.13	2	Q86476	staphylococ
21	97.5	6.4	4.32	10	Q9SPJ1	juglans nig
22	97.5	6.4	8.28	12	Q9W292	drosophila
23	97	6.4	14.52	12	Q8UYV8	strawberry
24	96	6.3	8.03	5	Q8T2J0	dictyosteli
25	95	6.2	12.56	5	Q9YAY9	cyanorhabdi
26	91.5	6.0	4.30	10	Q9SEX6	
27	91	6.0	2.74	10	Q9IWA7	oryza sativ
28	91	6.0	3.02	5	Q8SU46	encephalito
29	91	6.0	4.59	16	Q9KDR5	beta vulgaris
30	90.5	5.9	4.31	10	Q9AWA8	
31	90.5	5.9	4.33	10	Q9XFJ1	mesembryant
32	90	5.9	6.49	11	Q9D296	mus musculus
33	90	5.9	7.73	16	Q9R04	
34	89.5	5.9	4.32	8	Q95AG1	glycine max
35	89.5	5.9	6.49	10	Q9CAL3	zizaniopsis
36	89.5	5.9	15.16	4	Q8TEL8	homino sapien
37	89.5	5.9	15.34	4	Q75093	omo sapien
38	89	5.8	4.49	16	Q8RG05	fusobacteri
39	89	5.8	9.03	12	Q69076	human herpe
40	88.5	5.8	8.65	16	Q8W75	anabena sp
41	88.5	5.8	10.71	5	Q17405	cyanorhabdi
42	88.5	5.8	16.50	11	Q9QVT6	rattus sp.
43	88	5.8	3.65	17	Q97273	plasmid
44	88	5.8	7.48	17	Q9HGL7	thermoplas
		5.8	7.91	3	Q08817	saccharomy

Page 6

SEQUENCE FROM N.A.									
Best Local Similarity 26.0%; Pred. No. 3.1e-12;									
Matches 75; Conservative 49; Mismatches 81; Indels 84; Gaps 14;									
X TISSUE-BRAIN; MEDLINE=2047713; PubMed=10970803;									
Zhao L., Zhou C., Tanaka A., Nakata M., Hirabayashi T., Amachi T., Shioda S., Ueda K., Inagaki N.; "Cloning, characterization and tissue distribution of the rat ATP-binding cassette (ABC) transporter ABC2/ABCA2."; Biochem. Biophys. Res. Commun. 2001; 285(3):875-872 [PubMed:11459193]; EMBL: AB037931; BAB1696; 1.; InterPro: IPR003535; AAA_Transpase; SMART: SM003439; ABC_Transporter.									
InterPro: IPR000561; EGF_1-like; InterPro: IPR00566; Lipocin_cytFABP; Pfam: PF00055; ABC_tran; 2.									
PRODOM: PD000006; ABC_transporter; 2.									
R PROSITE: PS00022; EGE_1; UNKNOWN_1.									
R PROSITE: PS00213; LIPOCALIN; UNKNOWN_1.									
W ATP-binding									
W SEQUENCE: 2434 AA; 270925 MW: CD42A9C4F63513F CRC64;									
Query Match 17.0%; Score 259.5; DB 11; Length 2434;									
Best Local Similarity 32.3%; Pred. No. 5.2e-13; Matches 29; Mismatches 71; Indels 55; Gaps 9;保守性 74; Mismatches 29; Mismatches 71; Indels 55; Gaps 9;结果 13									
Y 58 PCKQAGEEERTTAP-VPTTMDLFQNGNWTMQNSPAQCSSDTRKMLPVCPGKGGLPP 116									
b 1617 PPIAPGPTWTFWPSLPLRVHEPVVR-----CTCSAQGTGFS--CPSVWG-HP 1560									
Y 117 PQRQNTADILQDTGRISDLRGRVYGGFSLGVNSTQALP 176									
b 1661 PQMRRVTSIDLDITGHNVSEELFTSDRF-----RLHRIGATFF--NIQKSI 1707									
Y 177 PSQEVDNAIKQMKKKHLAKDSSADREFLNSLGREMTGLDTRNNVKWVNFKGWHAISSF 236									
b 1708 PAPGTRIPRLMVK-----IAVRVAQLYNNKGYHSMPTYL 1744									
Y 237 NTVNNAILRANLROKGE-NPSHGIGTAFNHLPLNLTKOOL-S-EVALMTTSV 283									
b 1745 NSLNNAILRANLPKSKGNPAATGIVTNHPMKTASLSLDDYLLQGTDV 1793									
RESULT 12									
C 96J7T3 PRELIMINARY; PRT: 2277 AA.									
D 096J7T3 PRELIMINARY; PRT: 2277 AA.									
C 096J7T3; 01-DEC-2001 (TREMBLrel. 19, Created)									
T 01-DEC-2001 (TREMBLrel. 19, Last sequence update)									
T 01-JUN-2002 (TREMBLrel. 21, Last annotation update)									
E ATP-binding cassette transporter family A member 12.									
N ABCA12									
S Homo sapiens (Human).									
C Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteostomi; Mammalia; Eutheria; Primates; Catarhinini; Hominidae; Homo.									
X NCBI_TaxID=9606; [1]									
N SEQUENCE FROM N.A.									
C TISSUE-RETINA; Bonner T.I., Moses T., Detra-Wadleigh S.; "A retinal cDNA for the ATP-binding cassette transporter ABCA12."; Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.									
X InterPro: IPR003436; AKM5455; 1.; InterPro: IPR003419; ABC_Transportr; InterPro: IPR003533; HHH_1.; Pfam: PF000006; ABC_Transportr; 2.									
SMART: SM00278; HH1_1.; PROTE; PS00211; ABC_Transportr; UNKNOWN_1.									
W ATP-binding									
W SEQUENCE: 2277 AA; 256970 MW; EDA2F00280361E2D CRC64;									
Q Query Match 16.4%; Score 250; DB 4; Length 2277;									
Best Local Similarity 26.0%; Pred. No. 3.1e-12;									
Matches 75; Conservative 49; Mismatches 81; Indels 84; Gaps 14;									
X TISSUE-BRAIN; MEDLINE=2047713; PubMed=10970803;									
Zhao L., Zhou C., Tanaka A., Nakata M., Hirabayashi T., Amachi T., Shioda S., Ueda K., Inagaki N.; "Cloning, characterization and tissue distribution of the rat ATP-binding cassette (ABC) transporter ABC2/ABCA2."; Biochem. Biophys. Res. Commun. 2001; 285(3):875-872 [PubMed:11459193]; EMBL: AB037931; BAB1696; 1.; InterPro: IPR003533; AAA_Transpase; SMART: SM003439; ABC_Transporter.									
InterPro: IPR000561; EGF_1-like; InterPro: IPR00566; Lipocin_cytFABP; Pfam: PF00055; ABC Tran; 2.									
PRODOM: PD000006; ABC_transporter; 2.									
R PROSITE: PS00022; EGE_1; UNKNOWN_1.									
R PROSITE: PS00213; LIPOCALIN; UNKNOWN_1.									
W ATP-binding									
W SEQUENCE: 2434 AA; 270925 MW: CD42A9C4F63513F CRC64;									
Query Match 17.0%; Score 259.5; DB 11; Length 2434;									
Best Local Similarity 32.3%; Pred. No. 5.2e-13; Matches 29; Mismatches 71; Indels 55; Gaps 9;保守性 74; Mismatches 29; Mismatches 71; Indels 55; Gaps 9;结果 13									
Y 58 PCKQAGEEERTTAP-VPTTMDLFQNGNWTMQNSPAQCSSDTRKMLPVCPGKGGLPP 116									
b 1617 PPIAPGPTWTFWPSLPLRVHEPVVR-----CTCSAQGTGFS--CPSVWG-HP 1560									
Y 117 PQRQNTADILQDTGRISDLRGRVYGGFSLGVNSTQALP 176									
b 1661 PQMRRVTSIDLDITGHNVSEELFTSDRF-----RLHRIGATFF--NIQKSI 1707									
Y 177 PSQEVDNAIKQMKKKHLAKDSSADREFLNSLGREMTGLDTRNNVKWVNFKGWHAISSF 236									
b 1708 PAPGTRIPRLMVK-----IAVRVAQLYNNKGYHSMPTYL 1744									
Y 237 NTVNNAILRANLROKGE-NPSHGIGTAFNHLPLNLTKOOL-S-EVALMTTSV 283									
b 1745 NSLNNAILRANLPKSKGNPAATGIVTNHPMKTASLSLDDYLLQGTDV 1793									
RESULT 12									
C 96J7T3 PRELIMINARY; PRT: 2277 AA.									
D 096J7T3 PRELIMINARY; PRT: 2277 AA.									
C 096J7T3; 01-DEC-2001 (TREMBLrel. 19, Created)									
T 01-DEC-2001 (TREMBLrel. 19, Last sequence update)									
T 01-JUN-2002 (TREMBLrel. 21, Last annotation update)									
E ATP-binding cassette transporter family A member 12.									
N ABCA12									
S Homo sapiens (Human).									
C Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteostomi; Mammalia; Eutheria; Primates; Catarhinini; Hominidae; Homo.									
X NCBI_TaxID=9606; [1]									
N SEQUENCE FROM N.A.									
C TISSUE-RETINA; Bonner T.I., Moses T., Detra-Wadleigh S.; "A retinal cDNA for the ATP-binding cassette transporter ABCA12."; Submitted (APR-2001) to the EMBL/GenBank/DBJ databases.									
X InterPro: IPR003436; AKM5455; 1.; InterPro: IPR003419; ABC_Transportr; InterPro: IPR003533; HHH_1.; Pfam: PF000006; ABC_Transportr; 2.									
SMART: SM00278; HH1_1.; PROTE; PS00211; ABC_Transportr; UNKNOWN_1.									
W ATP-binding									
W SEQUENCE: 2277 AA; 256970 MW; EDA2F00280361E2D CRC64;									
Q Query Match 16.4%; Score 250; DB 4; Length 2277;									
Best Local Similarity 26.0%; Pred. No. 3.1e-12;									
Matches 75; Conservative 49; Mismatches 81; Indels 84; Gaps 14;									
X TISSUE-BRAIN; MEDLINE=2047713; PubMed=10970803;									
Zhao L., Zhou C., Tanaka A., Nakata M., Hirabayashi T., Amachi T., Shioda S., Ueda K., Inagaki N.; "Cloning, characterization and tissue distribution of the rat ATP-binding cassette (ABC) transporter ABC2/ABCA2."; Biochem. Biophys. Res. Commun. 2001; 285(3):875-872 [PubMed:11459193]; EMBL: AB037931; BAB1696; 1.; InterPro: IPR003533; AAA_Transpase; SMART: SM003439; ABC_Transporter.									
InterPro: IPR000561; EGF_1-like; InterPro: IPR00566; Lipocin_cytFABP; Pfam: PF00055; ABC Tran; 2.									
PRODOM: PD000006; ABC_transporter; 2.									
R PROSITE: PS00022; EGE_1; UNKNOWN_1.									
R PROSITE: PS00213; LIPOCALIN; UNKNOWN_1.									
W ATP-binding									
W SEQUENCE: 2434 AA; 270925 MW: CD42A9C4F63513F CRC64;									
Q Query Match 17.0%; Score 259.5; DB 11; Length 2434;									
Best Local Similarity 32.3%; Pred. No. 5.2e-13; Matches 29; Mismatches 71; Indels 55; Gaps 9;保守性 74; Mismatches 29; Mismatches 71; Indels 55; Gaps 9;结果 13									
Y 58 PCKQAGEEERTTAP-VPTTMDLFQNGNWTMQNSPAQCSSDTRKMLPVCPGKGGLPP 116									
b 1617 PPIAPGPTWTFWPSLPLRVHEPVVR-----CTCSAQGTGFS--CPSVWG-HP 1560									
Y 117 PQRQNTADILQDTGRISDLRGRVYGGFSLGVNSTQALP 176									
b 1661 PQMRRVTSIDLDITGHNVSEELFTSDRF-----RLHRIGATFF--NIQKSI 1707									
Y 177 PSQEVDNAIKQMKKKHLAKDSSADREFLNSLGREMTGLDTRNNVKWVNFKGWHAISSF 236									
b 1708 PAPGTRIPRLMVK-----IAVRVAQLYNNKGYHSMPTYL 1744									
Y 237 NTVNNAILRANLROKGE-NPSHGIGTAFNHLPLNLTKOOL-S-EVALMTTSV 283									
b 1745 NSLNNAILRANLPKSK									

Qy	117	PQRKQNTAIDLQDLTGRN--ISDYLVKTVQITAKSL-----	-KNK1WNEFR 1.61
Dbb	698	-----DP1FDKIGVNE1PGEHYLNNLRIVLVS LAQVGSDCCYNO SANKL--SEYL 747	
Qy	162	YGGFSLGYS-NTQALPPS--QEYNDAIKOMKKHLKAQSSADR--FLNSLG-----	208
Dbb	748	YNGTAIEATLKTQAYCAGLRS TNEIYSRVQSDL-LSSSDSTDRLSF1SSLGCSSTS QL 806	
Qy	209	--RMTG LDTRNNV KWFNNKGWHAISSEINVINNAILRANLQGENPSHYGITA 261	
Dbb	807	-----LDFLRLSSTDNTNSL-----SYERTSLASRSR-----SPGLTA 842	

Search completed: February 4, 2003, 09:40:17
Job time : 43 secs